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Summary  
 
Obstructive sleep apnoea is a muscular disorder that disrupts breathing during sleep and is 
caused by a loss of muscle tone in the muscles of the upper airway which become flaccid 
and physically block the airway. Sleep is disrupted due to the restriction of air intake caused 
by upper airway resistance and is characterised by pauses in breathing which may last for up 
to 60 seconds. Individuals are forced to gasp for air in order for breathing to resume, and the 
disorder is characterised by daytime sleepiness, waking with a headache and disturbances in 
concentration and memory. If left untreated, obstructive sleep apnoea can lead to increased 
blood pressure and risk of stroke, brain damage or heart attack. Current treatment options 
include mechanical and non-mechanical devices to increase upper airway patency, and 
surgery to remove excess soft tissue which blocks the airway during sleep. These treatments 
have low adherence rates due to their impact on lifestyle, or are not suitable for all 
individuals. This project focussed on developing a novel treatment for obstructive sleep 
apnoea to correct the loss of muscle tone. Tetanus toxin produced by Clostridium tetani, 
causes spastic paralysis by preventing the release of inhibitory neurotransmitters within the 
central nervous system which normally signal muscles to relax. The result is an increase in 
muscle tone leading to rigid paralysis, which can be exploited for the treatment of obstructive 
sleep apnoea. Localised injection of tetanus toxin has been demonstrated to induce tetany in 
the upper airway of British Bulldogs, who naturally have sleep apnoea -like events during 
sleep, without systemic effects. Due to the widespread immunisation against tetanus toxin 
through vaccination with tetanus toxoid, this project aims to develop a chimeric holotoxin 
consisting of the heavy chain of tetanus toxin and the botulinum type A light chain to 
circumvent pre-existing immunity to tetanus toxin. Tetanus and botulinum toxins have 
structural similarities, and while they elicit opposing effects, their mode of action is similar. 
The individual domains, which retain function upon separation, have previously been 
substituted among domains of other Clostridial neurotoxins. In conclusion, individual toxin 
domains from tetanus and botulinum type A toxin will be developed and recombined to 
produce a novel chimeric holotoxin for the treatment of obstructive sleep apnoea.  
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Chapter 1  
Introduction 
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1.1 Sleep apnoea  
Sleep apnoea (SA) is a breathing disorder characterised by irregular breathing patterns 
during sleep. The condition is a form of sleep disordered breathing (SDB), with sufferers 
experiencing recurrent arousals during sleep caused by the brief cessation of breathing. 
There are three types of SA, (i) central sleep apnoea (CSA), caused by a neurological 
disorder; (ii) obstructive sleep apnoea (OSA), where sleep is interrupted as a result of a 
physical blockage of the upper airway; and (iii) complex sleep apnoea (CompSA), which is 
caused by a combination of both. The effects of SDB range from collapse of the upper 
airway, increased upper airway resistance, pauses in breathing, and decreased saturated 
oxygen levels in the blood which lead to hypoxia. Irregular breathing patterns continue 
throughout the night, and result in the individual feeling fatigued the following day (Wolk et 
al., 2003). 
 
In all types, the apnoea-hypopnoea index (AHI) is used as a quantitative measure of disease 
severity, and it refers to the number of apnoeas occurring per hour of sleep. An apnoea 
refers to the cessation of breathing, whilst a hypopnoea is a reduction in the volume of air 
passing through the upper airway, or a period of very shallow breathing (Young et al., 1993). 
SA is classified as obstructive or central, based on the whether or not respiratory effort is 
employed to reinstate breathing during sleep, respectively. The physical obstruction of the 
upper airway observed in OSA, results from the collapse of the surrounding tissue or 
muscles in the upper airway. Due to the narrowing of the airway, there is an increase in 
airway resistance, and sufferers are forced to gasp for air so that breathing may resume. 
CSA is a neurological disorder which does not allow for breathing to be restored through 
physical effort. Causes of CSA are of a central origin, and not due to a physical blockage of 
the airway. CompSA is seen when an individual with OSA continues to experience brief 
cessations of breathing and interrupted sleep, even once the obstruction has been removed. 
In such cases, the residual effects of SDB are attributed to CSA-like events, and are 
generally treated as such. Despite varying causes, all three types of SA display an overlap in 
symptoms and in all instances, treatment options are aimed at reducing the AHI (Young et 
al., 1993).  
 
Treatment options vary, depending on the type of SA, however mechanical devices to assist 
breathing during sleep are the most commonly prescribed. These forms of treatment are very 
effective in treating symptoms of SA and reducing the risk of comorbidities, however 
compliance is generally low due to the impact that these devices have on the patient’s 
lifestyle. In view of the necessity for more convenient treatment options, the focus of this 
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review will be on the options currently available, and the proposal of a novel therapeutic 
approach to the treatment of OSA.  
1.2 Central sleep apnoea 
Central sleep apnoea (CSA) is characterised by impaired central respiratory drive. An 
interruption of nerve impulses from the brain to the thoracic and abdominal muscles involved 
in respiration causes muscles to cease movement, and breathing pauses for at least 10 
seconds during sleep (Yumino and Bradley, 2008). Disturbances in electrical signals may 
result from damage to the region of the brainstem which controls breathing and may be from 
acute brainstem injury or central nervous system disease such as encephalitis, or from 
neurological disorders such as Parkinson’s disease (Aurora et al., 2012). CSA may also be 
seen in association with Cheyne-Stokes respiration or other medical conditions such as 
congestive heart failure, high altitude environments, illicit drug use, obesity, or in normal 
healthy subjects (Aurora et al., 2012; Eckert et al., 2007). 
 
CSA occurs because the central nervous system cannot react quickly enough to changes in 
CO2 levels in the blood. Upon expiration, the level of oxygen in the blood decreases and the 
level of CO2 increases, prompting the body to draw in more oxygen. The inhaled oxygen 
replaces the built up CO2 in the blood, and the cycle continues. These normal breathing 
patterns are controlled by chemoreceptors which respond to changes in CO2 levels through a 
shift in the concentration of hydrogen ions (Eckert et al., 2007). Over-responsive 
chemoresponses which are sensitive to small changes to CO2 levels, cause unstable 
ventilatory control and may result in irregular breathing patterns such as Cheyne-Stokes 
respiration. This irregular form of breathing occurs in CSA sufferers whereby individuals 
exhibit heavy, deep, often quick breathing, gradually becoming shallow, and then stopping 
temporarily. This pattern of breathing repeats to form an abnormal cycle of hyperventilation 
and apnoeas. The restricted air supply throughout the night results in inadequate ventilation 
and compromised gas exchange, inducing symptoms of restless sleep, waking with a 
headache and daytime sleepiness (Eckert et al., 2007).  
 
1.2.1 Symptoms of CSA 
Due to fragmented sleep caused by CSA, sufferers wake often during the night and 
experience nocturia, daytime sleepiness or fatigue, waking with a headache, and 
disturbances in concentration and memory (Eckert et al., 2007). Sympathetic activity is 
increased which has been shown to cause elevated left ventricular pressure and is a major 
contributor to the development of heart failure (Yumino et al., 2009).  
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1.2.2 Treatment of CSA 
Treatment to reduce the AHI in CSA sufferers includes continuous positive airway pressure 
(CPAP), or bi-level positive airway pressure (BPAP). Although generally used as the 
treatment of choice for OSA, CPAP has improved breathing during sleep in CSA sufferers, 
however the mechanisms are unclear (Eckert et al., 2007). Adaptive servo-ventilation (ASV) 
is used in patients with Cheyne-Stokes breathing and congestive heart failure, and may be 
used successfully in CSA patients (Aurora et al., 2012; Ramar et al., 2012). ASV works by 
precisely adjusting the air pressure delivered according to changes in breathing dynamic. 
Once the pressurised oxygen normalises breathing, the system reduces delivery to a level 
which maintains a patent airway, increasing again when breathing becomes unstable. ASV 
has been effective in improving breathing and AHI in CSA sufferers (Aurora et al., 2012; 
Morgenthaler et al., 2007).  
 
Pharmacotherapies for CSA act centrally to stimulate respiration. Metabolic alkalosis occurs 
in CSA patients from the loss of hydrogen ions and may cause unstable respiration. The use 
of medications such as Acetazolamide, a carbonic anhydrase inhibitor, has been shown to 
stabilise breathing in CSA patients by creating a mild metabolic acidosis, which increases 
hydrogen ion concentration and thus the drive to breathe (Selim et al., 2012; Yumino and 
Bradley, 2008). Side effects of high dose Acetazolamide include tingling sensations or 
shortness of breath, which may result from drug-induced increased ventilation, however low-
dose administration may reduce such effects (Javaheri, 2006). Theophylline, a 
bronchodilator and heart muscle stimulant, has also shown improvements in daytime 
sleepiness in CSA patients, but has been shown to cause arrhythmias and nausea (Aurora et 
al., 2012; Selim et al., 2012). It is not surprising that pharmacotherapy has limited supporting 
evidence for success as the sole source of treatment, since CSA is a systemic disorder, 
however, it may be suitable for use in conjunction with other therapies for the treatment of 
CSA (Selim et al., 2012).  
 
In cases of Cheyne-Stokes related CSA, where hypocapnia (reduced levels of CO2 in the 
blood) results, the administration of carbon dioxide during sleep increases the drive to 
breathe and may reduce hypopnoea (Aurora et al., 2012; Yumino and Bradley, 2008). 
Hypoxia (reduced dissolved O2 in the blood), may cause an over-response to subsequent 
increased levels of CO2 in the blood, and may result in hyperventilation after an apnoeic 
event. This condition may be treated by the delivery of oxygen (Yumino and Bradley, 2008). 
Effects of oxygen delivery may be patient-specific and there is still no definitive treatment for 
CSA or CSA associated with heart failure.  
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1.3 Obstructive sleep apnoea 
Obstructive sleep apnoea (OSA) is a muscular disorder that disrupts breathing during sleep. 
OSA is characterised by pauses in breathing, known as apnoeas, which occur a number of 
times per hour sleep. Unlike CSA, where thoraco-abdominal movement ceases due to an 
interruption in central signalling, these muscles continue to work in patients with OSA. 
However, a loss of muscle tone or rigidity causes the muscles to become flaccid or collapse, 
thereby obstructing the airway when the individual is recumbent (Ankichetty et al., 2011). 
Breathing pauses for at least 10 seconds as little air is able to pass through the blocked 
airway, and patients are forced to gasp for air in order for breathing to resume (Eckert et al., 
2007). The loss of a patent airway increases upper airway resistance and leads to loud 
snoring noises, as attempts to inhale air through the occluded airway are made. Increased 
upper airway resistance leads to a hypopnoea (period of shallow breathing), followed by an 
apnoea (pause in breathing), which may last for up to 60 seconds. This breathing-pause-
breathing cycle continues throughout sleep, with apnoea-hypopnoea events occurring 
between 5 and 30 times per hour sleep, depending on severity (Ankichetty et al., 2011). 
Although individuals are not always roused during sleep, additional respiratory drive is 
required to reinstate breathing. This results in restless sleep, accompanied by classical 
symptoms such as waking with a headache and drowsiness throughout the day.  
 
1.3.1 Pathophysiology of OSA 
OSA is caused by a collapse of the muscles in the upper airway causing increased upper 
airway resistance during sleep. The upper airway is separated into three regions: the 
nasopharynx (nasal passage); the oropharynx (hard palate on the roof of the mouth to the 
base of the epiglottis); and the hypopharynx or laryngopharynx (base of the tongue to the 
larynx (throat)) (Schwab, 2005). More than 20 muscles make up the pharyngeal region and 
are involved in breathing and swallowing. The position of the soft palate is coordinated by 11 
different muscles and both respiratory and non-respiratory functions such as swallowing, are 
controlled by the coordinated activity of all muscles (Series, 2002). The airway or pharynx is 
maintained in an open state by the action of the pharyngeal dilator muscle. The movement of 
air over the surface of the pharynx and increases in lung volume also aid in maintaining a 
patent airway (Schwab, 2005; Series, 2002). As the pharynx does not contain any bony 
structures for support, the activity of these muscles is crucial for the maintenance of a patent 
airway. 
 
A loss of tone of the dilator muscles, and soft tissue of the pharyngeal wall including the 
uvula (soft tissue which hangs from the posterior edge of the soft palate at the back of the 
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throat), causes the muscles to collapse and block the airway when the individual is supine 
(Figure 1.1). The airway, however, is not completely blocked, but its size is reduced and a 
much smaller volume of air passes at a much higher resistance during inspiration and 
expiration (Young et al., 1993). Enlargement of the adipose tissue surrounding the upper 
airway muscles, known as pharyngeal fat pads, are also a predisposing factor of OSA (Al 
Lawati et al., 2009; Schwab, 2005). Changes in craniofacial structure occur during sleep 
when the mandible relaxes and becomes shorter, reducing the space for the surrounding soft 
tissue structures, such as the tongue, to rest. The tongue and lateral pharyngeal walls 
become enlarged  in the limited space, and the walls of the pharynx repeatedly collapse, 
making breathing during sleep difficult (Schwab, 2005). Factors predisposing individuals to 
OSA may be a combination of genetic and behavioural, however, the basis of disease is an 
abnormal physiology of the upper airway. 
 
1.3.2 Risk factors of OSA 
Risk factors associated with OSA range from physical (reversible), genetic and other 
irreversible factors. Obesity is the only major reversible risk factor associated with OSA. A 
large neck circumference and skin folds present due to excess body fat, puts pressure on the 
upper airway and reduces the size of the pharynx during sleep. Individuals predisposed to 
seasonal rhinitis are at a higher risk of developing OSA and the AHI is higher in patients with 
rhinitis, suggesting that symptoms such as nasal congestion may play a role in OSA (Al 
Lawati et al., 2009). Smoking also increases the risk of OSA, possibly due to inflammation of 
the upper airway and the instability caused to sleep (Al Lawati et al., 2009). Alcohol may also 
increase upper airway resistance during sleep and exacerbate OSA symptoms (Young et al., 
1993).   
 
1.3.2.1 Age and sex 
Advanced age and the male sex are also risk factors with 4% of males aged 30 – 60, and 2% 
of women of the same age group affected by OSA (Young et al., 1993). Males tend to carry 
excess body fat in the upper body and have larger upper airway soft tissue structures than 
females. The incidence of OSA is thus increased in males, compared to females who have a 
predominantly lower body fat distribution (Al Lawati et al., 2009). With fat loss, neck 
circumference may be reduced, placing less pressure on the upper airway and allowing air to 
pass through the pharynx unobstructed. There is, however, an increased risk of OSA seen in 
post-menopausal women, irrespective of age or other risk factors. It may be that female   
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Figure 1.1: Muscles of the upper airway involved in OSA. Reproduced from Victor 
(1999). 
Normal airway (left) and abnormal airway showing obstruction during sleep (right). A loss of 
tone in the muscles of the soft palate may obstruct the airway when the individual is supine.  
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hormones play a role in protecting woman against OSA (Al Lawati et al., 2009; Launois et al., 
2007). It is difficult to estimate the effects of ethnicity on predisposition to OSA due to 
differences in environmental risk factors such as diet and lifestyle (Young et al., 1993). 
 
1.3.2.2 Genetic factors 
Although there is no direct association between genetic factors and OSA, these factors do 
determine the physiology of the upper airway. Deposits of adipose tissue in specific areas of 
the body is determined by genetic factors, and enlarged pharyngeal fat pads may increase 
the risk of OSA (Schwab, 2005). Differences in craniofacial structure between various 
ethnicities and/or people, such as the size and shape of the mandible and surrounding soft 
tissue structures, can reduce the size and therefore quality of the airway (Al Lawati et al., 
2009; Schwab, 2005). The thickness of the tongue and pharyngeal walls can also reduce 
airway quality and predispose individuals to OSA (Schwab, 2005). OSA has been observed 
at a higher incidence in African Americans and Asians at a given body mass index (BMI) (Al 
Lawati et al., 2009).  
 
1.3.3 Incidence of OSA  
OSA occurs in 2 – 4% of the developed world, and even with a wide, albeit general, range of 
symptoms, 1 out of 5 adults will show minimal symptoms or be asymptomatic (Young et al., 
1993). These cases cause a large burden of morbidity. Childhood OSA occurs in 2 – 3% of 
healthy children (Friedman and Goldman, 2011), whilst 5% of adults in the developed world 
are expected to have undiagnosed OSA (Young et al., 1993). With the increasing prevalence 
of obesity in the general population, it is likely that there will be an increased incidence of 
OSA with subsequent public health burdens also increasing over time (Young et al., 1993). 
 
1.3.4 Symptoms and consequences of OSA  
OSA is described as strenuous breathing due to the gasping or choking sounds which occur 
as attempts are made for breathing to resume after a pause in breath. Snoring is common in 
OSA, and sufferers may be roused during sleep when gasping for breath. Daytime 
sleepiness or fatigue results from interrupted sleep, and may be responsible for workplace 
and/or motor vehicle accidents (Akerstedt et al., 2002). A recent review of the literature 
showed that depression is seen in 5 – 63% of OSA sufferers and that the incidence of 
depression is higher in OSA sufferers than within the general population (Ejaz et al., 2011). 
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Alterations in mood may result in a decreased sex drive and overall poor quality of life, thus 
exacerbating depression (Ejaz et al., 2011; Malhotra and White, 2002).  
 
The sympathetic nervous system is activated by repeated arousals from sleep, which may 
cause irreversible neuronal damage when prolonged periods of hypoxia are repeatedly 
experienced during sleep (Ejaz et al., 2011). Activation of the sympathetic nervous system 
also results in sleep fragmentation, and hypoxia of the brain and heart (Malhotra and White, 
2002; Young et al., 1993). Hypoxia of the brain may result in decreased neurocognitive 
function and impairment of memory and attention (Bawden et al., 2011), and clinical 
manifestations include loss of grey matter in areas of the brain responsible for cognitive 
function, memory processing and learning (Morrell et al., 2003).  
 
Loss of sleep caused by OSA can alter monocyte proinflammatory cytokine responses and 
result in autoimmune disorders such as diabetes mellitus, arthritis and cardiovascular 
disease through the effects on the production of Interleukin-6, TNF-alpha and C-reactive 
protein, respectively (Irwin et al., 2010). OSA is an independent risk factor for enhanced 
platelet activation and aggregation (Kondo et al., 2011), hypertension, and therefore 
cardiovascular morbidity (Maruyama et al., 2012; Wolk et al., 2003; Young et al., 1993; 
Young et al., 2002). OSA is also an independent risk factor for atherosclerosis, which 
increases the risk of myocardial infarction or stroke (Drager et al., 2007). Cardiovascular 
events may result due to hypoxia of the heart and an increase in C-reactive protein, a 
biomarker for systemic inflammation, and atherosclerosis which may occur independently of 
other risk factors such as smoking, diabetes or hypertension. Other clinical manifestations of 
OSA include hypertension due to decreased circulating oxygen (hypoxaemia) and increased 
CO2 circulating in the blood (hypercapnia) (Young et al., 1993).  
 
Symptoms of OSA are exacerbated with the use of sedatives, anaesthetics and pain relief 
medication. Under general anaesthesia, arousal responses may be slowed (Ankichetty et al., 
2011), and snoring during intubation may cause uvular oedema and result in postoperative 
complications (Ankichetty et al., 2011; Ejaz et al., 2011). OSA sufferers may also be at an 
increased risk of type II diabetes and stroke, likely to be associated with obesity and 
hypertension (Fredheim et al., 2011; Malhotra and White, 2002; Olsen et al., 2008). It is 
possible to reverse the clinical consequences of OSA with adequate treatment. The first step, 
however, is to establish the cause of symptoms.  
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1.3.5 Diagnosis of OSA 
Diagnosis of OSA is initially based on observed symptoms, usually by the bed partner. A 
history of snoring, restless sleep and choking sounds may only be apparent to the bed 
partner, as the patient may be unaware of such events occurring throughout the night. 
Physical examination to measure neck circumference and BMI are typically performed, 
however definitive diagnosis is usually made via overnight polysomnography (PSG), or CT or 
MRI whilst the patient is awake, to examine the size of the upper airway. PSG serves as the 
standard diagnostic test for OSA and measures the number of apnoeas and hypopnoeas per 
hour of sleep, providing diagnosis based on an apnoea-hypopnoea index (AHI) (Olsen et al., 
2008; Punjabi, 2008). Diagnosis of OSA is usually considered if a patient displays >5 
respiratory events per hour sleep with concurrent symptoms of excessive daytime 
sleepiness, snoring, and arousals from sleep due to choking. An AHI>15 per hour sleep in 
the absence of other symptoms, is also considered as a positive OSA diagnosis (Olsen et al., 
2008).  
 
PSG is a test typically performed overnight in a sleep clinic for the diagnosis of sleep 
apnoea. It uses electroencephalogram, electromyogram, electrooculogram, oronasal airflow, 
and oxyhaemaglobin to measure physiological signals during sleep and determine the AHI, 
and snoring is recorded with a microphone (Shiomi et al., 2011). An apnoea occurs when 
breathing ceases for at least 10 seconds and it is at this point when the apnoea is classified 
as obstructive or central, based on whether effort is employed for breathing to resume. A 
hypopnoea is measured when a 25 – 50% reduction in oronasal airflow is observed, in 
addition to a reduction in oxyhaemoglobin saturation or with arousal from sleep (Punjabi, 
2008). A patient displaying AHI<5 per hour is considered normal, an AHI of 5 – 14 is 
considered to be mild OSA, an AHI of 15 – 29 is moderate OSA, and >30 events per hour is 
classified as severe OSA (Ejaz et al., 2011). An AHI>5 with concurrent excessive daytime 
sleepiness were once the only symptoms used for diagnosing OSA. However, due to the 
increased risk of life-threatening cardiovascular events, some sufferers who record an AHI>5 
with the absence of daytime sleepiness are also classified as having OSA (Ejaz et al., 2011). 
 
Overnight PSG is quite labour intensive and requires patients to stay overnight in a sleep 
clinic. Qualified personnel are required to carry out testing and interpret results, with some 
symptoms such as snoring counted manually by a sleep technician. Such observations may 
be subjective, especially in instances when severity of snoring is reported by sleep 
technicians (Shiomi et al., 2011). Inconsistencies between different sleep labs with regard to 
data collection and interpretation, may make it difficult to study trends amongst various 
populations (Punjabi, 2008).  
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1.3.6 Treatment of OSA 
It is well established that OSA has severe and potentially life threatening clinical 
consequences if left untreated. There are a number of treatment options which have been 
proven to be effective in reversing symptoms and clinical manifestations of OSA. Treatments 
range from mechanical devices which are used to regulate the pressure within the upper 
airway during sleep, oral devices to maintain an open airway, surgery, medications, and 
behavioural modifications which may aid in the reduction of OSA symptoms. Despite studies 
which have shown promising success rates for some treatments, patient compliance is 
usually the determining factor of individual success. Many patients will initially accept and 
adhere to the use of daily treatments used during sleep, but after a period of time, patients 
cease use and symptoms return. Some patients may not be good candidates for other 
methods of treatment such as surgery, or may be unwilling to adopt certain behavioural 
modifications. Treatment options currently available will be discussed.  
 
1.3.6.1 Continuous positive airway pressure (CPAP) 
Once OSA is confirmed by PSG, the treatment of choice by sleep specialists to reduce the 
AHI to below 5 and control OSA symptoms, is the continuous positive airway pressure 
(CPAP) device (Kushida et al., 2005). The device consists of a mask worn over the nose or 
face, depending on patient requirements, and connected to a pump which regulates pressure 
within the nasopharynx (Figure 1.2) (Bakker et al., 2012). A fixed air pressure, determined 
during a titration PSG, is applied and acts as a pneumatic splint to prevent the collapse of the 
muscles of the upper airway (Malhotra et al., 2000; Olsen et al., 2008). The patient is able to 
breathe normally while the CPAP device is in use, and the symptoms of snoring and choking 
arousals are eliminated. It is well documented that consistent CPAP use is able to decrease 
the AHI to less than 5 events per hour, decreases daytime sleepiness, improves oxygenation 
and cognitive performance and clinical manifestations may also be reversed (Aloia et al., 
2003; Cheng et al., 2011; Ejaz et al., 2011). Improvements in hypertension are also seen 
with the reduction of autonomic activity during sleep (Thomas et al., 2005).  
 
1.3.6.2 CPAP compliance 
Although CPAP is non-invasive and its use has been shown to improve symptoms of OSA, it 
is estimated that 50% of patients who are prescribed this therapy, are non-compliant after 1 
year (Ballard et al., 2007). The treatment is not widely accepted due to the uncomfortable 
nature of the device. The mask may restrict mobility during sleep, while the volume of the  
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Figure 1.2: CPAP device showing mask secured over the nose and mouth. 
Reproduced from Ejaz et al. (2011). 
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pump during operation may keep the individual, as well as other(s) sleeping in the same 
area, awake. There may also be problems with spontaneous intimacy with the bed partner 
while the device is in use (Zozula and Rosen, 2001). The mask can cause irritation to the 
face, stiffness of the nose, and/or claustrophobia, and air leaks around the mask may reduce 
its effectiveness (La Piana et al., 2011; Zozula and Rosen, 2001). Unfavourable effects from 
the device have been reported in 15 – 45% of patients (Zozula and Rosen, 2001). 
Modifications may be made to the device to assist in comfort, such as the use of humidifiers, 
sponge pads placed on the bridge of the nose to cushion the face, and pumps with reduced 
noise output (Malhotra et al., 2000). However, adherence rates have not increased at the 
same rate as the improvements made to these newer machines, possibly indicating that 
compliance is not solely based on mechanical issues with the CPAP device.  
 
Compliance is defined as use of the CPAP device for at least 4 h per night on at least 70% of 
nights over 3 months (Aloia et al., 2003). Of the patients who are prescribed CPAP treatment 
and take it home, only 50 – 75% actually use the treatment effectively (Zozula and Rosen, 
2001), and the suboptimal rate of CPAP adherence is a major cause of OSA treatment 
failure (La Piana et al., 2011; Olsen et al., 2008). Since CPAP compliance does not seem to 
be affected by the side effects from the mechanical parts alone, there may be psychological 
and motivational issues involved in adherence (Olsen et al., 2008).  
 
Social support seems to be important in patient adherence to CPAP use (Olsen et al., 2008). 
Training sessions to educate patients and their bed or living partners on the benefits of 
adherence, and familiarisation with the device has been effective in improving compliance 
rates. However, re-training may be required after 1 year in order to ensure compliance long-
term (La Piana et al., 2011; Smith, S. et al., 2004). It has been shown that CPAP compliance 
is high in married couples, and low in those who live alone or are working, thus indicating the 
importance of support in the form of encouragement of CPAP use from a living partner 
(Gagnadoux et al., 2011). Involvement of friends or co-workers may provide a strategy to 
improve compliance in unmarried patients. It is especially important for sufferers who are 
working to have social support, as excessive daytime sleepiness may result in occupational 
or motor vehicle accidents (Akerstedt et al., 2002). Often, those who travel for work or have 
competing interests will prioritise work over CPAP adherence (Gagnadoux et al., 2011). As 
compliance of CPAP use is low, and consistent use of treatment is critical in reversing OSA 
symptoms, there are other therapeutic options for patients who are not willing to use CPAP. 
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1.3.7 Other positive airway pressure devices 
Bi-level positive airway pressure (BPAP) devices can be used to deliver different inspiratory 
and expiratory pressures, which allows for less effort for expiration compared to CPAP. 
However, these devices are expensive and studies have indicated that CPAP is more 
effective in the treatment of OSA (Ballard et al., 2007; Reeves-Hoche et al., 1995). With 
adherence rates being generally similar between the two devices, CPAP is the superior 
option, therefore BPAP is rarely prescribed (Malhotra and White, 2002).  
 
Autotitrating devices deliver variable pressure in a similar manner to BPAP, but is determined 
by factors such as snoring and flow limitation (Malhotra and White, 2002). Autotitrating 
devices have been used for more hours per night than CPAP, but overall, long term 
adherence rates were similar, as were the effects of treatment on OSA symptoms (Hudgel 
and Fung, 2000).  
 
Expiratory positive airway pressure (EPAP) nasal devices are a disposable stand-alone 
device in the form of an adhesive patch worn over the nares. A valve, placed over the centre 
of the nares allows minimal resistance of air through the nose during inspiration and 
increases air flow resistance during expiration. Expiration pressure is created and time of 
expiration is longer, two factors which may stop the airway from collapsing, however the 
precise mechanism of this is unclear (Walsh et al., 2011). EPAP is not recommended as a 
stand-alone treatment for individuals who are non-adherent to CPAP, however it may be 
used in addition to other treatments for OSA.  
 
1.3.8 Alternative treatment options 
Other treatment approaches to reducing the symptoms of OSA include weight loss to reduce 
neck circumference, restriction of alcohol consumption and use of sedatives to prevent 
supine sleep (Ankichetty et al., 2011; Malhotra and White, 2002). Airway size may be 
enlarged through tonsillectomy or nasal steroids may be used to decrease inflammation of 
the airway in patients who suffer from chronic rhinitis (Friedman and Goldman, 2011). Long 
term outcomes of steroid use are still unknown. 
 
1.3.8.1 Oral appliances  
Oral appliances are recommended for patients who have mild OSA or primary snoring, and 
who do not meet the criteria or do not respond to treatment with behavioural modifications 
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such as weight loss. They can be used in patients with moderate to severe OSA who cannot 
use CPAP either because of non-compliance or intolerance (Sari and Menillo, 2011). Oral 
appliances can be used to maintain an open pharyngeal airway by preventing the tongue and 
surrounding tissue from collapsing and obstructing the airway.  
 
The mandibular advancement splint (MAS), is a non-adjustable block which rests on the 
mandible and retains it in an extended position during sleep. Titratable oral appliances 
perform as a splint and also create a space between the back of the tongue and the posterior 
pharyngeal wall, effectively inhibiting the tongue from blocking the airway when the patient is 
supine (Figure 1.3) (Sari and Menillo, 2011). Compliance of such devices is usually poor as 
they cause significant discomfort (Malhotra and White, 2002).  
 
1.3.8.2 Surgery 
If patients refuse to adhere to, or fail with CPAP and/or oral devices, another option for 
treatment of OSA is surgery of the upper airway. Surgical procedures involve removal of 
redundant soft tissue, which is causing blockage of the upper airway. The most common 
procedure is uvulopalatopharyngoplasty (UPPP), in which the soft tissue of the lateral 
pharyngeal walls and the uvula (fleshy part which hangs from the roof of the mouth at the 
back of the throat), are resected to increase the size of the airway. Aside from the invasive 
nature of this procedure and possible postoperative complications, about 41% of patients 
only see a reduction of the AHI to less than 20 events per hour sleep (Malhotra and White, 
2002), which is still classified as moderate OSA. Symptoms of snoring may cease, however, 
sleep disordered breathing continues in many cases, leading to silent sleep apnoea 
(Malhotra and White, 2002). There are instances where modified UPPP surgery in small test 
groups (N=<50) has been effective at improving patient AHI (Mackay et al., 2013). Laser-
assisted uvulopalatoplasty (LAUP) is usually performed to relieve symptoms of snoring, but 
has been used in the treatment of OSA to increase the size of the pharyngeal airway 
(Olszewska et al., 2012). Under local anaesthesia, the laser causes targeted thermal tissue 
damage to create vertical channels in the soft palette, thus widening the airway. This 
treatment may be required prior to UPPP surgery. Although the AHI may be reduced by as 
much as 50% after surgery, this may still not completely reverse symptoms in patients with 
severe OSA (Ejaz et al., 2011; Olszewska et al., 2012).  
 
Maxillomandibular advancement (MMA) is used to lengthen the upper (maxilla) and lower 
(mandible) jaw as much as 9 mm and 12 mm, respectively, and increase the calibre of the 
upper airway (Hsieh and Liao, 2012). The procedure may create cosmetic changes, and little 
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Figure 1.3: Oral appliances for the treatment of OSA. Reproduced from Sari and 
Menillo (2011). 
Titratable oral appliance (top) and the mandibular advancement splint (MAS) (bottom).  
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attention has been paid to the effects on the surrounding structures such as the skeleton and 
upper airway post-surgery. It is thus difficult to determine whether improvements to AHI are 
due to changes in the upper airway tissues or structure of the jaw (Hsieh and Liao, 2012). It 
has been shown to improve the AHI to a greater extent than UPPP, although scores remain 
above the threshold of AHI<5 (Blumen et al., 2009; Boyd et al., 2012). MMA in conjunction 
with UPPP may alleviate OSA symptoms, however patients of one study reported post-
operative complications such as difficulty swallowing and numbness of the lower lip for two 
years post-procedure (Liu et al., 2012). 
 
Surgery is an invasive procedure for which some patients may not be suitable candidates, or 
may be reluctant to undergo due to associated health risks. In obese patients with OSA there 
is a risk of perioperative morbidity associated with surgery (Gali et al., 2009). There is a 
significant risk associated with extubation after general anaesthesia which may result in 
oedema and collapse of the soft tissue or damage to the uvula, as well as risks associated 
with pharyngeal tone and arousal responses, which may be diminished after use of 
anaesthesia (Cavallone and Vannucci, 2013; Kaw et al., 2006).  
 
1.3.8.3 Pharmacotherapy 
Even with CPAP use, some sufferers may continue to experience daytime sleepiness. Whilst 
there is no effective drug treatment currently available for the treatment of OSA, drugs are 
available to reduce symptoms of daytime sleepiness with concurrent CPAP use. Madofinil, a 
wakefulness promoting drug has been approved by the U.S. Federal Drug Administration 
(FDA) for the treatment of narcolepsy, and has also been used to relieve residual daytime 
sleepiness in patients using CPAP (Darwish et al., 2010; Weaver et al., 2009). Armodafinil is 
the R-isomer of racemic Madofinil, and has a longer half-life. Both drugs have been used for 
the treatment of CPAP-treated OSA, however symptoms of increased blood pressure and 
chest pains have been noted for both medications (Black et al., 2010; Darwish et al., 2010). 
 
1.3.9 Treatment of OSA in children and the elderly 
OSA in children is usually caused by enlarged tonsils which obstruct the airway and may 
cause the airway to collapse during sleep. The resulting symptoms are similar to those seen 
in adults, with neurocognitive and behavioural dysfunction predominating, and may include 
failure to thrive (Friedman and Goldman, 2011). Surgical removal of the tonsils and adenoids 
is used in the treatment approach; however 20% of children who undergo 
adenotonsillectomy suffer residual OSA after surgery. It is also possible that tonsils may 
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regrow after surgical removal, thus anti-inflammatory treatment or the use of steroids 
delivered orally or intranasally, may be a better option to reduce adenotonsillar size and 
relieve the symptoms of OSA in children (Friedman and Goldman, 2011). 
 
OSA in the elderly (beyond age 60) may show signs of involuntary urination, nocturia, 
ophthalmic conditions and recurring falls due to disturbances in neurocognitive function. 
CPAP is the treatment of choice in the elderly (Launois et al., 2007).  
 
1.4 Complex sleep apnoea 
Complex sleep apnoea (CompSA) is described as the presence of apnoea-hypopnoea 
events in OSA patients, even once a patent airway is restored with CPAP treatment. Patients 
usually present as having OSA, however treatment with CPAP may not resolve SDB. The 
persistent events are central, rather than obstructive and are due to highly sensitive 
chemoresponses leading to unstable ventilatory control, as in the case of CSA (Kuzniar and 
Morgenthaler, 2008). Symptoms may improve over time with CPAP use; however the 
mechanism for this remains unclear. There are conflicting reports on the success of CPAP 
treatment in CompSA with some cases reporting no change or worsening of symptoms with 
CPAP use, therefore other methods of treatment are generally recommended (Gilmartin et 
al., 2005). Adaptive servo-ventilation (ASV) used in the treatment of CSA, and non-invasive 
positive pressure ventilation (NPPV) treatments have been shown to improve nocturnal 
breathing in CompSA patients with Cheyne-Stokes respiration, with ASV being a promising 
first candidate for treatment of CompSA (Allam et al., 2007; Morgenthaler et al., 2007; Ramar 
et al., 2012; Willson et al., 2001).  
 
1.4.1 Costs associated with diagnosis and treatment 
Costs associated with PSG for the diagnosis of OSA have increased over time in Australia. 
From 1995 – 2004, the Australian Medicare system has reimbursed patients AUD$162.8 
million for 417,533 PSG, with the annual cost of PSG increasing from AUD$9.2 million in 
1995 to AUD$26.7 million in 2004, and the demand for PSG per 100,000 between 1995 and 
2004 rising 150% above population growth (Marshall et al., 2007). Despite the increase in 
cost of PSG over time, it only accounted for 0.29% of the total Medicare budget in 2004, and 
it remains the gold standard diagnostic test for SA today. 
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The costs to the Australian government associated with surgery between 1995 and 2007 was 
AUD$8.2 million for almost 20,000 UPPP procedures, and AUD$1.1 million on just over 3000 
LAUP (laser-assisted) (Marshall et al., 2010). 
 
With the increasing costs to the public health system and the rising trend of OSA associated 
within the population and subsequent increase in cases of OSA, a more widely accepted and 
cost-effective treatment option is required.  
 
1.5 Proposal of a novel therapeutic for OSA 
Currently available treatment options for OSA have poor compliance rates due to significant 
impact on lifestyle or comfort, in the case of CPAP and oral devices, or increased risks 
associated with side effects in the case of surgery and pharmacotherapy. In obese patients, 
weight loss may improve SA symptoms, however not all patients are able to achieve 
significant weight loss in order to reverse symptoms of OSA. It is clear from the evidence 
presented, that a novel therapeutic approach to the treatment of OSA that is likely to be 
accepted by sufferers, has minimal impact on lifestyle and comfort, and is cost effective to 
patients and the government, is required.  
 
The underlying cause of OSA is the loss of muscle tone in the upper airway. A rational 
approach to correcting this problem is to increase the tone of these muscles, thus opening 
the airway and allowing the un-obstructed passage of air during nocturnal breathing. This is 
the rationale behind surgery, however due to the invasive nature of the procedure and the 
difficulties of performing it on obese individuals, a less invasive procedure that will be more 
widely accepted and elicit the same results, is necessary. A novel approach to the treatment 
of OSA to increase muscle tone in the upper airway involves the targeted delivery of bacterial 
toxins which cause muscle contraction.  
 
An agent known to increase muscle tone is tetanus neurotoxin (TeNT). This neurotoxin, 
formed in nature by the bacterium Clostridium tetani, acts to inhibit muscle relaxation, 
effectively paralysing the muscle in a rigid state. This event is termed tetany. Controlled 
administration of tetanus toxin to induce localised tetany in the area of the upper airway is a 
feasible approach to the treatment of OSA. Targeted delivery of the toxin in appropriate 
doses may increase muscle tone in the immediate area of administration without causing any 
adverse or widespread reaction to the individual. In the section to follow, the current use of 
tetanus toxin and the related botulinum type A neurotoxin (BoNT/A) will be discussed, and 
their potential to treat the cause and symptoms of OSA will be explored.  
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1.5.1 Genus Clostridium 
Clostridia are gram positive, spore-forming, obligate anaerobic bacilli found widespread in 
the environment, and are responsible for causing significant infection in humans and 
animals. Clostridia have played a significant role in both human and animal infections with 
some members of the genus responsible for colitis in humans (C. difficile), food poisoning in 
humans and necrotic enteritis in poultry (C. perfringens), wound infections in humans  
(C. sordellii) and gas gangrene (C. novyi, C. septicum and C. perfringens). In all cases, 
organisms cause disease through the production of toxins. Two species of great interest to 
the scientific community are Clostridium tetani and Clostridium botulinum, the toxins of which 
cause tetanus and botulism, respectively. These organisms are able to survive harsh 
environments by laying in a dormant state within spores which are resistant to extreme 
conditions. Due to their broad distribution, it is not uncommon for these organisms to 
contaminate foods and enter the body through abrasions and wounds. Once a spore enters 
the body, the host conditions allow the spores to germinate and produce live vegetative cells 
which are then free to produce toxin. The group of toxins produced by these bacteria are 
known as the family of Clostridial neurotoxins (CNTs) (Hatheway, 1990).  
 
1.5.2 Disease caused by C. tetani and C. botulinum 
1.5.2.1 Tetanus caused by C. tetani 
Tetanus was first reported by the Greeks more than 20 centuries ago and was initially 
thought to be a condition of the nervous system. In 1891, the bacterium was isolated, 
characterised and named Clostridium tetani, from the Greek word tetanos, meaning 
“contraction” (Kitasato, 1891). The bacterium itself is predominantly found in soil and is 
widespread in the environment and the intestines of mammals. Spore formation allows  
C. tetani to survive harsh environmental conditions such as dry heat and high moisture, and 
also gives C. tetani cells their drumstick appearance. Disease occurs when the spores enter 
a wound, gaining entry from an infected article, most commonly a rusty nail, or through 
contact with soil or manure. Spores may also gain entry through burns, ulcers, fractures, 
operative wounds or during intravenous drug use. The low oxygen environment of a wound 
promotes the germination of the spores to form active bacterial cells which then produce a 
toxin called tetanospasmin, producing the effects of tetanus. The toxin may lay dormant for a 
period of a few days to weeks after exposure and generally, the shorter the incubation 
period, the more severe disease which results (Hatheway, 1990).  
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A lesion formed in the infected area usually goes unnoticed, as the wound from which the 
spores gained entry is usually still evident, with the first symptoms being sporadic 
contractions of the muscles surrounding the wound site. The toxin then travels in a 
retrograde fashion from the axon terminals to the CNS, where it acts on nerves to 
continuously activate the contraction of muscles. Disease progression is demonstrated by 
spasms in facial and neck muscles, leading to trismus or lockjaw, where the muscles of the 
jaw become rigid due to the constant firing of nerve impulses which contract the muscles. 
Eventually, these muscle spasms spread down the torso and then very quickly throughout 
the body, giving way to generalised tetanus. If left untreated, death results from the paralysis 
of the muscles required for breathing (Hatheway, 1990).  
 
Neonatal tetanus mainly occurs from infection of the umbilical stump and usually occurs in 
third world countries where an infected instrument is used to cut the umbilical cord, or 
infected material is used to cover the stump (Hatheway, 1990). Initially, neonates are able to 
feed and cry normally in the first few days after birth, but then lose these abilities after a few 
days, and become rigid and suffer from spasms (WHO, 2006).  
 
1.5.2.2 Botulism caused by C. botulinum 
Botulism has been documented since the 18th century and was first referred to as “sausage 
poisoning”. In 1882 Justinus Kerner published the first correctly documented cases of 
foodborne botulism with associated neurological symptoms (Hatheway, 1990), however, it 
wasn’t until 1949 when Burgen and colleagues discovered that BoNT blocked 
neurotransmitter release (Burgen et al., 1949).  
 
There are various ways in which an individual may develop botulism. Disease may occur 
from infection with preformed toxin, or infection with the organism itself which produces toxin 
after growing in the gastrointestinal tract or a wound. In all cases of botulism, the toxin travels 
from the small intestine to the circulation via the lymphatic system, where it can then act 
locally on the peripheral nervous system to inhibit the neuronal signals that activate muscles. 
A flaccid muscular paralysis results within 24 h of toxin entry, with paralysis initiating at the 
head and descending symmetrically, affecting the muscles involved in breathing. Flaccid 
paralysis caused by BoNTs occurs by blocking the release of synaptic vesicles containing 
acetylcholine from motorneurons. 
 
Foodborne botulism is the most common form of botulism and occurs by the ingestion of 
food containing either preformed toxin, or the organism which then produces toxin in the gut, 
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with symptoms including nausea and vomiting (Hatheway, 1990). Foodborne botulism is 
most commonly contracted from home-preserved vegetables or fish which have been 
inadequately prepared, with the food rarely appearing spoiled (Davletov et al., 2005; 
Hatheway, 1990). The cooking process kills vegetative cells, however botulinal spores which 
are resistant to high temperatures survive the cooking process, and germinate if kept at the 
optimal temperature (Hatheway, 1990).  
 
Foodborne botulism occurs via toxin entry through the gut, and in order to avoid degradation 
within the acidic environment of the stomach, BoNTs are produced along with a complex of 
proteins which protect the toxin from the harsh environment. When present in a high dose, 
ingestion of pure toxin is able to cause disease, however most frequently the toxin is 
ingested as a progenitor toxin complex (Maksymowych et al., 1999). The toxin complex 
consists of the BoNT toxin, haemagglutinin (HA) proteins and non-toxic non-haemagglutinin 
(NTNH) proteins which are non-covalently associated with the toxin. These proteins ensure 
that BoNT is not degraded by the acidic environment of the stomach, which would otherwise 
degrade the toxin after direct ingestion from food or after toxin production within the gut 
(Hatheway, 1990; Simpson, 2004). For certain strains of C. botulinum, however, the toxin is 
released in its single-chain inactive form and the proteases present in the stomach convert it 
into the active di-chain form (Simpson, 2004).  
 
Wound botulism although rare, may occur in intravenous drug users or after bone fracture 
when the organism gains entry to a wound and produces toxin. The resulting disease is the 
same as foodborne botulism and the method of intoxication of the wound is similar to that 
observed for C. tetani (Hatheway, 1990; Schiavo et al., 2000).  
 
Inhalational botulism results from the aerosolisation of BoNT and is a risk to workers 
handling the toxin and as an agent of bioterrorism (Simpson, 2004). Both the progenitor toxin 
complex and pure BoNT are able to bind to airway epithelial cells and cross into the 
circulation via transcytosis to cause disease (Park and Simpson, 2003). Although the toxin is 
unstable in aerosols, there have been attempts to use BoNT as a bioweapon in Japan in the 
early 1990’s (Arnon et al., 2001), and in Iraq during the Gulf War (Patocka et al., 2005).  
 
Infant botulism occurs after the ingestion of spores. In adults, even if spores are ingested and 
are able to germinate, it is difficult for C. botulinum to compete for an adequate niche and 
colonise the gastrointestinal tract. In infants <1 year of age however, where the gut flora has 
not yet been established, C. botulinum may colonise the intestinal tract. Toxin produced in 
the gut is then absorbed into the bloodstream and causes botulism. Initial signs of infant 
botulism are infrequent bowel movements and constipation, followed by loss of head control, 
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lethargy, difficulty swallowing and feeding, and an altered cry. Most commonly, botulinal 
spores are ingested from honey, thus it is advised that honey should not be fed to children 
younger than 1 year of age (Hatheway, 1990; Simpson, 2004).  
 
1.6 Diagnosis and treatment 
1.6.1 Tetanus 
Due to the unique nature of clinical symptoms of tetanus, diagnosis of tetanus is usually 
based purely on observation. The presence of C. tetani may be confirmed by isolation of the 
organism from the wound, however this is usually not required as it takes 48 h for initial 
growth to be seen in culture and most standard biochemical tests are negative (Hatheway, 
1990).  
 
Initial treatment of tetanus is immunotherapy with human tetanus immunoglobulin which 
neutralises the tetanospasmin toxin. If the vaccination status for the individual is unknown or 
incomplete, patients are treated as non-immune and are given the tetanus vaccine 
immediately (Miyagi and Shah, 2011). A 114 kDa collagenase (ColT) protease is expressed 
by C. tetani along with TeNT and catalyses the cleavage of collagen to aid in tissue damage 
during infection (Bruggemann and Gottschalk, 2004). Surgical debridement may therefore be 
required to remove infected tissue in an attempt to limit the spread of infection (Trujillo et al., 
1987). Muscle relaxants and sedatives may also be used in the treatment of tetanus, and 
antibiotic therapy may be used to limit further progression of disease. Without hospitalisation 
to manage the symptoms of disease, mortality from tetanus is usually 100% (WHO, 2006).  
 
1.6.2 Botulism  
Culture methods are rarely used today due to time limitations, with C. botulinum requiring 5 
days growth under strict anaerobic conditions. Botulism can be diagnosed by the detection of 
toxin from the faces, serum, gastric contents or by the isolation of C. botulinum bacteria from 
the faeces or wound (Hatheway, 1990). The standard method of detection of BoNT in food 
was once the mouse bioassay, with diluted samples injected into mice to observe symptoms 
of disease. However, in an attempt to move away from in vivo diagnosis, in vitro assays have 
been developed for toxin detection (Stanker et al., 2008). Neutralisation bioassays employing 
ELISA are generally not as sensitive as the mouse bioassay, but may be ideal for same-day 
screening of samples (Kegel et al., 2007; Stanker et al., 2008). PCR methods may be used, 
however sample enrichment is usually required prior to performing PCR (Dahlenborg et al., 
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2001; Lindstrom et al., 2001). In cases where in vivo assays are required to observe 
systemic effects and/or for high sensitivity, assays involving animals may be required. Such 
assays may be lethal (observation of systemic paralysis), or non-lethal (local paralysis), with 
the former being the most sensitive (Lindstrom and Korkeala, 2006).  
 
Treatment of botulinum poisoning can be performed before or after exposure, by targeting 
any one of the three key steps involved in intoxication (Swaminathan, 2011). Despite its 
therapeutic benefits, botulinum toxins are still considered potential biological warfare agents, 
thus treatment options remain an important area of research. 
 
1.6.2.1 Antitoxin treatment of botulism 
Botulism is still considered a candidate for bioterrorism, thus appropriate measures for 
treatment are required (Middlebrook, 2005). A heptavalent antitoxin produced by the CDC in 
the U.S.A. contains equine-derived, neutralising monoclonal antibodies against all seven 
types of botulinum toxins (BoNT/A – /G). This antitoxin therapy has recently replaced the 
bivalent AB antitoxin and monovalent BoNT/E antitoxin (Mayers et al., 2001). Horses are 
used for the production of antitoxin antibodies as they are able to produce a large volume of 
blood in a short amount of time (Mayers et al., 2001). The efficacy of antitoxin production is 
limited by the risks associated with the use of heterologous preparations. Heterologous 
immunoglobulins, which are recognised as foreign by the human immune system may cause 
undesirable side effects such as serum sickness, which may lead to anaphylaxis. However, 
antitoxin therapy shortens the time of illness and reduces the risk of mortality from botulism 
and is thus still a standard method of treatment (Mayers et al., 2001).  
 
Treatment for infant botulism continues to use a human-derived bivalent antitoxin, BabyBIG 
(botulism immunoglobulin), for disease caused by BoNT/A and /B (CDC, 2010; Chalk et al., 
2011).  
 
1.6.2.2 Peptide inhibitors 
There is no pharmacotherapy currently available for the prevention or treatment of botulism, 
but attempts have been made to create peptide inhibitors of BoNT/A to inhibit the activity of 
the light chain (LC) which is responsible for the paralytic effects seen in botulism (Li, B. et al., 
2011; Silvaggi et al., 2008). Phage display has been used for the in vivo screening of peptide 
inhibitors against BoNT (Zdanovsky et al., 2001), as well as in vitro mRNA display, which 
identified peptide inhibitors that could inhibit the activity of the LC at a much lower 
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concentration than those identified by the former method (Yiadom et al., 2005). Peptide 
inhibitors which are able to inactivate circulating BoNT/A after poisoning may replace 
heterologous antitoxin therapy as the standard method of treatment for botulism.   
 
1.6.2.3 Neutralising antibodies 
The identification of neutralising antibodies is an important step in the development of 
monoclonal antibody/antitoxin treatment against BoNTs, and may also be useful for vaccine 
development. Phage display comparing human immune and non-immune sera (Amersdorfer 
et al., 2002), and a yeast display library (Levy et al., 2007), have been used to identify 
previously unknown neutralising epitopes of BoNT/A. These epitopes may be used in the 
development of human antibodies to replace the equine-derived antibodies currently used in 
the treatment of BoNT/A infection (Mayers et al., 2001).  
 
1.7 Prevention 
Clostridia typically have a high AT content which can impact expression of genes in a 
heterologous host, and so native toxin is used in the preparation of toxoid vaccines 
(Hatheway, 1990). Such methods pose a health risk to workers involved in preparing these 
vaccines, thus new strategies for vaccination against CNTs are under investigation. Although 
tetanus and botulinum toxins have therapeutic potential, vaccines are still required as they 
continue to be a cause of life-threatening disease. 
 
1.7.1 Tetanus toxoid vaccine 
Tetanus is successfully controlled through administration of a tetanus toxoid vaccine which 
induces humoral immunity. Formaldehyde treatment of the native toxin renders it non-toxic, 
however the conformation of the TeNT holotoxin remains intact, preserving its 
immunogenicity (Behrensdorf-Nicol et al., 2008). Three doses of tetanus toxoid are required 
to achieve protective levels of circulating antibodies in adults, and five doses are 
recommended for children, with a booster injection required every 10 years in order to 
maintain adequate levels of antitoxin antibodies (WHO, 2006). In immunised females, 
maternal antibodies to tetanus toxin are transmitted to the foetus via the placenta, preventing 
neonatal tetanus. In third world countries where immunisation rates are low, neonatal tetanus 
is still quite prevalent, with the World Health Organization (WHO) estimating 180,000 
neonatal deaths from tetanus in 2002 (WHO, 2006). The minimum amount of circulating 
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antitoxin antibodies required to maintain immunity to tetanus is 0.01 IU/mL, and is 
determined by ELISA, however, cases of tetanus in individuals with antibody titres above this 
threshold have been reported (Crone and Reder, 1992; Livorsi et al., 2010).  
 
The production of tetanus toxoid from native toxin poses a significant risk to workers due to 
the possibility of residual tetanus toxin activity after inactivation with formaldehyde 
(Behrensdorf-Nicol et al., 2008). Due to the dangerous nature of this method of vaccine 
preparation, novel methods to develop tetanus vaccines are being investigated. The C-
terminal 451 amino acid fragment of tetanus toxin (HC), termed fragment-C, is involved in the 
initial binding step of the toxin to its target cell (Francis, 2000). This domain is the most 
immunogenic region of the toxin, and can be prepared by recombinant methods in a 
heterologous host (Qazi et al., 2006). Such methods pose minimal risks to workers, thus 
fragment-C is a promising candidate for a novel, safer tetanus vaccine. Although fragment-C 
has been shown to induce protective levels of antibodies to tetanus neurotoxin, it did not 
produce antitoxin antibodies equivalent to the tetanus toxoid vaccine (Qazi et al., 2006). 
Attempts at vaccine production involving fragment-C have been made with this domain 
delivered alone (Qazi et al., 2006), or as part of a fusion molecule for the co-delivery of 
another immunoprotective peptide (Boucher et al., 1994). It has also been assessed as part 
of a DNA vaccine (Anderson et al., 1996), as an oral vaccine with fragment-C delivered in an 
attenuated Salmonella enterica (Terry et al., 2005), and as a nasal or epicutaneous vaccine 
with fragment-C delivered by an adenovirus vector (Shi et al., 2001). Efforts are ongoing, 
however tetanus toxoid prepared by formaldehyde treatment of native tetanus toxin is still the 
vaccine given today.  
 
1.7.2 Botulinum vaccines 
Aside from the threat of bioterrorism, botulism occurs rarely; therefore it is unnecessary to 
vaccinate entire populations against the disease. BoNT types A and B have cosmetic 
applications and are also used in the treatment of neuromuscular disorders, adding to the 
reasons it is impractical to vaccinate against C. botulinum.  
 
Two vaccines against botulism are licensed for use, a pentavalent vaccine which protects 
against BoNT/A – /E, which is no longer available from the Centres for Disease Control 
(CDC), due to issues with protective levels across all serotypes being maintained equally, 
and local reactions to booster injections (CDC, 2011; Henkel et al., 2011); and a heptavalent 
vaccine protecting against BoNT/A – /G, both of which are produced by chemically 
inactivated BoNT purified from C. botulinum. These vaccines are reserved for workers at risk 
of occupational exposure such as those who handle pure toxin during research or antitoxin 
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production, and military personnel who may be at risk of biological warfare (Keller, 2008; 
Patocka et al., 2005; Smith, T. J. et al., 2005).  
 
Due to the complex nature of toxoid vaccine preparation, alternative approaches to vaccine 
production against botulism have been investigated. A recombinant heptavalent subunit 
vaccine has been produced which comprises fragment-C (HC) from the seven BoNT 
serotypes (Baldwin et al., 2008), due to the highly immunogenic nature of this domain. A 
vaccine using fragment-C of BoNT/A (Clayton et al., 1995; Villaflores et al., 2013), and a 
trivalent vaccine encompassing fragment-C of BoNT/A, /B and /E has been shown to induce 
effective levels of antitoxin immunity in mice trials (Zichel et al., 2010), however, another 
study has shown that immunisation with a vaccine targeting one subtype of BoNT/A does not 
necessarily protect against other BoNT/A subtypes (Henkel et al., 2011). Sequence 
variability present within subtypes of the seven BoNT serotypes makes it difficult to create a 
vaccine using inactivated native toxin (Smith, T. J. et al., 2005). Thus, studies are underway 
to create a botulinum toxoid by targeted mutagenesis using recombinantly expressed BoNT 
sequences, thus negating the need to isolate BoNT from its native reservoir (Agarwal et al., 
2005). There is evidence to suggest that BoNTs can enter the circulation via inhalation, 
indicating that BoNT HC may also be a candidate for an inhalation vaccine (Park and 
Simpson, 2003).  
 
1.8 Clostridial family of neurotoxins 
The Clostridial neurotoxin family is comprised of eight immunologically distinct neurotoxins, 
tetanus neurotoxin (TeNT) produced by C. tetani, and seven botulinum neurotoxins (BoNTs), 
designated types A – G, produced by C. botulinum, which are the most potent toxins known 
to man. Botulinum toxin types E and F are also produced by Clostridium butyricum and 
Clostridium barattii, respectively, and Clostridium argentinense was previously known as  
C. botulinum type G (Ghanem et al., 1991; Hatheway, 1990). However, it is the toxins of  
C. botulinum which cause significant disease in humans and animals. The LD50 in humans is 
1 ng/kg body weight for BoNT and 2.5 ng/kg for TeNT, and the LD50 in mice is 0.5 ng/kg for 
BoNT and 1 ng/kg for TeNT (Gill, D. M., 1982). The toxins of C. tetani and C. botulinum are 
the causative agents of the diseases tetanus and botulism, respectively.  
 
CNTs interfere with the movement of skeletal and smooth muscle by interfering with the 
secretion of vesicles containing neurotransmitters at the neuromuscular junction (NMJ). All 
CNTs poison nerve terminals and have a similar mode of action; however TeNT and BoNT 
illicit opposing effects as their intracellular activity take place in different parts of the nervous 
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system. Tetanus is defined as spastic paralysis and occurs as a result of TeNT-mediated 
blockade of the release of inhibitory neurotransmitters from inhibitory interneurons in the 
CNS. Without a signal released from inhibitory interneurons to cease muscle contraction, 
skeletal muscle is continuously activated, resulting in spastic paralysis. Botulism has the 
opposite effect by inhibiting the release of the neurotransmitter acetylcholine (ACh) which is 
released from the NMJ of motorneurons in the peripheral nervous system to activate skeletal 
muscle. With the release of ACh blocked, the motorneuron is unable to activate the muscle 
and flaccid paralysis results (Rossetto et al., 2001).  
 
1.8.1 Toxin types 
The seven serologically distinct BoNT toxin serotypes are found in various reservoirs. 
BoNT/A, /B, /E and /F have been found in human outbreaks of botulism, whilst BoNT/C is 
found in birds such as ducks and poultry. Humans lack the neuronal receptor to which 
BoNT/D bind, rendering it ineffective in humans, but it can be found in cattle. BoNT/G is 
found in soil, but has also been linked to infection in humans (Davletov et al., 2005). 
Interestingly, rats and chickens are resistant to TeNT intoxication due to a single amino acid 
substitution at the TeNT cleavage site within the target substrate VAMP-2 (Kegel et al., 
2007). The following section will explore the genetic characteristics of TeNT and BoNT/A. 
 
1.8.1.1 Tetanus neurotoxin  
A single serotype of tetanus toxin occurs and it is able to infect both humans and animals in 
a similar manner (Driemeier et al., 2007; Langner et al., 2011). The gene for tetanospasmin 
(tetX) is situated on a 75 kb extra-chromosomal plasmid within C. tetani, designated pE88 
(Eisel et al., 1986; Finn et al., 1984), and non-toxigenic strains which lack this plasmid also 
exist in nature (Hatheway, 1990). The plasmid containing tetX has a 75.5% AT content and a 
high gene density, with 61 coding regions making up 67.1% of the plasmid (Bruggemann and 
Gottschalk, 2004).  
 
The tetX gene has an AT content of 72.1% and encodes a 1315 amino acid protein with a 
molecular weight of 150.7 kDa, which has sequence similarity to BoNT/A, /B and /E (Eisel et 
al., 1986), with both TeNT and BoNT/A translated from monocistronic mRNA (Binz et al., 
1990; Eisel et al., 1986). Toxin synthesis is regulated by the tetR gene which acts as an 
alternative RNA polymerase sigma factor. The TetR protein has a 67% similarity to the 
corresponding BotR/A protein expressed by BoNT/A (Bruggemann and Gottschalk, 2004; 
Couesnon et al., 2006). The TeNT toxin is produced as a single-chain protein after which the 
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N-terminal methionine is removed, converting the toxin to its mature form. The toxin is then 
released from the bacterium following cell lysis, however, there is no evidence of a signal 
peptide involved in the secretion of the toxin from the cell (Eisel et al., 1986). Upon release of 
the single-chain mature protein from the bacterial cell, the toxin is proteolytically nicked which 
converts the protein to its active di-chain form. The active holotoxin is a 151 kDa di-chain 
protein consisting of a 52.2 kDa LC comprising residues P2 – K446, linked by a disulfide 
bridge to the 98.3 kDa heavy chain (HC), residues S458 – D1315 (DiMari et al., 1982; Eisel 
et al., 1986; Krieglstein et al., 1990). The conversion of the single-chain protein to the di-
chain form is required for TeNT intoxication of neuronal cells.  
 
1.8.1.2 Botulinum neurotoxins 
Botulinum neurotoxins are chromosomally expressed and the botA gene encodes a 1,296 
amino acid single-chain BoNT/A protein. BoNT/A has a molecular weight of 149.4 kDa and 
displays an overall 33.8% sequence similarity to TeNT, with the translocation domain HN 
having a similarity of 47.9% (Binz et al., 1990). Like TeNT, mature BoNTs consist of an N-
terminal 50 kDa LC, residues P2 – K488, linked by a disulfide bridge to a C-terminal 100 kDa 
HC, residues A499 – L1296. BoNTs are also proteolytically nicked to create the active di-
chain form. Nicking occurs as a result of endogenous or exogenous proteases, depending on 
whether they are produced by proteolytic or non-proteolytic strains, respectively (Gordon and 
Leppla, 1994).  
 
Unlike TeNT which is produced as a pure toxin, BoNTs are expressed along with a complex 
of proteins which aid in the intoxication process. BoNTs entering the body through the gut 
are able to survive the harsh environment of the stomach due to the presence of non-toxic 
proteins including non-toxic non-haemagglutinin (NTNH/A), and haemagglutinin (HA) 
proteins, which are expressed simultaneously with BoNT/A to form complexes ranging from 
300 – 900 kDa (Couesnon et al., 2006). Together, these proteins form the progenitor BoNT/A 
toxin. These additional proteins remain non-covalently associated with BoNT and do not play 
a role in BoNT toxicity, but protect the toxins from the low pH environment and proteolytic 
enzymes present within the stomach until the toxin crosses the epithelial layer of the gut and 
enters the circulation (Hatheway, 1990; Kukreja and Singh, 2007; Maksymowych and 
Simpson, 1998).  
 
BoNT nomenclature is based on the order of discovery and does not reflect the duration of 
action of each of the BoNTs. BoNT/A is the longest acting toxin, with a duration of action of 
approximately 6 months in humans, followed by BoNT/C, /B, /F and /E (Davletov et al., 
2005). Various subtypes of BoNT/A exist, with BoNT/A1 being the subtype used in the 
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production of anti-toxin therapy. The various subtypes show differences in amino acid 
sequence, with the greatest variability seen in regions of the LC domain required for 
substrate recognition (Arndt et al., 2006b). Sequence variation between toxin types and 
within subtypes results in little cross-reactivity in monoclonal antibody binding and 
neutralisation, which has significant implications on the development of diagnostics, anti-
toxin therapy and vaccine production (Smith, T. J. et al., 2005).  
 
1.8.2 Toxin structure 
All CNTs undergo three post-translational modifications after expression as a single-chain 
polypeptide, to produce the active di-chain molecule. First, the N-terminal methionine residue 
is removed, then specific cysteine residues interact to form disulfide linkages, and finally 
proteolytic nicking of the molecule by endogenous (or exogenous) proteases converts the 
single-chain peptide into the active di-chain form (Helting et al., 1979; Krieglstein et al., 
1990). Nicking of CNTs to their activate di-chain form may also be performed by treatment 
with trypsin (Bergey et al., 1989; Dekleva and DasGupta, 1989). Cleavage of BoNT/A by 
endogenous or exogenous proteases, or by trypsin to create the active di-chain molecule, 
occurs at Lys439 and Lys449, thus removing a 10 amino acid linker sequence from the 
mature protein (DasGupta and Dekleva, 1990; Jensen et al., 2003), whilst cleavage of TeNT 
by endogenous and exogenous proteases occurs within residues 445 – 461 (Krieglstein et 
al., 1990). Treatment of the holotoxin with papain liberates fragment-C, which consists of the 
C-terminal binding domain of the heavy chain (HC). This fragment is used to investigate the 
binding, internalisation and trafficking of CNTs (Fairweather et al., 1986; Halpern et al., 
1990).  
 
CNTs share significant secondary structure homology, which is a function of their high 
sequence similarity (Lebeda and Olson, 1994). The ~150 kDa holotoxin consists of a 50 kDa 
LC and a 100 kDa HC, connected by a disulfide bond to give a classical A – B toxin type 
structure. All eight CNTs have a similar overall function and cleave soluble N-ethylmaleimide-
sensitive factor (NSF) attachment protein receptor (SNARE) proteins at presynaptic nerve 
terminals, however they target different substrates at different the peptide bonds and elicit 
paralysis of varying durations.  
 
BoNTs target vesicle fusion machinery at the neuromuscular junction of neurons in the 
peripheral nervous system, while TeNT blocks the release of inhibitory neurotransmitters 
from inhibitory interneurons in the CNS. Although they act on different parts of the nervous  
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system and illicit opposing effects, all CNTs share a similar intracellular function which is 
attributed to the conserved structure amongst the proteins (Figure 1.4).  
 
The LC is the catalytic portion of the toxin and acts as a zinc metalloprotease, with a zinc 
binding motif HexxH + E forming the active site of the LC (Simpson et al., 1993). The zinc 
atom plays a catalytic role and is essential for the inhibition of neurotransmitter release 
(Schiavo et al., 1992a; Schiavo et al., 1992b). The zinc ion is organised around residues 
His222, His226, Glu261 and a water-coordinated molecule through the first Glu in the zinc-
binding motif (Glu223) (Lacy et al., 1998), the arrangement of which is consistent with zinc 
proteins (Coleman, 1992). 
 
The heavy chain is divided into the 50 kDa N-terminal (HN) domain, involved in translocating 
the LC into the cellular cytosol, and the 50 kDa C-terminal (HC) domain, which contains 
residues involved in receptor binding. The C-terminal portion of the heavy chain (HC), can be 
further divided into an N-terminal (HCN) domain displaying a lectin-like jelly roll, and C-
terminal (HCC) domain, with a β-trefoil region (Emsley et al., 2000). The HCC domain contains 
residues critical for receptor binding, however the function of the HCN domain remains unclear 
(Swaminathan, 2011).  
 
The LC domains of CNTs share a high amino acid sequence similarity with a 36.5% similarity 
amongst the 8 CNT types, and the highest similarity is seen between TeNT and BoNT/B 
which share 51.6% identity (Kurazono et al., 1992). These two CNTs cleave the same 
SNARE substrate, albeit at different peptide bonds (Chen, S. et al., 2008b). The crystal 
structures of BoNT/A (Lacy et al., 1998), and TeNT (Umland et al., 1997) have been 
determined and show structural similarities between the catalytic and binding domains of 
both CNTs. The TeNT LC has a similar overall secondary structure to the LC of BoNT/A, /B 
and /E (Breidenbach and Brunger, 2005a), and the HC domains of TeNT and BoNT/A 
contain an N-terminal β-barrel and a C-terminal β-trefoil domain linked by an alpha helix 
(Lacy and Stevens, 1999). Whilst BoNT/A and TeNT share a considerable degree of primary 
sequence similarity, the highest similarity observed for the heavy chain domain is seen within 
the HN translocation domain, whilst the HC binding domain of TeNT and BoNT/A show the 
least degree of similarity. This is consistent with this region being highly immunogenic 
amongst the eight serologically distinct CNTs. It is also expected that the HC region would 
show some degree of difference due to the unique binding and intracellular trafficking routes 
amongst CNTs, a function which is determined by this domain (Lacy and Stevens, 1999).  
 
There are 6 half-cysteine residues in sulfhydryl form, and two disulfide bonds forming an 
intrachain disulfide bond linking Cys869 with Cys1093 within the HC, and an interchain bond  
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Figure 1.4: General structure of CNT domains. Reproduced from Brunger and Rummel 
(2009). 
General structure of CNT domains in the active di-chain form (bottom), and the crystal 
structure of BoNT/B (top). 
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joining Cys439 of the LC with Cys467 of the HC of TeNT (Figure 1.5) (Krieglstein et al., 
1990). The corresponding residues forming the interchain disulphide bond in BoNT/A are 
Cys429 and Cys453 (Lacy et al., 1998). The position of the interchain disulfide bridge is  
conserved in all CNTs and is necessary for toxicity, however the remaining cysteines are not 
conserved amongst CNTs (Krieglstein et al., 1990; Qazi et al., 2007).  
 
Proximal to the HN domain of CNTs lies the “belt” region which is composed of ~50 amino 
acid residues encoded by the translocation domain, but is associated with the catalytic light 
chain domain in the tertiary structure (Swaminathan, 2011). The belt has been shown to 
encircle the active site of the LC and is connected by a disulfide bond and other non-covalent 
interactions (Li, L. and Singh, 2000; Swaminathan, 2011), with the active site buried about  
20 Å within the protein beneath the belt region in the unreduced holotoxin (Brunger et al., 
2007). Although not directly involved in the activities dictated by the HN domain such as 
translocation of the LC and pore-formation, the belt may occlude the active site and protect it 
from solvent until the LC is able to reach its catalytic substrate (Fischer et al., 2012). BoNT/A 
LC (LC/A) is most catalytically active in the absence of the belt (Gul et al., 2010; Lacy et al., 
1998), which is consistent with the hypothesis that the belt acts only as a chaperone, 
assisting in the translocation of the toxin from the endosome to the cytosol (Brunger et al., 
2007).  
 
In order for CNT toxins to poison neurons, they must be present in the active di-chain form, 
and toxins are rendered non-toxic after the separation of the light and heavy chains (Eisel et 
al., 1986). The section to follow will explore the mode of action of CNTs by looking at the 
function of the individual domains. 
 
1.8.3 Toxin mode of action 
The presynaptic terminals of motorneurons where CNTs enter neuronal cells, is located in 
the periphery, while the cell body is located in the CNS. Once the toxin has bound to 
membrane receptors on the surface of neurons, it is internalised into the motor neuron and 
TeNT is transported in a retrograde fashion along the axon and across the blood-brain 
barrier to the cell body. Following secretion, TeNT is taken up by adjacent inhibitory 
interneurons via trans-synaptic spread, while BoNTs remain at the NMJ of motorneurons in 
the periphery. CNTs then cleave one of the SNARE proteins involved in synaptic vesicle 
fusion (Caleo and Schiavo, 2009; Lalli and Schiavo, 2002).  
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Figure 1.5: Location of disulfide bonds in tetanus toxin. 
Graphical representation of the location of sulfhydryl residues and the interchain and 
intrachain disulfide bonds in the tetanus toxin sequence. Adapted from Qazi et al. (2007) and 
Krieglstein et al. (1990).  
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There are four main steps involved in CNT toxicity, binding, internalisation, translocation and 
cleavage (summarised in Figure 1.6). Both TeNT and BoNTs act on the presynaptic 
terminals of NMJs, but within different types of neurons. The key difference between TeNT 
and BoNTs is that TeNT undergoes retrograde axonal transport which transmits the toxin 
toward the CNS, whilst BoNTs travels in an anterograde direction to act on motorneurons in 
the peripheral nervous system. The different cellular trafficking of TeNT and BoNT explains 
the distinct target sites and therefore the different clinical symptoms of the two diseases. 
 
1.8.3.1 Binding to neuronal cells is mediated by the HC domain 
CNTs enter the circulatory system from a point of entry via transcytosis (Maksymowych and 
Simpson, 1998), and enter neurons via receptor-mediated endocytosis (BoNTs) (Simpson, 
2004), or a clathrin-dependent pathway (TeNT) (Deinhardt et al., 2006). The key to the 
differential trafficking of TeNT and BoNTs is attributed to the cell surface receptors initially 
bound on target neuronal cells. It is hypothesised that after initial binding to gangliosides, 
TeNT and BoNTs bind a secondary protein receptor which results in differential sorting of 
CNTs after internalisation (Montecucco, 1986).  
 
Cell binding is a function of the HC domain which targets CNTs specifically to neuronal cells 
(Lalli et al., 1999). A dual receptor model was hypothesised in 1986 to explain how (i) CNTs 
undergo differential trafficking, and (ii) bind preferentially to gangliosides present on neuronal 
cells, as they are found in high concentrations on cells throughout the nervous system and 
within the spleen (Montecucco, 1986; Sinha et al., 2000). It is thought that gangliosides act 
as low affinity binding receptors and their presence in high concentrations accumulates 
CNTs on the surface of neurons, allowing them to then bind to a secondary high affinity low-
density protein receptor (Swaminathan, 2011). The hypothesis that the secondary receptor is 
a protein was confirmed when binding of TeNT to rat brain membranes was decreased 
following pre-treatment with proteases (Lazarovici and Yavin, 1986; Yavin and Nathan, 
1986). It is proposed that since TeNT and BoNTs bind to gangliosides, it is this secondary 
protein receptor which determines the internal trafficking of CNTs (Rummel et al., 2003).  
 
In the case of TeNT, targeted mutation of the HC domain affected both binding to 
gangliosides and retrograde axonal transport. Mutations which did not affect ganglioside 
binding, still decreased binding of the HC to motorneurons and also inhibited retrograde 
transport, indicating that this region contained a separate receptor site which was essential to 
retrograde trafficking of TeNT (Sinha et al., 2000). There is also a lack of competition 
between TeNT and BoNTs with regard to binding, suggesting that they bind to different 
cellular receptors on the surface of neuronal cells (Habermann and Dreyer, 1986). 
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Figure 1.6: CNT mode of action. Reproduced from Turton et al. (2002). 
Mode of action of botulinum toxin. 1) Binding to neuronal cell via toxin-specific receptors. 2) 
Internalisation into an intracellular vesicle. 3) Translocation of toxin from the endosome to the 
cytosol. 4) Cleavage of toxin-specific SNARE proteins prevents SNARE complex formation 
and inhibits fusion of secretory vesicles with the synaptic membrane.  
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1.8.3.2 Gangliosides  
Gangliosides are a class of glycosphingolipids comprised of a sialic acid oligosaccharide, 
and are found predominantly in the membranes of neuronal cells. They contain a common 
core to which one to four sialic acids are bound, with these regions exposed to the 
extracellular space, while the nonpolar regions are embedded in the plasma membrane 
(Mocchetti, 2005). The various types of gangliosides are composed of different combinations 
of sugar residues such as glucose, galactose, fructose, N-acetylglucosamine and N-
acetylgalactosamine, linked to a ceramide base. The total number of sialic acid residues 
contained within the gangliosides is used to classify the different species as 
monosialogangliosides (GM), disialogangliosides (GD), trisialogangliosides (GT), and 
tetrasialogangliosides (GQ) (Mocchetti, 2005). The nomenclature is further classified based 
on the order of migration of the gangliosides via thin layer chromatography, indicated by the 
numbers 1, 2, 3, etc., and finally, gangliosides are assigned to the series “asialo-”, “a”, “b”, or 
“c” to indicate 0, 1, 2, or 3 sialic acid residues linked to the inner galactose unit 
(Svennerholm, 1964). TeNT and BoNT bind to the GD1b and GT1b series of gangliosides 
(Rummel et al., 2003; Rummel et al., 2004), with TeNT showing a preference for ganglioside 
GT1b (Winter et al., 1996). 
 
Two ganglioside molecules can bind simultaneously to TeNT HC, while BoNTs only bind a 
single ganglioside with low affinity (Chen, C. et al., 2009; Dong et al., 2006; Rummel et al., 
2004). TeNT HC contains two carbohydrate binding pockets which bind to gangliosides, a 
sialic acid binding pocket and a lactose binding pocket (Chen, C. et al., 2008a; Chen, C. et 
al., 2009; Fotinou et al., 2001). The sialic acid binding site is crucial for the binding of the HC 
to gangliosides and for neurotoxicity while the lactose binding site is highly conserved in 
TeNT, and all BoNTs (except BoNT/D), indicating that it is essential for the binding of HC to 
gangliosides (Rummel et al., 2003).  
 
The position of binding site 1 is common to both TeNT and BoNTs and contains a lactose-
binding site and a sialic acid binding site, respectively. The second binding site in TeNT is a 
sialic acid binding site; however the corresponding site in BoNTs does not bind any part of 
gangliosides. This site may instead interact with a protein receptor and also indicates that the 
sialic acid-binding site (site 2), in TeNT may also be involved in the selective trafficking of 
TeNT to the CNS (Jayaraman et al., 2005).  
 
Oligomerisation is demonstrated by TeNT as seen by cross-linking of HC molecules upon 
binding to gangliosides (Fotinou et al., 2001). This is a concentration-dependent process 
thought to be used to accumulate TeNT (specifically HC), in lipid rafts in order to increase the 
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concentration of the toxin and bring it in close proximity to the secondary protein receptor to 
which it binds prior to endocytosis (Qazi et al., 2007). TeNT HC has been observed to bind 
cell membranes in a punctuate manner, with binding corresponding to the concentration of 
toxin in microdomains called lipid rafts (Herreros et al., 2001; Lalli et al., 1999). The C-
terminal domain of the TeNT heavy chain can undergo retrograde axonal transport in the 
absence of the remainder of the molecule with the 34 C-terminal residues of the tetanus 
heavy chain (residues 1282 – 1315), and particularly the region surrounding His1293, having 
been found crucial for binding to gangliosides (Emsley et al., 2000; Shapiro et al., 1997).  
 
TeNT may interact with multiple carbohydrate binding sites (Bizzini et al., 1977; Emsley et 
al., 2000; Halpern and Loftus, 1993). As well as binding to gangliosides GD1b and GT1b on 
the neuronal membrane, TeNT also binds glycosylphosphatidylinositol (GPI)-anchored 
proteins (Deinhardt et al., 2006). GPI-anchored proteins and gangliosides are present on 
lipid rafts, along with cholesterol and other sphingolipids and concentrate TeNT molecules at 
the cell membrane, which is thought to enhance uptake of the toxin into neuronal cells 
(Francis et al., 2004a; Herreros et al., 2001). A 15 – 20 kDa N-glycosylated protein has been 
shown to be a GPI-anchored protein and proposed to specifically bind TeNT on the surface 
of spinal cord cells and motorneurons, acting as a co-receptor for TeNT binding to neurones 
(Herreros et al., 2000; Herreros et al., 2001). 
 
BoNTs bind gangliosides and synaptic vesicle protein SV2, an integral membrane protein 
found on synaptic and endocrine secretory vesicles (Dong et al., 2006; Mahrhold et al., 
2006). It is hypothesised that once BoNT/A enters a cell and deactivates the neuron by 
inhibiting synaptic vesicle release, there is a decrease in the amount of SV2 receptors 
exposed on the surface of the cell thereafter. This phenomenon allows for BoNT present in 
the circulation to then bind active cells which have yet to be poisoned and still have a greater 
amount of SV2 receptors on their surface (Dong et al., 2006).  
 
1.8.4 Internalisation into neuronal cells 
Following attachment to neuronal cells, BoNTs are internalised through the plasma 
membrane via receptor-mediated endocytosis (Simpson, 2004), while TeNT employs a 
clathrin-dependent pathway after toxin bound to receptors has sorted through lipid rafts 
(Deinhardt et al., 2006). TeNT travels to the CNS within round vesicles and tubular structures 
to avoid acidification which would otherwise lead to degradation of the toxin (Lalli and 
Schiavo, 2002), and internalisation is enhanced by neurotrophic factors (Roux et al., 2006).  
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Once CNTs have entered neuronal cells, the di-chain molecule is localised in an acidic 
endosomal compartment and requires translocation into the cytosol to perform its catalytic 
function.  
 
1.8.5 Translocation of the LC into the cytosol  
Following internalisation of CNTs in their di-chain form into endosomes, the acidic 
environment of the endosome causes a conformational change in the holotoxin which results 
in the separation of the LC from the HC and the translocation of the LC into the cytosol, 
where it is free to cleave its substrate (Matteoli et al., 1996). This process occurs much like 
diphtheria toxin which is transported to the cytosol from acidic vesicles (Sandvig and Olsnes, 
1980). Translocation of the LC from the endosome into the cytosolic compartment involves 
six steps, summarised below. 
 
(i) pH-induced conformational changes expose hydrophobic regions 
(ii) HN domain creates a channel to the cytosolic compartment 
(iii) LC is translocated through the pore and into the cytosol  
(iv) Reduction of disulfide bond which links the light and heavy chains 
(v) non-covalent linkages holding the heavy and light chain together dissociate 
(vi) the light chain refolds into its active form 
 
The pH within the endosome which is lowered by the action of a protein pump, induces 
changes in structural conformation of the holotoxin. The structure-altering effects of the low 
pH environment within the endosome are completely reversible, as shown by the 
maintenance of enzymatic activity of LC/A before and after exposure to low pH (Li, L. and 
Singh, 2000). Acidification of the LC by the early endosome occurs from pH 4.55 to  
pH 4.40 (Puhar et al., 2004). Concanamycin A, which inhibits the acidification of intracellular 
compartments has been shown to inhibit the activity of BoNT/A, indicating that exposure to 
low pH within the endosome is crucial for toxicity (Keller et al., 2004). 
 
The di-chain molecule is partially unfolded, exposing hydrophobic regions, and the mostly 
alpha-helical HN domain inserts itself into the endosomal membrane, creating a channel 
(Blaustein et al., 1987; Boquet and Duflot, 1982; Hoch et al., 1985; Sheridan, 1998).  
 
The pore-forming ability of the HN domain facilitates transport of the toxin from the endocytic 
vesicle to the cytosol of the cell in an N- to C-terminus direction (Fischer and Montal, 2007; 
Koriazova and Montal, 2003). It is critical that the disulfide bond connecting the LC and HC 
remains intact during translocation, as premature reduction of the bridge prior to channel 
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formation prevents translocation from the endosome (Fischer and Montal, 2007; Schiavo et 
al., 1990; Wey et al., 2006). The LC is also partially unfolded as it moves into the cytosol, a 
step which is critical for the efficient translocation of the LC across the hydrophobic 
endosomal membrane (Bade et al., 2004).  
 
Upon entry to the cytosol, reducing conditions dissociate covalent and non-covalent 
interactions such as the disulfide bridge holding the LC and HC together, and the “belt” which 
covers the catalytic zinc endopeptidase domain of the LC (Li, L. and Singh, 2000; Puhar et 
al., 2004). Finally, the light chain structure refolds as it leaves the acidic environment of the 
endosome and enters the more neutral environment of the cytosol where it is then able to 
bind to a SNARE substrate on the presynaptic membrane and catalyse its target peptide 
bond (Fisher and Montal, 2006; Hoch et al., 1985; Simpson, 2004).  
 
1.8.6 Cleavage of SNARE proteins  
The selectivity of CNTs to cleave one of four proteins which make up the SNARE complex in 
neuronal cells is mediated by the LC. Substrates targeted by CNTs are the soluble NSF 
attachment protein receptors (SNAREs), which include the 25 kDa synaptosomal-associated 
protein (SNAP-25), synaptobrevin II, also known as vesicle associated membrane protein-2 
(VAMP-2), and syntaxin (Sutton et al., 1998). The SNARE complex is essential for the 
secretion of chemical signals in eukaryotic cells, and is not specific to neuronal cells.  
 
VAMP proteins such as synaptobrevin occur on the surface of synaptic vesicles, whilst 
SNAP-25 and syntaxin are bound to the plasma membrane. The SNARE complex (Figure 
1.7), is formed when synaptic vesicles come close to the pre-synaptic plasma membrane in 
order to release vesicular contents into the post-synaptic junction (Davletov et al., 2005).  
 
The light chains of CNTs are zinc-dependent endopeptidases which hydrolyse members of 
the SNARE family at a specific peptide bond, unique to each CNT (Schiavo et al., 1992a; 
Schiavo et al., 1992b), and zinc has been shown to be essential for the catalytic activity of 
CNTs (Simpson et al., 1993). Cleavage of SNARE proteins inhibits fusion of synaptic 
vesicles with the pre-synaptic membrane of the neuron, preventing exocytosis and release of 
neurotransmitters from the pre-synaptic membrane (McMahon et al., 1993). The LC has 
been shown to also cleave SNARE proteins in non-neuronal cells, indicating that neuronal 
specificity is solely a function of the heavy chain (Chaddock et al., 2000; Penner et al., 1986).  
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Figure 1.7: Formation of the SNARE complex. Reproduced from Humeau et al. (2000). 
Exocytosis occurs when a synaptic vesicle docks and fuses to the plasma membrane, 
through the formation of the SNARE complex. In its free state (A), the synaptic vesicle is 
sensitive to proteolytic attack by CNTs prior to formation of the SNARE complex (B). Once 
the SNARE complex is formed and the synaptic vesicle has docked (C), it is able to fuse with 
the plasma after an inflow of calcium ions (D1). D2 shows a cross section of the normal 
formation of the SNARE complex.  
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When the SNARE complex is fully assembled, it is resistant to proteolytic attack by CNTs as 
target cleavage sites may not be exposed in this configuration, thus CNTs must cleave 
individual SNARE proteins when present in their intermediate state, prior to SNARE 
assembly (Sutton et al., 1998). 
 
1.9 Toxin specificity and duration of action 
Unlike most proteases, CNTs require extended regions of substrate in order to bind and 
cleave efficiently, but do not require a consensus region for recognition of the cleavage site 
(Breidenbach and Brunger, 2005b).  
 
TeNT and BoNT/B both cleave VAMP-2 at the same peptide bond however they have unique 
recognition sites, with TeNT requiring an additional 20 amino acids to form a stable 
interaction with the substrate and cleave VAMP-2 (Figure 1.8) (Chen, S. et al., 2008b). 
These differences can be attributed to the different location of the amino acid residues 
responsible for cleavage in the active site of the LC (Rao et al., 2005). TeNT requires 51 
amino acid residues of VAMP-2 for cleavage, and hydrolyses the Gln76 – Phe77 peptide 
bond in the substrate (Sikorra et al., 2008).  
 
BoNT/D, /F, and /G also cleave VAMP, but at different peptide bonds to TeNT and BoNT/B, 
while BoNT/A, /E, and /C cleave SNAP-25. BoNT/C also cleaves syntaxin and is the only 
CNT able to cleave two different substrates (Baldwin and Barbieri, 2007). LC/A binds directly 
to residues 80 – 110 of SNAP-25 on the plasma membrane in order to cleave the SNARE 
protein (Chen, S. and Barbieri, 2011). The deletion of 10 N-terminal residues or 68 C-
terminal residues from TeNT LC renders the domain nontoxic (Kurazono et al., 1992). 
 
BoNT/A initially binds to SNAP-25 along the belt region at residues 156 – 202, and cleavage 
occurs at the Gln197 – Arg198 peptide bond of SNAP-25 (Breidenbach and Brunger, 2004; 
Chen, S. et al., 2007). Nine amino acid residues are removed from the C-terminus of SNAP-
25, allowing it to maintain its association with syntaxin (Chen, S. and Barbieri, 2006). The 10 
N-terminal and 57 C-terminal residues from LC/A are required for catalytic activity (Kurazono 
et al., 1992). 
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Figure 1.8: Target SNARE cleavage sites of CNTs. Reproduced from Humeau et al. 
(2000). 
Cleavage sites of TeNT and BoNT/A – /G are indicated by arrows and the open boxes 
indicate the binding sites of the CNT light chains. 
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BoNT/E also cleaves SNAP-25, but requires a much shorter recognition region (residues  
167 – 186), than BoNT/A, and cleaves at the peptide bond between residues 180 – 181. 
Cleavage by BoNT/E removes 26 amino acids from SNAP-25, which leads to the 
dissociation of SNAP-25 from synatxin (Chen, S. and Barbieri, 2006). The difference in 
length of SNAP-25 removed between the toxin types does not however, translate to an 
increased duration of action. In fact, paralysis by BoNT/A persists the longest of all BoNTs, 
while BoNT/E displays the shortest paralytic time of less than 4 weeks and is thus generally 
not clinically useful (Eleopra et al., 1998). BoNT/E is able to poison neurons at a faster rate 
than BoNT/A, possibly due to the translocation step occurring more quickly in BoNT/E (Wang 
et al., 2008). It has been demonstrated that simultaneous injection of BoNT/A and BoNT/E 
saw muscle activity reinstated in the shorter time after BoNT/E paralysis, and not of the 
longer acting BoNT/A (Eleopra et al., 1998). 
 
The speed of recovery of vesicle fusion machinery is also affected by the rate at which 
damaged SNARE proteins are replaced with newly synthesised proteins (Foran et al., 2003). 
For example, SNAP-25 cleaved by LC/E is quickly removed and replaced, thus permitting the 
SNARE complex to reform and reinstate synaptic vesicle fusion in a shorter period of time 
than when cleaved with BoNT/A (Meunier et al., 2003). Reasons for such differences may be 
due to the sub-cellular localisation of the LCs. LC/A has been found to localise at the plasma 
membrane in a punctuate manner, with localisation directed by a di-leucine motif present 
within the first eight amino acids of the LC/A sequence. LC/E is found mainly within the 
cytosol where proteases may degrade the LC protein over time (Fernandez-Salas et al., 
2004). 
 
Further supporting evidence on the effects of the di-leucine motif come from a study which 
showed that fusing active LC/E to catalytically inactive full-length BoNT/A delivered LC/E to 
cholinergic neurons and extended the duration of action of LC/E to that of LC/A. It was 
revealed that C-terminal di-leucine motif present in BoNT/A was responsible for its long 
duration of action (Wang et al., 2011).  
 
1.10 Therapeutic utility of CNTs 
A striking feature of CNTs, much like other toxins with an A – B type toxin structure, is that 
individual domains maintain their function in the absence of the other domains. This trait 
opens a door for the use of individual toxin domains from CNTs as tools in the treatment of 
disorders involving secretory abnormalities and the nervous system. CNTs may be delivered 
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as whole toxins for a targeted, low-dose treatment, or as individual domains fused to other 
CNT or non-CNT proteins to exploit the function of individual domains.  
 
In the absence of the light chain, the heavy chain is a sophisticated delivery vehicle and 
fragment-C of TeNT has been used to deliver cargo proteins attached in place of the LC to 
the CNS, without systemic TeNT poisoning. The LCs of TeNT and BoNT can be targeted to a 
desired cell type by attachment to a specific cell-binding receptor to disrupt SNARE 
assembly, even in cells outside of the nervous system. It was first realised that the muscle 
relaxing effects of BoNTs could be useful as a therapeutic in the 1970’s, 150 years after 
Justinus Kerner’s first observations of botulism in a patient (Chaddock and Marks, 2006). 
 
CNTs can be used for the delivery of cargo proteins to the cytosol of neuronal cells. If CNT 
toxicity is not desired, the cargo protein may be coupled to a deactivated LC after mutation of 
the active site (Bade et al., 2004; Li, Y. et al., 2001), or the cargo protein may completely 
replace the LC region (Goodnough et al., 2002). Such molecules are termed targeted 
secretion inhibitors and they may be engineered to target cell types outside the nervous 
system, with cell targeting determined by the binding domain included in the toxin molecule 
(Stancombe et al., 2012). Targeted delivery of controlled amounts of toxin has been shown 
to assist in the treatment of muscular disorders. However, the effects of both CNTs are 
reversible, so therapeutic use requires recurrent application, determined by the length of time 
the toxin remains active at the target site.  
 
1.10.1 Therapeutic use of tetanus toxin 
In cases where the effects of the native TeNT are desired, delivery of low-dose TeNT to a 
targeted area will illicit the effects of the native toxin in a controlled manner. TeNT fragment-
C was first suggested as a non-toxic carrier of cargo proteins to neurons within the CNS by 
Bizzini and colleagues in 1977 (Bizzini et al., 1977). Fragment-C of TeNT is generally 
included in the production of therapeutic molecules as it retains the binding and trafficking 
properties of TeNT, but lacks the catalytic activity of the light chain. A key feature of TeNT 
fragment-C is that it is able to avoid degradation during retrograde axonal transport, ensuring 
the attached cargo protein is delivered to the CNS intact (Lalli and Schiavo, 2002).  
 
Drugs cannot usually penetrate the blood-brain barrier because of specialised capillary 
endothelial cells which prohibit entry of large molecules such as peptides, proteins and 
viruses (Pardridge, 2002). However, the ability of TeNT to travel in a retrograde fashion via 
the motorneuron allows it to act as a non-viral delivery system to transport small molecules to 
the CNS. TeNT has been suggested for use in the treatment of Alzheimer’s disease and 
47 
 
spinal cord injury as a non-viral carrier for the delivery of therapeutic molecules (Singh et al., 
2010).  
 
Chemical conjugation of molecules to fragment-C or expression as a recombinant protein 
with the cell-binding domain, has been shown to deliver the cargo protein to the CNS in vivo 
and in vitro (Schiavo et al., 2000). Cargo proteins delivered by fragment-C include 
therapeutic proteins and growth factors, with some examples listed below.   
 
A glial cell line-derived neurotrophic factor (GDNF) chemically conjugated to TeNT fragment-
C showed increased neuronal survival and repair in vitro and in vivo, which has the potential 
for use in the treatment of neurodegenerative disorders such as Parkinson’s disease and 
amyotrophic lateral sclerosis (Larsen et al., 2006).  
 
Superoxide dismutase-1 (SOD-1) has been shown to be protective in cases of stroke and 
trauma and in Parkinson’s disease. Delivery of SOD-1 to the CNS may be therapeutic to 
disease, however it is rapidly cleared from circulation when delivered orally (Francis et al., 
1995). To overcome this, the 19 kDa subunit of SOD-1 was expressed as a recombinant 
protein with TeNT fragment-C in E. coli, and delivered by both intramuscular injection and 
directly into the CNS through injection into the CSF. The amount of SOD-1-TTC delivered 
was enhanced and it was also retained for longer in the brain matter than when SOD-1 was 
injected alone (Benn et al., 2005; Francis et al., 2004a; Francis et al., 1995).  
 
TeNT fragment-C has been fused to the diphtheria catalytic and transmembrane domains as 
a novel approach to deliver a cargo molecule linked to the CNS (Francis et al., 2004b).  
 
One study of particular interest used native tetanus toxin for the treatment of obstructed 
breathing in British Bulldogs. British bulldogs are at risk of obstructed breathing caused by 
laryngeal collapse in the upper airway, which is usually treated with surgery (Torrez and 
Hunt, 2006). Localised injections of TeNT in the upper airway increased muscle tone 
compared to the placebo and this study is an excellent indicator for the use of TeNT to 
increase muscle tone in the upper airway (Sasse et al., 2005). 
 
These examples provide unequivocal support for the potential of tetanus neurotoxin, or 
fragments thereof, for use in the delivery of therapeutic molecules to the CNS in the 
treatment of neuromuscular disorders.  
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1.10.2 Therapeutic use of botulinum toxin 
BoNTs have been used in controlled toxicity since the 1970’s, when American scientist Alan 
Scott first showed that small doses of BoNT injected into over-stimulated muscles could 
cause muscle relaxation without any adverse systemic effects in primates, and later used 
BoNT/A for the treatment of strabismus in humans (Scott, 1981). Well known for its cosmetic 
uses and for the treatment of muscular disorders involving excessive muscle contraction, 
BoNTs have also been used in the treatment of other muscle spasticity disorders due to their 
ability to reversibly block the innervation of both striated and smooth muscles.  
 
BoNT/A is the most commonly used serotype due to its longevity of action, and was 
approved for the treatment of eye conditions and hemifacial spasms in 1989 by the U.S. 
FDA, under the commercial name Oculinum, and after its acquisition by Allergan in 1989, 
BoNT/A was marketed as BOTOX®. BoNT/A is also available as Dysport which is distributed 
by Ipsen and has been approved for the treatment of blepharospasm (eyelid twitch), cervical 
dystonia (neck and shoulder muscle spasms), hemifacial spasm (spasms on one side of the 
face), muscle spasms in children and opthalmological disorders, and BoNT/B (Myobloc, 
approved in 2000), has also been used in treatment of dystonia (Goldman and Wollina, 2010; 
Wortzman and Pickett, 2009). BoNTs have also been used in the treatment of overactive 
smooth muscles and constipation by inhibiting the contraction muscle in the gastrointestinal 
system, and also sphincters, in the case of anal fissure (Brisinda et al., 2004).  
 
BoNT/A has been used in the treatment of a range of dystonias (overactive muscle 
contractions of a neurological origin), such as oramandibular dystonia, writer’s and other 
occupational cramps, foot dystonia, axial dystonia (affecting the midline of the body), 
Tourette’s syndrome, tremor and spasticity (Truong and Jost, 2006). BoNT/A has also been 
used in the treatment of secretory disorders such as hyperhydrosis (excessive sweating), 
and sialorrhea (excessive salivation) (Keith and John, 2010).  
 
BoNTs have been used as a muscle relaxant for headaches (Jabbari, 2008) and BOTOX® is 
commonly used for cosmetic purposes to soften lines and wrinkles around the eyes, 
forehead and mouth (Goldman and Wollina, 2010). The local paralysis caused by targeted 
injection of BoNT/A relaxes the muscles and flattens the skin, preventing the appearance of 
deep lines in the face.  
 
A range of medical disorders are associated with chronic pain, such as multiple sclerosis, 
chronic migraines, arthritis, and back and shoulder pain, and these afflictions are associated 
with a decreased quality of life. In cases where sufferers do not respond to commonly 
available medications for the alleviation of pain or fail to respond due to overuse, botulinum 
49 
 
toxin serves as an alternative treatment option (reviewed in Dolly and O'Connell (2012) and 
Mahant et al. (2000)). The 100 kDa LC and HN fragment of BoNT/A (LHN/A) has been 
coupled to a lectin in order to cleave SNAP-25 within neurons responsible for transmitting 
pain signals to the CNS, for the treatment of pain in rats. The lectin targeting moiety from 
Erythrina cristagalli delivers LHN/A to nociceptive afferent neurons located in the periphery, 
where it is then able to inhibit SNARE complex formation and prevent the release of synaptic 
vesicles containing substance P, involved in transmission of signals to the CNS which are 
then perceived as pain (Duggan et al., 2002).  
 
The LHN/A has also been chemically conjugated to wheat germ agglutinin (WGA), targeting 
pancreatic B-cells to inhibit the release of insulin. This WGA binding domain permitted 
binding to the cell line which is normally resistant to the effects of BoNT/A, and the LHN/A 
was able to translocate the LC to the cell cytosol and inhibit neurotransmitter release in a 
manner analogous to the native toxin (Chaddock et al., 2000). Another study fused the LHN/C 
to epidermal growth factor to prevent hypersecretion of mucus in asthma and chronic 
obstructive pulmonary disease patients (Foster et al., 2006).  
 
The aim of BoNT use is to deliver a targeted and controlled dose of toxin to reduce the level 
of neuronal activity, without completely inhibiting it. In cases where excessive and 
uncontrolled peripheral cholinergic neuronal activity occurs, therapeutic doses of BoNT will 
reduce the level to near normal. These characteristics of BoNT action have been exploited 
successfully for use in cosmetic applications and therapeutic treatment of muscular 
disorders. 
 
1.11 Rationale of the project 
This review has shown that a novel approach to the treatment of OSA which is more widely 
accepted to sufferers will not only show improvements in the quality of life, but also have an 
impact on the financial burden associated with treatment of this disease. It has been well 
established that a loss of tone in muscles of the upper airway obstruct breathing during 
sleep, and that current treatment options seek to increase muscle tone with surgery, or 
maintain a patent airway through the use of mechanical and/or non-mechanical devices. A 
novel approach to the treatment of OSA is proposed whereby CNT toxins may be used to 
increase muscle tone in the upper airway. It has been demonstrated in the literature that 
botulinum toxin is able to cause localised paralysis and it is commonly accepted for use in 
cosmetic purposes. It has also been demonstrated that tetanus toxin is able to elicit muscle 
contracting effects in a dose-dependent manner.  
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It is proposed that tetanus toxin is used to cause targeted, localised muscle contraction in 
muscles of the upper airway to increase muscle tone, and remove the obstruction to the 
airway in OSA sufferers.  
 
The use of native tetanus toxin is limited due to widespread immunity in the population from 
routine vaccination. It is also important that individuals maintain a protective level of 
circulating antibodies, and continue to receive booster vaccinations for the remainder of their 
lives. For this reason, the wild-type tetanus toxin is not practical for therapeutic use. To 
address this issue, it is proposed that a chimeric neurotoxin comprised of the cell-binding and 
translocation domains of tetanus neurotoxin fused to the catalytic light chain domain of 
botulinum type A toxin will create a novel chimeric CNT which is able to illicit the effects of 
native tetanus after localised injection. The use of the BoNT/A light chain in place of the 
TeNT LC is for two reasons: (i) BoNT/A LC has been shown to maintain paralysis for the 
longest duration of time of all CNTs (Davletov et al., 2005; Eleopra et al., 1998); and (ii) its 
use will assist in evading host immune responses to the chimeric toxin, as the majority of the 
population should not display immunity to this domain. Although the vast majority of the 
developed world has been vaccinated against tetanus toxin, the use of the TeNT heavy chain 
may still be applicable (Fishman et al., 2006). 
 
Antibody responses to TeNT occur prior to the toxin binding to neuronal cells. When 
delivered intramuscularly, THC may evade circulating antibodies and bypass the immune 
response. The injected toxin may have enough time to bind to neuronal cells due to an 
insufficient level of circulating antibodies to neutralise the entire injected toxin before it is able 
to bind, even in a newly vaccinated animal. In that time, TeNT may bind neuronal cells and 
be internalised (Fezza et al., 2000; Fishman et al., 2006). 
 
The use of the tetanus toxin heavy chain will ensure that LC/A is delivered to the CNS where 
it can effectively cause tetany in the muscles surrounding the injection site. It is anticipated 
that over time, much like the case with the use of BOTOX®, that injection of the novel 
chimeric toxin will induce neutralising antibodies. Thus, the future aims of this project are to 
alter the immunogenic regions of the toxins in order to evade the host immune system, but 
still maintain native activity. 
 
The scope of this thesis is to use recombinant DNA technology to express the LC/A and 
TeNT HC in a heterologous host and reconstitute these toxin domains to produce a novel 
chimeric CNT holotoxin. The chimeric toxin should be able to bind to motorneurons and 
display retrograde axonal transport to inhibitory interneurons within the CNS and cleave the 
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SNAP-25 substrate. A potential novel treatment for OSA involving a simple set of injections 
given up to twice per year would be less invasive and far more reliable than surgery, which 
may improve compliance rates of treatment. Thus, the proposed novel toxin molecule could 
be the future of OSA treatment, a disorder impacting millions of people worldwide. 
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Chapter 2  
General Materials and Methods 
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2.1 General procedures 
General materials and methods are listed below, with specific details for methods listed in the 
respective chapters. Chemicals used were of analytical or molecular grade and were stored 
at ambient temperature unless stated otherwise. 
 
All reagents were of analytical or molecular grade and were prepared with deionised water 
from the Millipore Milli-Q® water system (MQ water) (Millipore, USA); whilst media was 
prepared using distilled water (dH2O).  
 
All glassware, media and solutions were sterilised by autoclaving at 121°C for 20 min. Media 
containing supplements and/or antibiotics were autoclaved and cooled to 55°C before the 
addition of any supplement(s) or antibiotic(s). All media was prepared using aseptic 
technique and stored at 4°C until required.  
 
Solutions were delivered using Finnpipette® digital pipettes (ThermoFisher Scientific, U.S.A.) 
which included ranges of 0.5 – 10 μL, 5 – 50 μL, 20 – 200 μL, 200 – 1000 μL, 1 – 5 mL, 2 – 
10 mL, and a 50 – 300 μL multichannel pipette. Volumes above 10 mL measured with a 
measuring cylinder. 
 
Volumes of 1.5 mL or less were separated by centrifugation with the Eppendorf 
microcentrifuge 5415D and volumes up to 50 mL were separated by centrifugation using 
either the Beckman Allegra™ 21R centrifuge or the Heraeus Multifuge 1S-R centrifuge. High 
speed centrifugation was performed using a Beckman J2-21 M/E Super Centrifuge.   
 
Weighing of solids less than 2 g was performed using the Mettler Toledo XS105 Dual Range 
top loading analytical balance, and weighing of solids greater than 2 g was performed using 
the ISSCO Model 300 top loading balance.  
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2.2 General equipment and suppliers 
96-well, colourless, flat bottom plates  Nunc, Denmark 
96-Well Microplate Polystyrene Black (350µl well 
volume)  
Chromacol, United Kingdom 
Acrodisc® (0.2 μm and 0.45 μm) Pall, U.S.A. 
Balances:  
 XS105 Dual Range analytical balance  Mettler Toledo, Australia 
 ISSCO Model 300 balance  ISSCO, Australia 
Biological safety cabinet class II, BH2000 series Clyde-Apac, Australia 
BioPhotometer  Eppendorf, Germany 
Centrifuge tubes:  
 1.5 mL microfuge tubes  Sarstedt, Germany 
 10 mL centrifuge tubes  Sarstedt, Germany 
 15 mL centrifuge tubes  Sarstedt, Germany 
 50 mL centrifuge tubes  Greiner Bio-One, Germany 
Centrifuges:  
 Eppendorf 5414D bench top centrifuge 
 (maximum speed 16,000 x g)  
Eppendorf, Germany 
 Heraeus Multifuge 1S-R centrifuge  
           (maximum speed 5000 x g)  
Thermo Electron Corporation, 
U.S.A. 
 Allegra™ 21R centrifuge  
           (maximum speed 5000 x g)  
            Beckman J2-21 M/E Super centrifuge    
           (maximum speed 50,400 x g)  
Beckman Coulter, U.S.A. 
 
Beckman Coulter, U.S.A. 
 
Cryovials (1.8 mL) Iwaki, Japan 
Dry block heater Ratek, Australia 
Electrophoresis power supply:  
 EPS 3000xi (BioRad Laboratories, U.S.A.). 
 PowerPac 300 (BioRad Laboratories, U.S.A.). 
Electrophoresis units and components:  
DNA  
 Mini gel (Mini-sub cell GT cell)  BioRad Laboratories, U.S.A. 
 Midi gel (Wide mini-sub cell GT cell)  BioRad Laboratories, U.S.A. 
Protein  
 Mini-PROTEAN® Te tra  Ce ll BioRad Laboratories, U.S.A. 
Electroporation cuvettes (0.2 cm) Molecular Bio Products, U.S.A. 
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GelDoc imaging system BioRad Laboratories, U.S.A. 
FLUOstar Optima microplate reader BMG Labtech, Germany 
iBlot dry gel transfer device Invitrogen Corporation, U.S.A. 
iMark microplate absorbance reader BioRad Laboratories, U.S.A. 
Milli-Q® water filtration system Millipore, U.S.A. 
Petri dishes BioLab, Australia 
pH meter Metrohm AG, Switzerland 
Platform orbital shaker Ratek, Australia 
Polypropylene gravity flow column (1 mL) Qiagen, Germany 
Pulse controller & Gene pulser apparatus  BioRad Laboratories, U.S.A. 
Px2 Thermal Cycler:  Thermo Electron Corporation, 
U.S.A. 
Syringes:   
 1, 3, 5, 10, 20, and 60 mL Terumo, Australia 
 SGE 100 µL glass syringe  SGE Analytical Science, Australia 
Transilluminator (UV) Novex, Australia 
UVette® (10 mm) Eppendorf, Germany 
Vivaspin 20  
 30,000 Da MWCO 
 50,000 Da MWCO  
 500 Da MWCO 
 Diafiltration cup 
Sartorius-Stedim, Germany 
Water bath Ratek, Australia 
  
2.3 General materials and suppliers 
2.3.1 General solutions 
1,4-Ditiothreitol: (Roche, Germany), stored at 4°C. 
2-(N-morpholine)-ethanesulfonic acid (MES): (Sigma-Aldrich, Germany). 
β-mercaptoethanol: electrophoresis purity (BioRad Laboratories, U.S.A.). 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES): 1 M (Invitrogen 
Corporation, U.S.A.), stored at 4°C. 
Acetic acid (glacial): (Merck, Germany). 
Acrylamide/bisacrylamide solution: 40% acryl/bis (Amresco, U.S.A.), stored at 4°C. 
Acqua Stain: (Bulldog Bio Inc., U.S.A.), stored at 4°C. 
Adenosine triphosphate (ATP): 20 mM ATP (Sigma-Aldrich, Germany), stored at -20°C. 
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Agarose: 1.5-2.5 % (w/v) agarose, DNA grade (Bioline, England). 
Ammonium persulphate (APS): 10% (w/v) ammonium persulphate (Sigma-Aldrich, 
Germany), stored at 4°C. 
Ampicillin: 100 mg/mL ampicillin stock solution (CSL, Australia), filtered through a 0.2 μm 
filter. Working concentration of 100 μg/mL, aliquots stored at -20°C. 
Bacteriological agar: (Oxoid, England). 
BCIP/NBT substrate solution: BCIP/NBT (Amresco, U.S.A.), stored at 4˚C. Mixed 1:1 with 
detection buffer before use. 
Blocking buffer: 5% skim milk (Diploma, Australia) prepared in TBS before use. 
Blocking solution: PBS containing 3% BSA prepared before use.  
Bovine serum albumin (BSA): 1 – 10 mg/mL BSA (Promega, U.S.A.), aliquots stored at  
-20°C. 
Bradford reagent: 100 mg Coomassie Brilliant G-250 (Sigma-Aldrich, Germany) dye 
dissolved in 50 mL 95% (v/v) ethanol (Merck, Germany), then mixed with 100 mL 85% (v/v) 
phosphoric acid (Chem Supply, Australia), and brought up to 1 L with dH2O. Stored at 4°C 
and filtered through a 0.45 μm filter before use. 
Bromophenol blue: (BDH, U.S.A.). 
Chelating sepharose™ fast flow: (GE healthcare, Sweden), charged with 0.2 M nickel 
sulphate (NiSO4) (BDH, U.S.A.) or 0.2 M cobalt chloride (Co2Cl) (BDH, U.S.A.) 
Chloramphenicol: 34 mg/mL Chloramphenicol stock solution (Sigma-Aldrich, Germany) in 
96% ethanol (Merck, Germany), filtered through a 0.45 μm filter. Working concentration of  
34 μg/mL, aliquots stored at -20°C. 
ClearPAGE Instant Blue Stain: (C.B.S. Scientific Company, U.S.A.), stored at 4°C. 
Cobalt chloride (Co2Cl): 0.2 M Co2Cl (BDH, U.S.A.), filtered through a 0.45 μm filter. 
Coomassie Brilliant G-250: (Sigma-Aldrich, Germany). 
Deoxynucleoside triphosphates (dNTP): 10 mM of each dATP, dTTP, dGTP, and dCTP 
(Bioline, England), stored at -20°C. 
Detection buffer: 100 mM Tris-HCl (Merck, Germany), 100 mM NaCl (BDH, U.S.A.), pH 9.5. 
Dextran sulfate: 10 mg/mL dextran sulfate (Sigma-Aldrich, Germany), stored at -20°C. 
DNA loading buffer (11x): 10% (w/v) ficoll®-400 (BDH, U.S.A.), 50% (v/v) glycerol (BDH, 
U.S.A.), 0.5% (w/v) Orange G (Sigma-Aldrich, Germany), 1% (w/v) SDS (Merck, Germany), 
10 mM EDTA (BDH, U.S.A.), 50 mM Tris-HCl (pH 8.0) (Merck, Germany). 
Ethanol: 70% (v/v), 96% (v/v), 100% (v/v) (Merck, Germany).  
Ethidium bromide (EtBr): 6 mg EtBr (Sigma-Aldrich, Germany) in 2 L MQ water. 
Ethylenediaminetetra-aetate (EDTA): 0.5 M EDTA (Merck, Germany). 
Formaldehyde: 37% (Sigma-Aldrich, Germany). 
Glycerol: 10% (v/v) sterile glycerol (BDH, U.S.A.). 
HisPur Cobalt 1 mL spin columns: (ThermoFisher Scientific, U.S.A.), stored at 4°C. 
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Hydrochloric acid (HCl): 32% (Merck, Germany). 
iBlot Transfer stacks: iBlot gel transfer stacks (nitrocellulose), Regular (2 gels) or Mini (1 
gel) (Invitrogen Corporation, U.S.A.). 
IMAC stripping solution: 0.5 M NaCl (BDH, U.S.A.), 50 mM EDTA (Merck, Germany). 
Imidazole: 5 M Imidazole (Sigma-Aldrich, Germany), filtered through a 0.45 μm filter, stored 
at 4°C in a light-proof container. 
Isopropyl-β-D-thiogalactopyranoside (IPTG): 1 M IPTG (Progen, Australia) filtered through 
a 0.2 μm filter, aliquots stored at -20°C. 
Lambda (λ) DNA: stored at -20°C (Promega, U.S.A.). 
MES/NaCl buffer: 20 mM 2-(N-morpholine)-ethanesulfonic acid (Sigma-Aldrich, Germany), 
0.1 M NaCl (BDH, U.S.A.), pH 5.0. 
Methanol: 100% (Merck, Germany). 
Mini-PROTEAN TGX Precast gels: 4 – 15% (BioRad Laboratories, U.S.A.), stored at 4°C. 
Molecular grade water (MGH2O): Distilled water, DNAse and RNase free (Invitrogen 
Corporation, U.S.A.). 
Nickel sulfate (NiSO4): 0.2 M NiSO4 (BDH, U.S.A.), filtered through a 0.45 μm filter. 
PBST: PBS (Oxoid, England) with 0.05% (v/v) Tween 20 (Promega, U.S.A.).  
Phenylmethanesulfonyl fluoride (PMSF): 200 mM (Sigma-Aldrich, Germany) in anhydrous 
(100%) ethanol (Merck, Germany), stored at 4°C. 
Phosphate buffered saline (PBS): 1 tablet Dulbecco’s A PBS (Oxoid, England) in 100 mL 
mH2O (sodium chloride 0.8%, potassium chloride 0.02%, disodium hydrogen phosphate 
0.115% potassium dihydrogen phosphate 0.02%). 
Phosphoric acid: 85% (Chem-Supply, Australia). 
Precision Plus ProteinTM Dual Colour Standard: 10 μL per well (BioRad Laboratories, 
U.S.A.), stored at -20°C. 
Precision Plus ProteinTM KaleidoscopeTM prestained standard: 10 μL per well (BioRad 
Laboratories, U.S.A.), stored at -20°C. 
Precision Plus ProteinTM standard: 10 μL per well (BioRad Laboratories, U.S.A.), stored at  
-20°C. 
Protein binding buffer: 50 mM Tris-HCl (pH 8.0) (Merck, Germany), 150 mM NaCl (BDH, 
U.S.A.), 10 mM imidazole (Sigma-Aldrich, Germany), prepared before use. 
Protein elution buffer: 50 mM Tris-HCl (pH 8.0) (Merck, Germany), 150 mM NaCl (BDH, 
U.S.A.), 100 mM – 200 mM Imidazole (Sigma Aldrich, Germany), prepared before use.  
Protein lysis buffer: 50 mM Tris-HCl (pH 8.0) (Merck, Germany), 150 mM NaCl (BDH, 
U.S.A.), 20 mM imidazole (Sigma-Aldrich, Germany), 1 mg/mL lysozyme (Amresco, U.S.A.), 
prepared before use. 
Protein storage buffer: 50 mM Tris-HCl (pH 8.0) (Merck, Germany), 150 mM NaCl (BDH, 
U.S.A.), stored at 4°C. 
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Protein wash buffer: 50 mM Tris-HCl (pH 8.0) (Merck, Germany), 150 mM NaCl (BDH, 
U.S.A.), with increasing concentrations of imidazole (20, 50, 100, and 150 mM), prepared 
before use. 
Resolving SDS-PAGE gel: For 10 mL of 10% separating gel: 4.8 mL dH2O, 2.5 mL 40% 
(v/v) acryl/bis (Amresco, U.S.A.), 2.5 mL 1.5 M Tris-HCl (pH 8.8) (Merck, Germany), 0.1 mL 
10% (w/v) SDS (Merck, Germany), 0.1 mL 10% (w/v) ammonium persulfate (Sigma-Aldrich, 
Germany), 0.004 mL Tetra-methyl-ethylenediamine (TEMED) (BioRad Laboratories, U.S.A.). 
Ribonuclease A (RNaseA): 0.1 µg/µL (Sigma-Aldrich, Germany), stored at -20°C.  
S30 T7 High-Yield Protein Expression System: stored at -80°C (Promega, U.S.A.). 
SDS sample loading buffer (5 x): 60 mM Tris-HCl (Merck, Germany), 25% (v/v) glycerol 
(BDH, U.S.A.), 2% (w/v) SDS (Merck, Germany), 1.4 mM 2-mercaptoethanol (BioRad 
Laboratories, U.S.A.), 0.1% (w/v) bromophenol blue (Sigma-Aldrich, Germany), stored at  
-20°C. 
SDS-PAGE running buffer (1 x): 3% (w/v) Tris-HCl (Merck, Germany), 14.2% (w/v) glycine 
(Amresco, U.S.A.), 1% (w/v) SDS (Merck, Germany). 
Skim milk: powder (Diploma, Australia). 
SNAPtide® hydrolysis buffer: 50 mM HEPES (pH 7.4) (Invitrogen Corporation, U.S.A.), 
0.05% Tween 20 (Promega, U.S.A.).  
Sodium acetate (NaOAc): 3 M NaOAc (pH 5.2) (BDH, U.S.A.). 
Sodium Chloride (NaCl): 0.15 M to 5 M NaCl (BDH, U.S.A.). 
Sodium dodecyl sulphate (SDS): 10% (w/v) (Merck, Germany) 
Sodium Hydroxide (NaOH): 0.1 M NaOH (Merck, Germany). 
Stacking SDS-PAGE gel: For 5 mL of 5% stacking gel: 3.4 mL dH2O, 0.83 mL 40% (v/v) 
acryl/bis (Amresco, U.S.A.), 0.63 mL 1.0 M Tris-HCl (pH 6.8) (Merck, Germany), 0.05 mL 
10% (w/v) SDS (Merck, Germany), 0.05 mL 10% (w/v) ammonium persulfate (Sigma-Aldrich, 
Germany), 0.005 mL TEMED (BioRad Laboratories, U.S.A.). 
Sulphuric acid (H2SO4): 1 M sulphuric acid (BDH, USA). 
TBST: TBS with 0.05% (v/v) Tween 20 (Promega, U.S.A.). 
TEMED (N,N,N’,N’-tetramethylethylenediamine): Electrophoresis purity (BioRad 
Laboratories, U.S.A.). 
Tetramethylbenzidine (TMB): TMB substrate reagent A and substrate reagent B (BD 
Biosciences, U.S.A.) were mixed in a ratio of 1:1 and used within 10 min, stored at 4°C. 
Tris (hydroxymethyl) amino methane (Tris-HCl): 1 M stock solution (Merck, Germany), 
adjusted to pH 8.0 with HCl. 
Tris-Acetate-EDTA (TAE) buffer (1x): 40 mM Tris-HCl (pH 8.0) (Merck, Germany), 20 mM 
acetic acid (Merck, Germany), 2 mM EDTA (Merck, Germany). 
Tris Buffered Saline (TBS): 25 mM Tris-HCl (pH 7.4) (Merck, Germany), 0.18 M NaCl 
(BDH, U.S.A.). 
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Tryptone: (Oxoid, England). 
Tween 20: polyoxyethylene sorbitan monolaurate (Promega, U.S.A.). 
Urea: 2 to 8 M urea (BDH, U.S.A.) in 0.1 M Tris-HCl (pH 8.0). 
VAMP-2 Cleavage buffer: 20 mM Tris-HCl (pH 8.0) (Merck, Germany), 50 mM NaCl (BDH, 
U.S.A.). 
Whole cell lysis buffer: 0.1 M Tris-HCl (pH 8.0) (Merck, Germany), 2% (w/v) SDS (Merck, 
Germany), 15% (v/v) glycerol (BDH, U.S.A.). 
Yeast extract: (Oxoid, England). 
 
2.3.2 General media 
All media was prepared using distilled water and sterilised by autoclaving at 121°C for 15 
min. For agar media, bacteriological agar was added prior to autoclaving. 
 
EnPressoTM tablet cultivation set: EnBase® medium tablets (white bag), booster tablet 
(black bag), EnzI'm (600 U/L) stored at 4°C, AirOtop seal flask closures (BioSilta, Finland). 
Luria-Bertani (LB) broth: 1% (w/v) tryptone (Oxoid, England), 0.5% (w/v) yeast extract 
(Oxoid, England), 1% (w/v) NaCl (BDH, U.S.A.). For LB agar 1% (w/v) bacteriological agar 
(Oxoid, England) was added. 
 
2.3.3 Enzymes 
All enzymes were used in the supplied buffer according to the manufacturer’s instructions, 
and were stored at -20°C unless otherwise stated. 
 
Deoxyribonuclease I (DNAse I): 10 U/μL DNAse A (Sigma-Aldrich, Germany).  
EKMaxTM Enterokinase: 1.0 U/μL (Invitrogen Corporation, U.S.A.). 
Expand polymerase: Expand long template enzyme (ELT), system 1 (Roche, Germany). 
Lysozyme solution: 10 mg/mL lysozyme (Boehringer Mannheim, Germany) in dH2O, 
filtered through a 0.45 μm filter, stored at -20°C.  
T4 DNA ligase: 3 U/μL T4 DNA ligase (Promega, U.S.A.). 
 
2.3.3.1 Restriction enzymes 
Restriction enzymes were used in the supplied buffer according to the manufacturer’s 
instructions and stored at -20°C. The recognition sequences are listed in Table 2.1.  
 
60 
 
EcoRI: 12 U/μL (Promega, U.S.A.). 
PstI: 10 U/μL (Promega, U.S.A.). 
PvuII: 12 U/ μL (Promega, U.S.A.). 
XhoI: 10 U/μL (Roche, Germany). 
 
2.3.4 Antibodies 
Goat anti-rabbit IgG – AP: stored at 4°C (Abcam, England). 
Goat anti-rabbit IgG – HRP: stored at 4°C (Abcam, England). 
Mouse anti-His IgG: stored at -20°C (GE Healthcare, Sweden). 
Rabbit anti-Clostridium botulinum A toxoid IgG: stored at -20°C (Abcam, England). 
Rabbit anti-mouse IgG – AP: stored at 4°C (Abcam, England). 
Rabbit anti-tetanus toxin IgG: stored at 4°C (Abcam, England). 
 
2.3.5 Commercial kits 
DNA sequencing kit (ABI version 3.1): Big Dye, 5x dilution buffer, stored at -20˚C (Monash 
University, Australia). 
Enterokinase removal kit: stored at 4°C (Invitrogen Corporation, U.S.A.). 
PureYieldTM plasmid miniprep system: (Promega, U.S.A.). 
QIAquick gel extraction kit: (Qiagen, Germany). 
QIAprep spin miniprep kit: (Qiagen, Germany). 
 
2.3.6 Toxins 
Botulinum type A light chain, recombinant protein: 10 µg, stored at -20˚C (List Biological 
Laboratories, U.S.A.). 
Tetanus toxin light chain: 10 µg, stored at -20˚C (List Biological Laboratories, U.S.A.). 
Tetanus toxin C-fragment: 10 µg, stored at 4˚C (List Biological Laboratories, U.S.A.). 
Tetanus toxin C-fragment: 10 µg, stored at 4˚C (Sigma-Aldrich, Germany). 
Tetanus toxin from C. tetani: 25 µg, stored at 4˚C (Sigma-Aldrich, Germany).  
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Table 2.1: Restriction enzymes used in this study and their recognition sequence. 
 
Restriction enzyme Recognition sequence 
EcoRI 
KpnI 
…G▼AATTC… 
…GGTAC▼C… 
PstI …CTGCA▼G… 
PvuII …CAG▼CTG… 
XhoI …C▼TCGAG… 
Where ▼ represents the point of cleavage. 
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2.3.7 Substrates 
GST-Synaptobrevin-2 (GST-VAMP-2), recombinant protein: 100 µg, stored at -20˚C (List 
Biological Laboratories, U.S.A.). 
SNAPtide® (FITC/DABCYL) FRET substrate: 200 nmoles, stored at -20˚C (List Biological 
Laboratories, U.S.A.). 
 
2.4 Microbiological methods 
2.4.1 Bacterial strains, plasmids and recombinant proteins 
The description of all the bacterial strains used throughout this study is listed in Table 2.2. A 
description of all plasmid vectors used and those developed throughout the study is listed in 
Table 2.3 and Table 2.4, respectively.  
 
2.4.2 Bacterial storage conditions 
Escherichia coli strains were stored at -80°C in 15% glycerol. 
 
2.4.3 Bacterial Culture Conditions  
All E. coli bacteria containing plasmids were grown in LB broth or on LB agar containing  
100 μg/mL ampicillin and 34 μg/mL Chloramphenicol at 37°C unless stated otherwise. 
Escherichia coli BL21(DE3)pLysS not containing any plasmid construct was grown in LB 
broth with 34 μg/mL chloramphenicol for maintenance of the pLysS plasmid at 37°C unless 
stated otherwise. All media was sterilised by autoclaving at 121°C for 15 min. All broths 
inoculated with E. coli were shaken on a Ratek orbital shaker at 200 revolutions per min 
(rpm).  
 
63 
 
Table 2.2: Bacterial strains used throughout this study. 
Bacterial strain Genotype/description Source 
E. coli BL21(DE3)pLysS  E. coli B F– dcm ompT hsdS (rB– mB–) gal 
λ(DE3) [pLysS CamR]  
 
Invitrogen 
Corporation, 
U.S.A.  
E. coli DH5α  F’/endA1 hsdR17(rK-, mK+) supE44 thi-1 
recA1 gyrA96 (NalR) relA1 ∆(lacZYAargF) 
U169 Φ80d lacZ_M15 
deoR phoA λ- 
Hanahan (1983) 
E. coli 
OrigamiTM2(DE3)pLysS 
 
Δ(ara-leu)7697 ΔlacX74 ΔphoA PvuII phoR 
araD139 ahpC galE galK rpsL F′ [lac+ lacIq 
pro] (DE3) gor522::Tn10 trxB pLysS (CamR, 
StrR, TetR) 
Novagen, 
Germany 
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Table 2.3: Plasmids used throughout this study. 
Plasmid Genotype/description Diagram Source 
pUC57 2.7 kb cloning plasmid Figure 3.1 Fermentas, Canada 
pRSET-A 2.9 kb protein expression plasmid, 
N-terminal His6-tag, T7 promoter, 
AmpR 
Figure 3.2 Invitrogen Corporation, 
U.S.A. 
Vector maps in Chapter 3. 
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Table 2.4: Expression plasmids and description of the proteins used and developed 
throughout this study. 
Expression plasmid Protein Description/Genotype Source 
pTLC TLC Recombinant codon optimised tetanus 
toxin light chain 
GenScript, 
U.S.A. 
pTHC THC Recombinant codon optimised tetanus 
toxin heavy chain 
GenScript, 
U.S.A. 
pB/ALC B/ALC Recombinant codon optimised botulinum 
toxin type A light chain 
GenScript, 
U.S.A. 
Vector maps in cloning chapter 
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2.4.4 Bacterial manipulation 
2.4.4.1 Preparation of electrocompetent cells 
Two millilitres of an overnight E. coli culture was used to inoculate 200 mL LB broth and the 
cells were grown at 37°C with vigorous shaking until absorbance at 600 nm was 0.3 – 0.4 
(early mid log phase). When cells reached mid log phase, the flask was chilled on ice for  
15 – 30 min. All centrifugation steps were carried out in a 4°C centrifuge for 15 min at  
4,000 x g. Aliquots of 50 mL were transferred to 50 mL sterile tubes and pelleted by 
centrifugation. The cells were resuspended in 50 mL ice-cold sterile MQ water and pelleted 
by centrifugation. The cells were then resuspended in 25 mL ice-cold sterile MQ water and 
pelleted again. Cells were resuspended in a total of 5 mL of ice-cold 10% sterile glycerol, and 
cells were then combined and pelleted a final time. Ten per cent ice-cold sterile glycerol was 
added to a final volume of 50% of the cell pellet and divided into 40 μL aliquots. 
Electrocompetent cells were stored at -80°C. 
 
2.4.4.2 Electrotransformation 
This method was obtained from the manual supplied with the BioRad Gene Pulser 
apparatus. One microliter of purified ligation mixture was added to 40 μL of electrocompetent 
E. coli cells prepared above. The cells and ligation mixture were transferred to an ice-cold 
sterile electroporation cuvette (Section 2.2) and tapped lightly to settle the mixture to the 
bottom and remove bubbles. The cuvette was placed in the apparatus and the Gene Pulser 
(Section 2.2) was set at 25 μF, 200 Ω, and 2.50 kV. The sample was pulsed once and 1 mL 
of LB broth was immediately added to the cuvette to resuspend the cells. After transferring 
the medium to a 1.5 mL microfuge tube, samples were incubated on a shaker at 37°C for 1 
h. One hundred microliters of sample was plated onto LB agar containing the appropriate 
antibiotics and the remaining sample pelleted by centrifugation and resuspended in 150 μL of 
supernatant, then spread onto LB agar containing antibiotics, and incubated at 37°C 
overnight. 
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2.5 DNA methods 
2.5.1 Nucleic acid isolation 
2.5.1.1 Plasmid DNA extraction (miniprep) 
Plasmids were grown in E. coli DH5a and purified using the QIAprep Spin Miniprep kit 
(Qiagen, Germany) as per the manufacturer’s protocol.  
 
2.5.1.2 Plasmid DNA extraction for cell-free expression (miniprep) 
The PureYieldTM plasmid miniprep system (Promega, U.S.A.) was used to achieve highly 
pure and endotoxin-free plasmid DNA for use in cell-free expression. Plasmids were grown in 
E. coli DH5a and purified according to the manufacturer’s protocol. 
 
2.5.1.3 DNA extraction from agarose  
Digested inserts were separated by electrophoresis on a 1.5% - 2.5% agarose gel. The DNA 
was excised from the gel and then purified using the QIAquick gel extraction kit (Qiagen, 
Germany), as per the manufacturer’s protocol.  
 
2.5.2 DNA analysis 
2.5.2.1 Lambda DNA marker 
A solution of 50 ng/μL digested λ-DNA was prepared by incubating 50 μg λ-DNA (Promega, 
U.S.A.) with 180 U of PstI, 90 μL of 10x Buffer H, 1 mg/mL BSA and MQ water made up to 
900 μL, at 37°C overnight. Two microliters of 11x DNA loading buffer was added to 18 μL of 
the digested λ-DNA and run on a 1.5% DNA agarose gel to check for complete digestion. 
Eighty eight microlitres of 11x DNA loading buffer was then added to the remaining digestion 
to make up the standard marker. Twenty microliters was run on each DNA agarose gel. The 
marker was stored at 4°C. A diagram of PstI digested λ-DNA is shown in Appendix 1.  
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2.5.2.2 Agarose gel electrophoresis 
Agarose gels ranging from 1.5% – 2.5% were used to separate and visualise DNA samples. 
DNA samples mixed with 2 μL of 11x DNA loading buffer, and 20 μL of λ-PstI marker 
containing loading dye were loaded onto the gel. After electrophoresis at voltages ranging 
from 60 V to 100 V, gels were stained in a 3 mg/mL EtBr water bath for 5 min, and then 
destained under running water for 30 min. 
 
DNA products were visualised with a BioRad GelDoc transilluminator (Section 2.2) and 
photographed using the GelDoc imaging system (Section 2.2). The relative sizes of DNA 
products were estimated by comparison to the λ-PstI marker (Appendix 1).  
 
2.5.3 Quantification of nucleic acids 
Quantitation of nucleic acids was performed using one of two methods. For precise 
quantitation of DNA, a spectrophotometer was used, and for approximate quantitation of 
DNA, DNA was separated on an agarose gel and compared to known standards of the λ-PstI 
marker (Appendix 1).  
 
2.5.3.1 Quantitation of DNA by gel electrophoresis 
Lambda DNA marker (Section 2.5.2.1) was separated on an agarose gel along with sample 
DNA fragments. The quantity of each digested sample fragment was compared with 
intensities of known quantities of DNA within the DNA marker.  
 
2.5.3.2 Spectrophotometric quantification of DNA 
The Eppendorf BioPhotometer was used to determine the optical density (OD) of a DNA 
solution at a wavelength of 260 nm. Protein contamination was indicated by reading at  
280 nm. An OD of 1.0 was equal to 50 µg/mL of double-stranded DNA.  
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2.5.4 DNA manipulation 
2.5.4.1 Restriction enzyme digestion of DNA  
The restriction enzymes used in this study are listed in Table 2.1. Five units of each 
restriction enzyme was used in the supplied buffer for restriction enzyme digestion of  
50 – 100 ng of plasmid DNA, with 2 µg BSA in a final volume of 20 µL. Reactions were 
incubated in a 37°C water bath for 4 h. After digestion, the entire volume was separated on a 
1.5% – 2.5% agarose gel. 
 
2.5.4.2 Sequencing PCR 
Forward or reverse T7 promoter primers were used for sequence analysis of constructs. This 
analysis was performed to confirm the presence and orientation of inserts and to confirm all 
inserts were in frame with the start codon of the plasmid vector. Sequencing components 
(Table 2.5), cycling conditions (Table 2.6) and precipitation of PCR products (Section 2.5.4.4) 
were performed as per the protocol provided by Micromon DNA Sequencing Facility, Monash 
University, Melbourne, Australia. 
 
2.5.4.3 Primers 
Primers were obtained as lyophilised samples from Geneworks, Australia. The description of 
the sequencing primers used in this study is shown in Table 2.7.  
 
2.5.4.4 Precipitation of DNA from solution 
For 20 μL of DNA, 2 μL of 3 M sodium acetate pH 5.2, and 50 μL of absolute ethanol (96%) 
were added, mixed and left at room temperature for 10 min. Samples were pelleted by 
centrifugation for 15 min and the DNA recovered by ethanol precipitation. Samples were 
centrifuged for 2 min and the DNA pellet was left to dry at room temperature under sterile 
conditions. DNA was resuspended in 10 μL of MG H2O. 
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Table 2.5: Sequencing reaction components. 
 
Reagent  Volume (μL) 
T7 Forward OR Reverse Primer (50 ng/μL) 1 
Big Dye 2 
5x Dilution buffer 3 
Template DNA 300 ng 
MQ water To 20 μL 
Total reaction volume 20 μL 
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Table 2.6: Sequencing reaction cycling conditions. 
 
Step Temp (ºC) Time 
STAGE 1   
Initial denaturation 96 1 min 
STAGE 2   
Denaturation 96 10 sec 
Annealing  50 5 sec 
Extension 60 4 sec 
Number of cycles 25  
 Hold 4 ∞ 
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Table 2.7: Sequencing primers. 
 
Name Sequence 5’-3’ Description  
T7 Forward TAATACGACTCACTATAGGG Sequencing primer for pRSET-A 
T7 Reverse GCTAGTTATTGCTCAGCGG Sequencing primer for pRSET-A 
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2.5.4.5 Ligation 
Ligations were performed using digested and purified DNA at a ratio of 1:3 (vector:insert), as 
calculated using the formula below from Sambrook (2001).  
 
 
Typically, ligations were performed with the addition of 2 Weiss Units of T4 DNA ligase in the 
supplied buffer, and 1 mM ATP in a final volume of 10 μL. Reactions were incubated in a 
16ºC water bath overnight. The ligated DNA was then purified prior to electrotransformation. 
 
2.5.4.6 Purification of ligation DNA for electroporation 
In preparation for electroporation, ligation products were precipitated from the buffers used in 
the reaction, to prevent arcing during electrotransformation. For a 10 μL ligation reaction,  
0.5 μL of dextran sulfate (10 mg/mL stock) and 1 μL of 3 M sodium acetate were added and 
mixed. Twenty five microliters of absolute ethanol was added to the mix and precipitated 
DNA was pelleted by centrifugation for 15 min at 16,000 x g. The pellet was resuspended in 
100 μL 70% (v/v) ethanol and centrifugation was repeated for 5 min. The supernatant was 
removed and the pellet left to dry at room temperature under sterile conditions. The DNA was 
resuspended in 5 μL of molecular grade water and 1 μL was used for electrotransformation. 
The remaining DNA was stored at -20ºC. 
 
ng of vector required x size of insert (kb)      x      molar ratio of     =        ng of insert  
                Size of vector (kb)                              insert to vector             required for   
                                                                                (1:3)                         ligation 
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2.6 Protein methods 
2.6.1 Protein quantitation 
2.6.1.1 Bradford Assay 
The protein concentration of purified samples was determined by the Bradford method. 
Standard albumin solution (1 mg/mL) was used to prepare protein standards of 0 to 20 µg. 
Ten microlitres of sample was made up to 100 μL with 0.15 M NaCl to which 1 mL of 
Bradford reagent (Section 2.3.1) was added, mixed well and allowed to stand for 2 min at 
room temperature. Two hundred microlitre aliquots of each sample were transferred to a 96-
well microtitre tray in duplicate and absorbance was read at 600 nm.  
 
2.6.1.2 Spectrophotometric quantification of protein 
The Eppendorf BioPhotometer was used to determine the optical density (OD) of a protein 
solution at a wavelength of 280 nm. The concentration of the protein sample (mg/mL) was 
equal to the absorbance at 280 nm (with a path length of 1 cm).  
 
2.6.2 Protein visualisation 
2.6.2.1 SDS-PAGE 
Proteins were separated by one-dimensional 10% reducing SDS-PAGE. After pouring the 
resolving gel, distilled water was poured over the gel to ensure the gel interface was level 
after it set. After the gel had set and the water removed, the 5% stacking gel was then 
layered over the top of the resolving gel and a cast inserted between the glass slides to form 
the wells. The protein gel system was assembled as per the manufacturer’s protocol (BioRad 
Laboratories), and then placed within the gel tank containing 1 x SDS-PAGE running buffer. 
Protein samples were added to 5 x SDS sample loading buffer, boiled for 3 min and then 
loaded onto the gel together with a Precision Plus ProteinTM Standard (Appendix 2). The 
prestained KaleidoscopeTM protein standard (Appendix 2), or Precision Plus ProteinTM Dual 
Colour Standard (Appendix 2), was used if the gel was to be used for immunoblotting, while 
the unstained Precision Plus ProteinTM standard was used for gels that were to be stained by 
Coomassie. Electrophoresis was performed at 60 V for 30 min, and then 180 V for 50 min.  
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2.6.2.2 Coomassie instant stain 
Instant stain was used in place of Coomassie staining for some gels. Thirty millilitres of 
ClearPAGE Instant Blue Stain (C.B.S. Scientific Company, U.S.A.), or Acqua Stain 
(Geneworks, Australia) (Section 2.3.1), (or enough to cover gel(s)) was used for staining 
SDS-PAGE gels after electrophoresis. Bands were visible within 10 – 15 min, however 
Coomassie instant Stain was allowed to resolve bands for up to 1 h. A destaining step was 
not required with the use of ClearPage Instant Stain and Acqua Stain.  
 
2.6.2.3 Immunotransfer 
Western blotting was used to transfer proteins from an SDS-PAGE gel to a nitrocellulose 
membrane for further analysis. After SDS-PAGE, the gel was removed from the gel system 
and the stacking gel removed. The iBlot dry blotting system was used according to the 
manufacturer’s instructions. The order of materials set up for the iBlot system is shown below 
built from the anode stack, bottom: 
 
1. Anode stack, bottom 
2. Protein gel 
3. iBlot filter paper (pre-soaked in deionised water) 
4. Cathode stack, top 
5. Disposable sponge (attached to the lid of the apparatus) 
 
The cassette was closed after removing any air bubbles from the sandwich with the blotting 
roller and the transfer was performed (Program 3; 7 min). After transfer was complete, the 
nitrocellulose membrane was used for immunoblotting and all other components were 
discarded. 
 
2.6.2.4 Immunoblotting 
The nitrocellulose membrane was removed from the iBlot system and blocked in blocking 
buffer (Section 2.3.1), for 1 h. All incubations and washes were performed on a rotating 
shaker. The membrane was washed twice in TBS for 2 min, and then the primary antibody 
diluted in blocking buffer was added to the blot and left for 2 h at room temperature (or 
overnight at 4ºC). The blot was washed twice in TBS for 5 min, and the secondary antibody 
conjugated with AP was added and incubated at room temperature for up to 2 h. The blot 
was washed three times in TBST for 5 min and then incubated in detection buffer for 5-10 
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min. To develop the AP conjugate, the blot was immersed in BCIP/NBT substrate solution 
until the desired resolution was achieved. The blot was washed in dH2O to stop the reaction. 
 
2.6.3 Protein expression and purification 
2.6.3.1 Protein expression 
For protein expression, constructs were electrotransformed into E. coli BL21(DE3)pLysS or 
E. coli OrigamiTM2(DE3)pLysS for each expression (Section 2.4.4.2). The next step varied for 
the growth medium used for protein expression; however, in all cases E. coli 
BL21(DE3)pLysS or E. coli OrigamiTM2(DE3)pLysS containing the expression vector was 
grown in the presence of 100 mg/mL ampicillin and 34 mg/mL chloramphenicol. 
 
2.6.3.2 Pilot expression study 
Following electrotransformation of constructs into E. coli BL21(DE3)pLysS or E. coli 
OrigamiTM2(DE3)pLysS and overnight grown on LB agar containing antibiotics, a single 
colony was inoculated into 2 mL LB broth containing antibiotics and grown at 37°C until the 
absorbance at 600 nm reached 0.6 – 1.0, after which time the culture was left at 4°C 
overnight. The next day, the 2 mL pre-culture was pelleted by centrifugation and 
resuspended in 2 mL fresh LB broth. Fifty millilitres of LB broth was inoculated with 1% pre-
culture and antibiotics, and grown at 37°C until the absorbance at 600 nm reached 0.3 – 0.6. 
A 1 mL aliquot was taken before a final concentration of 1 mM IPTG was added to the 
remaining culture. One millilitre aliquots were taken at 1 – 5 h after IPTG induction. Cell 
pellets were washed twice in 1 mL of 10 mM Tris-HCl, pH 8.0, resuspended in 0.5 mL whole 
cell lysis buffer (Section 2.3.1), and then boiled for 3 min. Samples were separated by SDS-
PAGE gel (Section 2.6.2.1). 
 
2.6.3.3 Protein expression in LB broth 
The next day, a single colony was inoculated into 2 mL LB broth containing antibiotics and 
grown at 37°C until the absorbance at 600 nm reached 0.6 – 1.0, after which time the culture 
was left at 4°C overnight. The next day, the 2 mL pre-culture was pelleted by centrifugation 
and resuspended in 2 mL fresh LB broth. Two hundred millilitres of LB broth in a 1 L flask 
was inoculated with 1% pre-culture and antibiotics and grown at the desired temperature 
(25°C, 30°C, 37°C, 42°C), until the absorbance at 600 nm reached 0.3 – 0.6. A final 
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concentration of 1 mM IPTG was added and protein expression was induced at the required 
temperature for the length of time found to be optimal through the pilot study.  
 
2.6.3.4 Protein expression with EnPressoTM tablet media set (BioSilta) 
Protein expression was conducted following the manufacturer’s protocol. Briefly, following 
electrotransformation of the construct into E. coli BL21(DE3)pLysS or E. coli 
OrigamiTM2(DE3)pLysS, the next day a single colony was inoculated into 2 mL LB broth 
containing antibiotics and grown at 37°C for 7 h. Five hundred microlitres of the pre-culture 
was added to 50 mL sterile dH2O in a 500 mL flask along with the antibiotics, the white bag 
containing the media in tablet form, and 25 µL of EnzI’m, both of which were supplied in the 
kit from BioSilta (Section 2.3.2). The flask was sealed with an AirOtop seal (BioSilta). The 
culture was grown overnight at 30°C and the next day a final concentration of 1 mM IPTG 
was added along with the black bag containing the glucose tablet and 50 µL of EnzI’m 
(BioSilta) to the culture and induction of protein expression was allowed to proceed for 8 h.  
 
2.6.3.5 Preparation of cell lysate 
Following induction of expression, cells were harvested by centrifugation at 4,700 x g for  
15 min at 4°C. The cell pellet was resuspended in 5 mL of protein lysis buffer per gram 
weight of pellet and left at -80°C overnight (first freeze). The next day, a total of four 
freeze/thaw cycles was performed using a -80°C freezer and a 37°C water bath. Thirty units 
of DNase I was added after the second cycle and incubated at 37°C for 10 min. For some 
samples, a final concentration of 1 mM PMSF was added at each thaw step for a total of four 
times. Cell debris was pelleted by centrifugation at 4,700 x g for 15 min at 4°C. Clarification 
was repeated if necessary. The cell lysate was then applied to nickel or cobalt charged 
sepharose resin pre-equilibrated with binding buffer containing the same concentration of 
imidazole as was in the protein lysis buffer. 
 
2.6.3.6 Cell-free protein expression 
Expression vectors used in cell-free expression were first purified using the PureYieldTM 
plasmid miniprep system (Promega, U.S.A.), following the manufacturer’s instructions.  
 
Cell-free protein synthesis was performed using the S30 T7 High-yield protein expression 
system (Promega, U.S.A.), as per the manufacturer’s protocol. Briefly, T7 S30 extract 
(circular), S30 Premix plus and the plasmid DNA template with a T7 promoter were 
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combined and incubated at 37°C with shaking at 300 rpm. Reactions were performed in  
50 µL volumes. Reaction components are listed in Table 2.8. 
 
Reactions were stopped by incubation in an ice water bath for 5 min. Five microliters of the 
cell-free reaction was combined with 14 µL of TBS and 1 µL of 0.1 µg/µL RNaseA and 
incubated at room temperature for 5 min. Samples representing 10% of the total cell-free 
reaction were analysed by SDS-PAGE (Section 2.6.2.1).   
 
2.6.4 Detection and solubilisation of inclusion bodies 
2.6.4.1 Detection of inclusion bodies 
Following induction of protein expression in E. coli BL21(DE3)pLysS or E. coli 
OrigamiTM2(DE3)pLysS, 1 mL of culture was pelleted by centrifugation at 10,000 x g for 1 
min. The cell pellet was resuspended in 100 µL protein lysis buffer (Section 2.3.1). Cells 
were lysed by a total of four freeze/thaw cycles using a -80°C freezer and a 37°C water bath, 
and 30 U DNase I was added after the second cycle and incubated at 37°C for 10 min. Cell 
debris was pelleted by centrifugation at 16,000 x g for 5 min. The supernatant was 
transferred to a new tube and the remaining pellet was resuspended in 100 µL of MQ water. 
Ten microliters of the pellet and supernatant samples were analysed by SDS-PAGE (Section 
2.6.2.1) and visualised using with Coomassie instant stain (Section 2.6.2.2) and 
immunoblotting with appropriate antisera (Section 2.6.2.3 – 2.6.2.4).  
 
2.6.4.2 Pilot solubilisation of inclusion bodies 
Following induction of protein expression in E. coli BL21(DE3)pLysS or E. coli 
OrigamiTM2(DE3)pLysS, the cell pellet was resuspended in 5 mL of protein lysis buffer per 
gram weight of pellet. Cells were lysed by a total of four freeze/thaw cycles using a -80°C 
freezer and a 37°C water bath, and 30 U DNase I was added after the second cycle and  
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Table 2.8: Reaction components for cell-free transcription/translation procedure.  
 
Component Per 50 µL reaction 
T7 S30 extract, circular 18 µL 
S30 Premix plus 20 µL 
DNA template 1 µg 
Nuclease-free water Up to 50 µL 
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incubated at 37°C for 10 min. Cell debris was pelleted by centrifugation at 1,000 x g for 5 min 
at 4°C. Inclusion bodies remaining in the supernatant were pelleted by centrifugation at 
27,000 x g for 15 min at 4°C. The pellet, containing inclusion bodies was resuspended in 1.5 
mL MQ water and 100 µL aliquots were separated into 1.5 mL microfuge tubes. Aliquots 
were pelleted by centrifugation at 1,000 x g for 5 min and the supernatant was discarded. 
Inclusion bodies were washed in 100 µL of 0.1 M Tris-HCl of varying pH (pH 8, 9, 10, 11.5, 
12 and 12.5), or 100 µL of 0.1 M Tris-HCl of varying pH and 2 M urea. Inclusion bodies were 
pelleted by centrifugation at 1,000 x g for 5 min and the supernatant was transferred to a new 
1.5 mL microfuge tube, and pellets were resuspended in 100 µL of MQ water. Ten microliters 
of the pellet and supernatant samples were analysed by SDS-PAGE and visualised using 
with Coomassie instant stain (Section 2.6.2.2) and immunoblotting with appropriate antisera 
(Section 2.6.2.3 – 2.6.2.4). 
 
2.7 Protein purification 
2.7.1 Immobilised metal affinity chromatography (IMAC) 
2.7.1.1 IMAC column preparation 
A 1 mL gravity flow column was charged before use by passing 0.5 CV of 0.2 M nickel 
sulphate (NiSO4) (Ni2+), or 0.2 M cobalt chloride (Co2Cl) (Co2+) through the column. The 
column was then washed with at least 5 CV of distilled water to remove unbound metal ions 
and equilibrated with 5 CV of binding buffer.  
 
2.7.1.2 IMAC purification 
Cell lysate containing expressed recombinant protein was applied to a pre-equilibrated IMAC 
column. The column was washed with 5 CV of wash buffer containing increasing 
concentrations of imidazole and the flow through was collected in 1 mL fractions and 
analysed for unbound protein via the Bradford method (Section 2.6.1.1). No colour change 
indicated the absence of protein in the wash. Protein was eluted with 5 CV of elution buffer 
and collected in 1 mL aliquots. Samples were analysed by SDS-PAGE (Section 2.6.2.1).  
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2.7.1.3 IMAC column cleaning and regeneration 
Gravity flow columns were re-used up to 4 times, and stripped and cleaned between 
purifications. The column was cleaned by stripping the nickel from the column with 5 CV of 
IMAC stripping solution. Residual EDTA from the stripping solution was removed by washing 
the column with 5 - 10 CV of 2 M NaCl, followed by washing with 5 - 10 CV of MQ water,  
5 CV of 1 M NaOH and a final wash with 5 - 10 CV of MQ water. Columns were stored in 
20% ethanol at 4°C and recharged with nickel or cobalt before re-use. 
 
2.7.1.4 IMAC purification – HisPur Cobalt spin columns 
HisPur Cobalt 1 mL spin columns (ThermoFisher Scientific, U.S.A.) were purchased pre-
charged with cobalt and were used following the manufacturer’s instructions. All 
centrifugation steps were performed at 700 x g for 2 min at 4°C. Prior to use, the resin was 
rinsed twice with 2 CV MQ water and pre-equilibrated with binding buffer. Cell lysate was 
applied to the column and incubated on a rotating platform shaker for 30 min on ice, to allow 
binding of the His6-tagged proteins to the cobalt-charged resin. The flow through was 
collected by centrifugation and the column was then washed 3 times with 2 CV wash buffer. 
The His6-tagged proteins were eluted 3 times in 1 CV elution buffer. Samples were analysed 
by SDS-PAGE (Section 2.6.2.1).  
 
2.7.1.5 HisPur Cobalt spin column cleaning and regeneration 
After use, the HisPur Cobalt spin column was washed with 10 CV of MES/NaCl buffer 
(Section 2.3.1) and then 10 CV dH2O. Resin was stored as 50% slurry in 20% ethanol at 4°C. 
 
2.7.1.6 Batch purification (protein miniprep) 
For small scale protein purification, His6-tagged proteins were purified using a batch 
purification method. One hundred microlitres of sepharose resin in a 1.5 mL centrifuge tube 
was charged with 0.5 CV of 0.2 M NiSO4. All centrifugation steps were performed at 1000 x g 
for 2 min. Excess nickel was removed by rinsing 3 times with 5 CV dH2O and resin was pre-
equilibrated with 5CV binding buffer. His6-tagged protein samples were applied to the resin 
and incubated for 10 min on ice before washing with 5 CV wash buffer and eluting in 5 CV 
protein elution buffer. Samples were analysed by SDS-PAGE (Section 2.6.2.1).  
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2.7.2 Protein processing 
2.7.2.1 Protein concentration and buffer exchange  
Proteins purified by IMAC underwent ultrafiltration using a centrifugal device to concentrate 
the sample and to remove any small molecular weight proteins still present after IMAC 
purification. Buffer exchange was performed to replace the protein elution buffer with a buffer 
required for downstream protein assays and for protein storage at -20ºC. After pre-rinsing the 
Vivaspin 20 (30 kDa or 50 kDa MWCO) centrifugal device twice with 10 mL MQ water, the 
protein in elution buffer was added and ultracentrifugation was performed at 5,000 x g for 10 
min at 4°C. After the protein elution buffer filtered through the device, and <2 mL of protein, 
10 mL of protein storage buffer (PSB) (Section 2.3.1) was added to the diafiltration cup 
(Section 2.2) inserted into the device, and centrifugation was repeated in 10 min intervals 
until the volume of PSB was reduced to less than 1 mL. The retentate was then recovered 
and transferred from the device to a 1.5 mL microfuge tube. Typically, 250 – 500 μL of 
retentate was recovered. If required, concentration was adjusted so that it was no higher 
than 1.5 mg/mL with protein storage buffer.  
 
2.7.2.2 Storage 
Proteins were stored at -20°C for up to 2 months in protein storage buffer (Section 2.3.1). 
 
2.7.2.3 His6-tag removal 
Removal of the N-terminal affinity tag was performed by treatment with EKMaxTM 
Enterokinase (Invitrogen Corporation, U.S.A.). A pilot study was performed whereby 20 µg of 
His6-tagged protein was incubated with various amounts of enterokinase (0, 0.001, 0.01, 0.1, 
1, 4 U/reaction), for various lengths of time (1 h, 2 h, 16 h), at room temperature. Reactions 
were analysed by SDS-PAGE (Section 2.6.2.1), and a Western blot (Section 2.6.2.3 – 
2.6.2.4), probing with antisera to the His6-tag (mouse anti-His IgG) (Section 2.3.4). 
 
Once enterokinase treatment was optimised, the enzyme was removed from the reaction 
using the Enterokinase removal kit (Invitrogen Corporation, U.S.A.) (Section 2.3.5), following 
the manufacturer’s instructions. Following enterokinase removal from the reaction, the 
cleaved His6-tag was then removed by batch purification (protein miniprep), (Section 2.7.1.6). 
Enterokinase-treated samples were applied to sepharose resin pre-charged with 0.2 M 
NiSO4 and equilibrated with protein wash buffer without imidazole. The enterokinase-free 
sample was added to the charged resin and the His6-tag was allowed to bind for 30 min on 
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ice. After centrifugation at 1000 x g for 2 min, the His6-tag-free supernatant was recovered 
and analysed by SDS-PAGE (Section 2.6.2.1). 
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Chapter 3  
Construction of neurotoxin 
chains from Clostridium tetani 
and Clostridium botulinum  
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3.1 Introduction  
The preceding section outlined the literature relating to the problem of OSA and the 
requirement of a novel, less-invasive and acceptable treatment option to surgery and 
mechanical and non-mechanical devices. The potential of exploiting the function of CNTs to 
create a novel chimeric CNT neurotoxin for the treatment of OSA was also presented. In this 
chapter, individual toxin domains, namely botulinum type A light chain (B/ALC), and the light 
and heavy chains of tetanus toxin (TLC and THC), are engineered using recombinant DNA 
technology for expression in an E. coli heterologous host.  
 
In order for the novel chimera to be useful in the treatment of OSA, the toxin is required to (i) 
retain the specific cell-binding activity of native TeNT and undergo retrograde axonal 
transport to inhibitory interneurons in the CNS, mediated by the HC domain; (ii) translocate 
the LC from the endosome into the cytosolic compartment of the inhibitory interneuron, 
mediated by the HN domain; and (iii) cleave one of the SNARE proteins to block 
neurotransmitter release from the inhibitory interneuron, mediated by the LC (Turton et al., 
2002).   
 
After recombinant protein expression of the toxin domains in E. coli, the purified proteins will 
joined via conjugation of the free thiol groups present at the C- and N-terminus of the LC and 
HC chains, respectively, creating the di-chain molecule which mimics the structure of native 
CNTs. This final chimeric toxin will comprise the catalytically active B/ALC, and the heavy 
chain cell-binding and translocation domains of tetanus toxin (THC). The native tetanus toxin 
will also be re-created by conjugating the recombinantly expressed TLC and THC, to serve 
as an experimental control. This recombinant tetanus toxin will be used to assess the 
efficiency of the expression and conjugation procedure by comparing its activity with that of 
native tetanus toxin.  
 
TeNT and BoNT domains will be expressed individually and later reconstituted to create the 
di-chain toxins, as opposed to expression as full-length single-chain holotoxins. Safety 
concerns over the potential toxicity of recombinant single-chain toxins which have been 
shown to retain catalytic function in the un-nicked form, underpins the basis of this approach 
(Li, Y. et al., 2001). Although it has been documented that recombinantly expressed 
individual toxin domains may display a reduced biological activity to the native toxin 
(Fairweather et al., 1993), it has also been demonstrated that CNT toxin domains can be 
expressed individually and later reconstituted to create an active di-chain molecule with 
activity comparable to that of the native holotoxin (Li, Y. et al., 1999; Li, Y. et al., 1994).  
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The recombination of CNT domains has previously been performed to create chimeric 
holotoxins comprising recombinant fragments from both BoNTs and TeNT (Poulain et al., 
1991; Wang et al., 2008), and full-length native TeNT (Li, Y. et al., 1999; Li, Y. et al., 2001), 
and BoNTs (Band et al., 2010; Pellett et al., 2011), have also been recombinantly expressed. 
TeNT HC fragments have been joined to non-CNT proteins for the delivery of therapeutic 
molecules to the CNS (Barati et al., 2002; Benn et al., 2005; Francis et al., 2000; Francis et 
al., 2004b; Francis et al., 1995; Larsen et al., 2006; Roux et al., 2006), and BoNT fragments 
have also been joined to non-CNT proteins to exploit their cell-targeting and catalytic 
functions (Bade et al., 2004; Duggan et al., 2002).  
 
It is well known that C. tetani and C. botulinum genomes have a low GC content (Hatheway, 
1990). Due to the codon bias displayed by E. coli for certain transfer RNA (tRNA), 
recombinant expression of genes with a low GC content (or high AT content), in E. coli has 
been reported to affect translation efficiency, and may lead to a reduction in the yield of 
protein expression (Andersson and Kurland, 1990). Due to the differences in codon usage 
within Clostridia, the three toxin sequences were codon optimised to suit the expression host; 
a method which has previously been used to increase recombinant protein expression of 
CNTs in E. coli (Makoff et al., 1989). 
 
The objectives of this part of the study are to obtain codon optimised sequences of TLC, 
THC and B/ALC. The sequences will be cloned into the expression vector, pRSET-A. 
Escherichia coli will be used for the heterologous expression of the recombinant toxin 
domains from pRSET-A, and the recombinant proteins will contain an N-terminal His6-tag. 
The affinity tag will be used to aid in the purification and identification of the recombinant 
proteins in the next part of the study. A pilot expression study is performed on each of the 
proteins to assess the time and temperature required to obtain an optimal yield of 
recombinant protein expression. The results from the pilot study will determine the conditions 
used for the expression of protein in the following section.  
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3.2 Materials and Methods 
3.2.1 Construct design 
3.2.1.1 CNT genes 
The gene sequences of tetanus toxin (Accession no. X06214) and botulinum type A toxin 
strain Hall 183 (Accession no. EF033126), were obtained from the NCBI nucleotide 
database.  
 
The tetanus toxin coding sequence (CDS) consists of 4,338 nucleotides, with the TLC 
encoded by nucleotides 1 – 1,371, and the heavy chain by nucleotides 1,372 – 2,577. The 
mature TeNT protein lacks the N-terminal methionine in the LC, therefore the recombinant 
TeNT proteins express residues P2 – A457 of the LC, and S458 – D1315 of the HC (Eisel et 
al., 1986).  
 
The botulinum type A LC is encoded by nucleotides 1 – 1,344. The mature B/ALC also lacks 
the N-terminal methionine, and the recombinant protein expresses residues P2 – K448 
(Zhang et al., 2003).  
 
Sequences were manipulated using the SE Central suite of analysis tools (Clone Manager), 
and construct maps for TLC, THC and B/ALC in pRSET-A were created using Clone 
Manager. 
 
3.2.2 Codon optimisation and gene synthesis 
The services of GenScript Corporation (NJ, USA), were employed to synthesise the toxin 
chains. Codon optimisation of the three nucleotide sequences was performed using the 
OptimumGeneTM codon optimisation tool (GenScript Corp., U.S.A.), and sequences were 
optimised for expression in E. coli.  
 
The synthesised toxin domains were cloned by EcoRV into pUC57 (Fermentas) plasmid 
cloning vector (Figure 3.1), and supplied as a 4 μg plasmid miniprep by GenScript. Following 
receipt, sequences were sub-cloned into pRSET-A (Figure 3.2), and further investigated for 
protein expression. Pilot expression was performed in E. coli BL21(DE3)pLysS (Invitrogen), 
and THC was also expressed in E. coli OrigamiTM 2(DE3)pLysS (Merck Millipore), to observe  
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Figure 3.1: pUC57 vector (Fermentas, U.S.A.).  
Reproduced from pUC57 product specifications sheet (Fermentas, Canada). 
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Figure 3.2: pRSET vector map (top) and multiple cloning site of pRSET-A (bottom) 
(Invitrogen, U.S.A.).  
Reproduced from pRSET-A user manual (Invitrogen, U.S.A.). 
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the optimal temperature for expression and duration of induction following addition of the 
inducer, IPTG.  
 
3.2.2.1 Analysis of codon optimisation 
The codon adaptation index (Sharp and Li, 1987), GC content and codon frequency 
distribution (Grosjean and Fiers, 1982), analysis was performed using online resources from 
GenScript (GenScript, 2013).  
 
3.2.3 In silico protein characterisation 
The SE Central suite (Clone Manager) was used to estimate the molecular weight and 
isoelectric point (pI) of the recombinant His6-tagged proteins, and PeptideCutter (ExPASy) 
(Gasteiger E., 2005) was used to predict protease cleavage sites within the codon optimised 
sequence of the toxin chains. Hydropathicity profiles were constructed using the Hopp-
Woods (Hopp and Woods, 1981) and Kyte-Doolittle algorithms (Kyte and Doolittle, 1982), 
and plots were created using a generator from Colorado State University (Toolkit, 2013). 
Protein templates for modelling were obtained from the Protein Data Bank (PDB) (Berman et 
al., 2000). The crystal structure of tetanus toxin light chain (PDB ID. 1Z7H) (Breidenbach and 
Brunger, 2005a), heavy chain (PDB ID. 1FV3) (Zozula and Rosen, 2001), and botulinum type 
A toxin (PDB ID. 3BTA) (Lacy et al., 1998), were used as templates to create a model of the 
proposed novel chimeric holotoxin consisting of B/ALC and THC. Models were constructed 
using Modeller 9.10 (Sali and Blundell, 1993), and viewed using Swiss-PDB Viewer version 
4.0.1 (Guex and Peitsch, 1997).  
 
3.2.4 Cloning of toxin chains into pRSET-A 
3.2.4.1 Cloning of TeNT light chain into pRSET-A 
To facilitate cloning of TLC into the multiple cloning site (MCS) of pRSET-A, 5’ XhoI and  
3’ PstI restriction enzyme sites were added to the nucleotide sequence during synthesis. 
Sequence analysis performed using the SE Central suite (Clone Manager), indicated that no 
additional nucleotide bases were required to ensure the TLC coding sequence remained in 
frame with the ATG start codon of pRSET-A.  
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Codon optimised TLC containing the above-mentioned 5’ and 3’ restriction sites was 
supplied by GenScript in the pUC57 vector (Figure 3.3). Restriction enzyme digestion of TLC 
from pUC57 and pRSET-A containing no insert, was performed using XhoI and PstI (Section 
2.5.4.1). Following digestion, reactions were separated on a 1.5% DNA agarose gel (Section 
2.5.2.2). Excision of the double digested TLC and pRSET-A from the agarose gel was 
performed and the DNA was purified using the QIAquick gel extraction kit (Section 2.3.5), 
then concentrated to a smaller volume (Section 2.5.4.4) to facilitate ligation. After overnight 
ligation at 16°C (Section 2.5.4.5), the DNA was purified (Section 2.5.4.6), and 1 μL was used 
for electrotransformation (Section 2.4.4.2) into electrocompetent E. coli DH5α cells. Colonies 
that grew on LB agar containing 100 mg/mL ampicillin were screened for the presence of the 
TLC insert. 
 
3.2.4.2 Cloning of TeNT heavy chain into pRSET-A 
The restriction sites used to facilitate cloning of THC into the MCS of pRSET-A were 5’ XhoI 
and 3’ PvuII which were added to the nucleotide sequence during synthesis. Sequence 
analysis performed using the SE Central suite (Clone Manager), indicated that the addition of 
these restriction enzyme sites was sufficient for the THC coding sequence to remain in frame 
with the ATG start codon of pRSET-A.  
 
Codon optimised THC was supplied by GenScript in the pUC57 vector with 5’ XhoI and  
3’ PvuII restriction sites (Figure 3.4). Restriction enzyme digestion of THC from pUC57 and 
pRSET-A containing no insert, was performed using XhoI and PvuII (Section 2.5.4.1). 
Following digestion, reactions were combined and the DNA was concentrated to a smaller 
volume (Section 2.5.4.4) to facilitate ligation. After overnight ligation at 16°C (Section 
2.5.4.5), the DNA was purified (Section 2.5.4.6), and 1 μL was used for electrotransformation 
(Section 2.4.4.2) into electrocompetent E. coli DH5α cells. Colonies that grew on LB agar 
containing 100 mg/mL ampicillin were screened for the presence of the THC insert.  
 
3.2.4.3 Cloning of BoNT/A light chain into pRSET-A 
The restriction sites used to facilitate cloning into the MCS of pRSET-A were 5’ PstI and  
3’ EcoRI, which were added to the nucleotide sequence during synthesis. Sequence analysis 
using the SE Central suite (Clone Manager) indicated that the B/ALC coding sequence was 
not in frame with the start codon of pRSET-A, so a single C nucleotide was added between 
the restriction enzyme recognition sequence at the 5’ end of B/ALC to allow the sequence to 
be translated in frame with the ATG start codon of pRSET-A.  
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Figure 3.3: Codon optimised gene encoding TLC in pUC57 (Fermentas), supplied by 
GenScript, U.S.A. 
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Figure 3.4: Codon optimised gene encoding THC in pUC57 (Fermentas), supplied by 
GenScript, U.S.A. 
94 
 
Codon optimised B/ALC was supplied by GenScript in the pUC57 vector with 5’ EcoRI and  
3’ PstI restriction sites (Figure 3.5). Restriction enzyme digestion of B/ALC from pUC57 and 
pRSET-A containing no insert, was performed using EcoRI and PstI (Section 2.5.4.1). 
Following digestion, reactions were separated on a 1.5% DNA agarose gel (Section 2.5.2.2). 
Excision of the double digested B/ALC and pRSET-A was performed and the DNA was 
purified using the QIAquick gel extraction kit (Section 2.3.5), then concentrated to a smaller 
volume (Section 2.5.4.4) to facilitate ligation. After overnight ligation at 16°C (Section 
2.5.4.5), the DNA was purified (Section 2.5.4.6), and 1 μL was used for electrotransformation 
(Section 2.4.4.2) into electrocompetent E. coli DH5α cells. Colonies that grew on LB agar 
containing 100 mg/mL ampicillin were screened for the presence of the B/ALC insert. 
 
3.2.4.4 Colony screening 
All clones were analysed for the presence and orientation of inserts and to confirm that all 
inserts were in frame with the start codon of the pRSET-A expression vector by sequencing 
PCR (Section 2.5.4.2) (results not shown), and by restriction digestion using the restriction 
enzymes which corresponded to the 5’ and 3’ restriction sites engineered into the 
synthesised sequences (Section 2.5.4.1). 
 
3.2.5 Pilot protein expression study 
Following successful cloning of inserts into pRSET-A and confirmation by sequencing PCR, 
a pilot expression study (Section 2.6.3.2), was performed to assess the optimal temperature 
and time required for induction of protein expression. One millilitre aliquots were collected at 
0 – 5 h after induction of protein expression with IPTG, and 10 – 15 µg of protein was 
analysed by SDS-PAGE (Section 2.6.2.1) and staining with Coomassie instant stain (Section  
2.6.2.2). Western blot (Section 2.6.2.3 – 2.6.2.4) was also performed, probing with antibodies 
directed at the His6-tag (mouse anti-His IgG), and to the toxin domains (rabbit anti-tetanus 
toxin IgG, and rabbit anti-C. botulinum A toxoid IgG) (Section 2.3.4). 
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Figure 3.5: Codon optimised gene encoding B/ALC in pUC57 (Fermentas), supplied by 
GenScript, U.S.A.  
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3.3 Results 
3.3.1 Codon optimisation 
Codon optimisation of the wild-type Clostridial nucleotide sequences showed improvements 
in percentage GC content of the toxin domains, codon adaptation index (CAI) scores, and 
codon frequency distribution (CFD) (Figures 3.6A and B, 3.7A and B, and 3.8A and B). The 
GC content of all three toxin chains was increased from below 30% in the wild-type to above 
40% in the codon optimised sequences, with increases in GC content of between 12 – 17% 
across the three sequences. CAI scores increased from ~0.6 to above 0.8 in all sequences 
after codon optimisation, with increases of between 0.2 – 0.3. Finally, all CFD results showed 
an increase in the number of codons present in the pool of codons most frequently used by 
E. coli (91 – 100%) after codon optimisation, with increases of between 20 – 32 codons now 
present in the most frequently used pool.  
 
Alignments of the wild-type and codon optimised nucleotide sequences of TLC, THC and 
B/ALC is shown in Figures 3.9, 3.10 and 3.11, respectively. After codon optimisation, 
sequences displayed differences in primary sequence identity of 22% for TLC, 25% for THC 
and 26% for B/ALC (data not shown).  
 
3.3.2 Cloning of toxin chains into pRSET-A 
The pRSET-A expression vector (Figure 3.2) contains an ATG start codon upstream of the 
MCS, from where initiation of the His6-tag, enterokinase cleavage site and ribosomal binding 
site (along with other elements) begins. Transcription of the sequence inserted into the MCS 
is also initiated from this site. For this reason, the synthesised toxin sequences lack the initial 
methionine at the 5’ position, with the exception of THC which does not contain an N-terminal 
start codon in the native amino acid sequence. A 3’ stop codon was added to both light chain 
sequences to terminate transcription. Insertion of a stop codon was not required for THC, 
which retained the stop codon at the 3’ end of the native amino acid sequence.  
 
The N-terminal affinity tag encoded by the pRSET-A expression vector added 39 residues to 
the N-terminus of the recombinant TLC and THC, and 42 residues to the N-terminus of the 
recombinant B/ALC (due to the position of the MCS) (data not shown).   
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Figure 3.6A: Wild-type TLC Codon Adaptation Index, GC content and Codon Frequency Distribution. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6B: TLC Codon Adaptation Index, GC content and Codon Frequency Distribution after codon optimisation by GenScript. 
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Figure 3.7A: Wild-type THC Codon Adaptation Index, GC content and Codon Frequency Distribution.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7B: THC Codon Adaptation Index, GC content and Codon Frequency Distribution after codon optimisation by GenScript.  
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Figure 3.8A: Wild-type B/ALC Codon Adaptation Index, GC content and Codon Frequency Distribution. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8B: B/ALC Codon Adaptation Index, GC content and Codon Frequency Distribution after codon optimisation by GenScript. 
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Figure 3.9:  Alignment of wild-type (TLC) and codon optimised (TLC CO) tetanus toxin 
light chain nucleotide sequences. 
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Figure 3.10: Alignment of wild-type (THC) and codon optimised (THC CO) tetanus toxin 
heavy chain nucleotide sequences. 
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Figure 3.11: Alignment of wild-type (B/ALC) and codon optimised (B/ALC CO) 
botulinum type A toxin light chain nucleotide sequences. 
 
103 
 
3.3.2.1 Tetanus toxin light chain (TLC) 
The codon optimised TLC nucleotide sequence consists of 1,371 bp encoding the 456 amino 
acid native tetanus toxin light chain. The final construct pTLC is 4,266 bp in length, and 
consists of the 1,371 bp TLC and the ~2,900 bp pRSET-A vector (Figure 3.12A). TLC  
(~1.3 kb) was digested from the pUC57 vector (~2.7 kb) using XhoI and PstI (Figure 3.12B), 
and following ligation, screening of clones with XhoI and PstI (Figure 3.12C) and sequencing 
PCR (data not shown) confirmed the presence of TLC in pRSET-A (pTLC).  
 
3.3.2.2 Tetanus toxin heavy chain (THC) 
The codon optimised THC nucleotide sequence consists of 2,577 bp encoding the 858 amino 
acid native tetanus toxin heavy chain. The final construct pTHC is 5,469 bp in length, and 
consists of the 2,577 bp THC and the ~2,900 bp pRSET-A vector (Figure 3.13A). THC  
(~2.5 kb) was digested from the pUC57 vector (~2.7 kb) using XhoI and PvuII (Figure 3.13B), 
and following ligation, screening of clones with XhoI and PvuII (Figure 3.13C) and 
sequencing PCR (data not shown) confirmed the presence of THC in pRSET-A (pTHC). 
 
3.3.2.3 Botulinum type A toxin light chain (B/ALC) 
The codon optimised B/ALC nucleotide sequence consists of 1,344 bp encoding the 447 
amino acid native botulinum type A toxin light chain. The final construct pB/ALC is 4,231 bp 
in length, and consists of the 1,344 bp B/ALC and the ~2,900 bp pRSET-A vector (Figure 
3.14A). B/ALC (~1.3 kb) was digested from the pUC57 vector (~2.7 kb) using PstI and EcoRI 
(Figure 3.14B), and following ligation, screening of clones with PstI and EcoRI (Figure 3.14C) 
and screening PCR (data not shown) confirmed the presence of B/ALC in pRSET-A 
(pB/ALC).  
 
3.3.3 Pilot expression study 
All three constructs expressed recombinant protein at the predicted molecular weight, 
(estimated by Clone Manager, data not shown), when visualised using SDS-PAGE and 
Western blotting.  
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Figure 3.12: Construction of pTLC. 
(A) Diagrammatic representation of pTLC. The pTLC construct encodes the codon optimised sequence for the mature TLC, spanning residues P2 – 
A457 of the wild-type amino acid sequence, with an N-terminal His6-tag and C-terminal stop codon. The gene is inserted within the MCS of the 
pRSET-A vector and is expressed under the control of a T7 promoter. (B) Double digest of TLC in pUC57. Lane 1, λ-PstI; Lane 2, pUC57/TLC 
digested with XhoI and PstI. (C) Cloning into pRSET-A. Lane 1, λ-PstI; Lane 2, TLC insert in pRSET-A (pTLC) digested with XhoI and PstI.  
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Figure 3.13: Construction of pTHC. 
(A) Diagrammatic representation of pTHC. The pTHC construct encodes the codon optimised sequence for the mature THC, spanning residues S458 
– D1315 of the wild-type amino acid sequence, with an N-terminal His6-tag and C-terminal stop codon. The gene is inserted within the MCS of the 
pRSET-A vector and is expressed under the control of a T7 promoter. (B) Double digest of THC in pUC57. Lane 1, λ-PstI; Lane 2, pUC57/THC 
digested with XhoI and PvuII. (C) Cloning into pRSET-A. Lane 1, λ-PstI; Lane 2, THC insert in pRSET-A (pTHC) digested with XhoI and PvuII.  
MC
S 
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Figure 3.14: Construction of pB/ALC. 
(A) Diagrammatic representation of pB/ALC. The pB/ALC construct encodes the codon optimised sequence for the mature B/ALC, spanning residues 
P2 – K488 of the wild-type amino acid sequence, with an N-terminal His6-tag and C-terminal stop codon. The gene is inserted within the MCS of the 
pRSET-A vector and is expressed under the control of a T7 promoter. (B) Double digest of B/ALC in pUC57. Lane 1, λ-PstI; Lane 2, pUC57/B/ALC 
digested with PstI and EcoRI. (C) Cloning into pRSET-A. Lane 1, λ-PstI; Lane 2, B/ALC insert in pRSET-A (pB/ALC) digested with PstI and EcoRI.   
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3.3.3.1 pTLC pilot expression study 
The recombinant His6-tagged TLC, encodes amino acids P2 - A457 of native tetanus toxin 
and consists of 495 amino acids with a predicted molecular weight of 56.7 kDa. Expression 
vector pTLC was expressed in E. coli BL21(DE3)pLysS and the pilot expression study was 
performed in LB broth at 30°C (Figure 3.15), and 37°C (Figure 3.16). TLC expression was 
optimal at 30°C for 3 h after induction with IPTG.   
 
3.3.3.2 pTHC pilot expression study 
The recombinant His6-tagged THC, encodes the C-terminal 858 amino acids of the native 
tetanus toxin (S458 – D1315), and consists of 897 amino acids with a predicted molecular 
weight of 102.7 kDa. Expression vector pTHC was expressed in E. coli BL21(DE3)pLysS and 
the pilot study was performed in LB broth at 30°C (Figure 3.17), and 37°C (Figure 3.18). THC 
expression was optimal at 30°C for 3 h after induction with IPTG.   
 
Expression vector pTHC was also expressed in E. coli OrigamiTM 2(DE3)pLysS and the pilot 
study was performed in LB broth at 30°C (Figure 3.19), and 37°C (Figure 3.20). THC 
expression in this strain was optimal at 30°C for 3 h after induction with IPTG.   
 
3.3.3.3 pB/ALC pilot expression study 
The recombinant His6-tagged B/ALC encodes amino acids P2 – K448 of native botulinum 
type A toxin and consists of 489 amino acids with a predicted molecular weight of 56 kDa. 
Expression vector pB/ALC was expressed in E. coli BL21(DE3)pLysS and the pilot 
expression study was performed in LB broth at 30°C (Figure 3.21), and 37°C (Figure 3.22). 
B/ALC expression was optimal at 30°C for 3 h after induction with IPTG.  
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Figure 3.15: pTLC 30°C pilot expression in E. coli BL21(DE3)pLysS. 
Lane 1, Marker; Lane 2 - 7, time-point samples collected 0 – 5 h pre- and post-induction with 
1 mM IPTG, 10 µg/well. (A) Pilot expression of TLC at 30°C visualised by SDS-PAGE and 
Coomassie instant stain. (B) Pilot expression of TLC at 30°C as detected by immunoblotting 
with mouse anti-His IgG. (C) Pilot expression of TLC at 30°C as detected by immunoblotting 
with rabbit anti-tetanus toxin IgG.  
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Figure 3.16: pTLC 37°C pilot expression in E. coli BL21(DE3)pLysS. 
Lane 1, Marker; Lane 2 - 7, time-point samples collected 0 – 5 h pre- and post-induction with 
1 mM IPTG, 10 µg/well. (A) Pilot expression of TLC at 37°C visualised by SDS-PAGE and 
Coomassie instant stain. (B) Pilot expression of TLC at 37°C as detected by immunoblotting 
with mouse anti-His IgG. (C) Pilot expression of TLC at 37°C as detected by immunoblotting 
with rabbit anti-tetanus toxin IgG. 
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Figure 3.17: pTHC 30°C pilot expression in E. coli BL21(DE3)pLysS. 
Lane 1, Marker; Lane 2 - 7, time-point samples collected 0 – 5 h pre- and post-induction with 
1 mM IPTG, 10 µg/well. (A) Pilot expression of THC at 30°C visualised by SDS-PAGE and 
Coomassie instant stain. (B) Pilot expression of THC at 30°C as detected by immunoblotting 
with mouse anti-His IgG. (C) Pilot expression of THC at 30°C as detected by immunoblotting 
with rabbit anti-tetanus toxin IgG. 
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Figure 3.18: pTHC 37°C pilot expression in E. coli BL21(DE3)pLysS. 
Lane 1, Marker; Lane 2 - 7, time-point samples collected 0 – 5 h pre- and post-induction with 
1 mM IPTG, 10 µg/well. (A) Pilot expression of THC at 37°C visualised by SDS-PAGE and 
Coomassie instant stain. (B) Pilot expression of THC at 37°C as detected by immunoblotting 
with mouse anti-His IgG. (C) Pilot expression of THC at 37°C as detected by immunoblotting 
with rabbit anti-tetanus toxin IgG. 
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Figure 3.19: pTHC 30°C pilot expression in E. coli OrigamiTM 2(DE3)pLysS. 
Lane 1, Marker; Lane 2 - 7, time-point samples collected 0 – 5 h pre- and post-induction with 
1 mM IPTG, 10 µg/well. (A) Pilot expression of THC at 30°C visualised by SDS-PAGE and 
Coomassie instant stain. (B) Pilot expression of THC at 30°C as detected by immunoblotting 
with mouse anti-His IgG. (C) Pilot expression of THC at 30°C as detected by immunoblotting 
with rabbit anti-tetanus toxin IgG. 
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Figure 3.20: pTHC 37°C pilot expression in E. coli OrigamiTM 2(DE3)pLysS. 
Lane 1, Marker; Lane 2 - 7, time-point samples collected 0 – 5 h pre- and post-induction with 
1 mM IPTG, 10 µg/well. (A) Pilot expression of THC at 37°C visualised by SDS-PAGE and 
Coomassie instant stain. (B) Pilot expression of THC at 37°C as detected by immunoblotting 
with mouse anti-His IgG. (C) Pilot expression of THC at 37°C as detected by immunoblotting 
with rabbit anti-tetanus toxin IgG. 
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Figure 3.21: pB/ALC 30°C pilot expression in E. coli BL21(DE3)pLysS. 
Lane 1, Marker; Lane 2 - 7, time-point samples collected 0 – 5 h pre- and post-induction with 
1 mM IPTG, 15 µg/well. (A) Pilot expression of B/ALC at 30°C visualised by SDS-PAGE and 
Coomassie instant stain. (B) Pilot expression of B/ALC at 30°C as detected by 
immunoblotting with mouse anti-His IgG. (C) Pilot expression of B/ALC at 30°C as detected 
by immunoblotting with rabbit anti-C. botulinum A toxoid IgG.  
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Figure 3.22: pB/ALC 37°C pilot expression in E. coli BL21(DE3)pLysS.  
Lane 1, Marker; Lane 2 - 7, time-point samples collected 0 – 5 h pre- and post-induction with 
1 mM IPTG, 15 µg/well. (A) Pilot expression of B/ALC at 37°C visualised by SDS-PAGE and 
Coomassie instant stain. (B) Pilot expression of B/ALC at 37°C as detected by 
immunoblotting with mouse anti-His IgG. (C) Pilot expression of B/ALC at 37°C as detected 
by immunoblotting with rabbit anti-C. botulinum A toxoid IgG.  
 
116 
 
3.3.4 Characterisation of recombinant His6-tagged proteins 
3.3.4.1 Hydropathicity profiles 
Hydropathicity profiles of the His6-tagged protein sequences were performed in silico using 
the Kyte-Doolittle and Hopp-Woods algorithms. All plots showed peaks for all three His6-
tagged protein sequences were above 0 using the Hopp-Woods algorithm for hydrophilicity 
(Figures 3.23A, B and C). Hydrophobicity plots showed that peaks were below 1.6 overall, 
when using the Kyte-Doolittle algorithm (Figures 3.24A, B and C). The exception was THC 
which has one peak around residue 255 which approaches 1.6 on the Kyte-Doolittle scale 
(Figure 3.24B).  
 
3.3.4.2 Isoelectric point (pI) 
The theoretical pI estimated using Clone Manager are shown in Table 3.1. 
 
3.3.4.3 Protease cleavage sites 
The His6-tagged protein sequences were screened for potential protease cleavage sites 
using PeptideCutter (ExPASy), and the proteases found to cleave the recombinant proteins 
are listed in Table 3.2. Numbers correspond to the number of times the recombinant protein 
is cleaved by the listed protease, and proteases listed in bold are inhibited by the protease 
inhibitor phenylmethanesulfonyl fluoride (PMSF). 
 
3.3.4.4 Protein modelling  
A model of the proposed novel chimeric holotoxin was constructed by joining the B/ALC and 
THC sequences in Modeller 9.10 (Sali and Blundell, 1993), and viewed using Swiss-PDB 
Viewer version 4.0.1 (Guex and Peitsch, 1997). The BoNT/A holotoxin template (3BTA) 
(Figure 3.25A), and the chimeric holotoxin superimposed on the BoNT/A holotoxin (Figure 
3.25B), show that the proposed chimeric holotoxin is structurally similar to the native BoNT/A 
structure, with differences mainly seen in the heavy chain domain.  
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Figure 3.23: Hydrophilicity plots of (A) TLC, (B) THC and (C) B/ALC performed using 
the Hopp-Woods algorithm. 
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Figure 3.24: Hydrophobicity plots of (A) TLC, (B) THC and (C) B/ALC performed using 
the Hopp-Woods algorithm. 
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Table 3.1: Theoretical pI of the recombinant His6-tagged proteins. 
 
Toxin Isoelectric point (pI) 
TLC 5.38 
THC 6.14 
B/ALC 6.35 
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Table 3.2: Protease cleavage sites of the recombinant His6-tagged proteins as 
predicted by PetideCutter (ExPASy). 
 
Protease THC B/ALC TLC 
Arg-C proteinase 27 17 17 
Asp-N endopeptidase 61 31 39 
Asp-N endopeptidase + N-terminal Glu 109 60 65 
BNPS-Skatole 13 3 2 
CNBr - 11 16 
Chymotrypsin-high specificity (C-term to [FYW], not before P) 95 62 52 
Chymotrypsin-low specificity (C-term to [FYWML], not before P) 198 123 118 
Clostripain 27 17 17 
Enterokinase 1 1 1 
Formic acid 61 31 39 
Glutamyl endopeptidase 48 29 26 
Hydroxylamine 5 3 1 
Iodosobenzoic acid 13 3 2 
LysC 75 41 34 
LysN 75 - 34 
NTCB (2-nitro-5-thiocyanobenzoic acid) 5 4 5 
Pepsin (pH1.3) 281 152 139 
Pepsin (pH>2) 181 111 97 
Proline-endopeptidase [*] 1 - 1 
Proteinase K 398 214 198 
Staphylococcal peptidase I 45 25 25 
Thermolysin 245 133 132 
Trypsin 100 57 47 
Caspase1 - 2 1 
Caspase4 - 1 - 
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Figure 3.25: (A) The BoNT/A (3BTA) holotoxin. (B) Superimposition of BoNT/A (3BTA) 
holotoxin (blue), and the proposed novel chimeric CNT neurotoxin (red) comprised of 
B/ALC and THC.  
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3.4 Discussion 
This chapter described the development of three expression vectors pTLC, pTHC and 
pB/ALC, which contain the codon optimised sequences of the tetanus toxin light chain (TLC) 
and heavy chain (THC), and the botulinum type A light chain (B/ALC), respectively. Codon 
optimised gene sequences were synthesised by GenScript, U.S.A. and provided in a pUC57 
vector. Following sub-cloning into pRSET-A, clones expressed a recombinant His6-tagged 
protein which migrated at the predicted molecular weight when visualised by SDS-PAGE 
after a pilot expression study. All three proteins were reactive with anti-His6 antisera, the TLC 
and THC were also reactive with anti-tetanus toxin antisera, and B/ALC was reactive with 
anti-BoNT/A antisera.  
 
Only a single toxin type exists amongst the various strains of C. tetani (Accession no. 
X06214) (Eisel et al., 1986), while the sequence of botulinum type A toxin strain Hall 183 
(Accession no. EF033126) (Zhang et al., 2003), was used in chain construction. 
 
The initial methionine present in the light chain sequences was omitted from the synthesised 
sequences, as it is not present in the native mature toxin. This residue was not required in 
the recombinant sequence as translation was initiated from the start codon in pRSET-A. It 
has also been demonstrated that inclusion of the initial methionine may negatively impact on 
protein stability and biological activity and may induce an immunogenic response when 
included in therapeutic proteins (Liao et al., 2004).  
 
3.4.1 Codon optimisation 
The genomes C. tetani and C. botulinum, like many Clostridium spp., are rich in A-T 
nucleotides and therefore employ tRNA codons that do not occur frequently in non-AT-rich 
genomes. Escherichia coli, used as the heterologous host to express the recombinant 
proteins, is known to have an alternate codon usage to that of AT-rich genomes such as 
Clostridia (Grantham et al., 1980). 
 
Genes which are highly expressed within an organism, such as the tetanus and botulinum 
neurotoxins, generally employ a large number of codons which are rarely used in 
heterologous organisms such as E. coli. These rare codons are present in low quantities in 
E. coli and are usually only required for weakly expressed genes (Grantham et al., 1981; 
Grosjean and Fiers, 1982). During expression in an E. coli host, the low availability of tRNA 
codons employed by Clostridial genes may have detrimental effects on heterologous 
translation efficiency (Zdanovsky and Zdanovskaia, 2000). The outcomes may be a low yield 
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of full-length recombinant protein expression and/or premature termination of the polypeptide 
chain (Andersson and Kurland, 1990).  
 
It has been demonstrated that the yield of heterologous expression of Clostridial proteins 
increased after codon optimisation of sequences (Makoff et al., 1989; Stratford et al., 2000; 
Tregoning et al., 2003; Zdanovsky and Zdanovskaia, 2000). In order to enhance recombinant 
protein expression yield in E. coli, the toxin chains used in this study were codon optimised. 
 
Codon optimisation was performed by GenScript Corporation (NJ, USA), using the 
OptimumGeneTM codon optimisation tool with requirements for codon bias indicated for 
expression in an E. coli host. Rare codons were removed from the nucleotide sequence and 
replaced with codons which have a higher frequency of use in E. coli, while amino acid 
sequences remained unchanged. The CAI, GC content and CFD of the codon optimised 
sequences were improved compared to that of the wild-type sequence for each TLC, THC 
and B/ALC, as shown in Figures 3.6 – 3.8, respectively.  
 
3.4.1.1 Codon adaptation index (CAI) 
Sequence analyses included the use of a Codon Adaptation Index (Sharp and Li, 1987) to 
measure the relative codon usage frequency within the target nucleotide sequence. The CAI 
tool functions on the hypothesis that codons used throughout highly expressed proteins will 
be available in larger quantities than those only used in weakly expressed proteins, and that 
codons contained in this pool may differ from those used in highly expressed genes of other 
organisms (Ermolaeva, 2001; Grantham et al., 1981). A score is calculated by comparing the 
target sequence with a set of reference codons known to be used in highly expressed genes 
in the target E. coli host. Through this index, a CAI of 1.0 is ideal, and the lower the score, 
the higher the likelihood that protein expression yield will be low. Using GenScript’s 
OptimumGeneTM codon optimisation tool the CAI score was increased from approximately 
0.6 to >0.8 in all three toxin sequences.  
 
3.4.1.2 GC content adjustment 
The optimal percentage range of GC content for heterologous expression in E. coli ranges 
from 30 – 70% (Han et al., 2010). The wild-type sequences contained a very low GC content 
(<20%), which may have had a negative effect during expression in E. coli. Codon 
optimisation increased the GC content to an average of 43% across the three sequences.  
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3.4.1.3 Codon frequency distribution (CFD)  
The CFD tool calculates frequently used codons present in E. coli and groups them based on 
availability (GenScript, 2013). Sequences were analysed for the types of codons they require 
and from which computed group those codons belong. The ideal sequence would require 
codons from the highest group based on availability, and contain no codons from the lower 
groups which are present in small quantities in E. coli or not at all. The CFD scale computed 
groups from 0 – 100 based on their usage frequency. Codons with values below 30 were 
altered to enhance expression efficiency by the OptimumGeneTM codon optimisation tool.  
 
3.4.2 Expression host and vector choice 
3.4.2.1 Bacterial expression host – E. coli 
Escherichia coli is a commonly used bacterium for the expression of recombinant proteins. 
Its attractive features include fast growth using minimal growth medium, and high growth 
yield from relatively small volumes of culture. The smaller volumes of culture used allow for 
greater ease of handling and purification and induction of expression is specific and can be 
controlled by the addition of a chemical inducer. Using this heterologous host provided a 
quick and safe method for expression of the individual toxin domains. 
 
3.4.2.2 Bacterial expression strain – E. coli BL21(DE3)pLysS 
The host strain used for recombinant expression of neurotoxin chains was E. coli 
BL21(DE3)pLysS. This strain carries the DE3 bacteriophage lambda lysogen which contains 
the T7 RNA polymerase gene, responsible for driving transcription of the target gene cloned 
into the pRSET-A expression vector. The pLysS plasmid contains a chloramphenicol 
resistance gene (CamR) and encodes a T7 phage lysozyme to restrict basal level expression 
of T7 polymerase, and subsequently of the target gene. The T7 lysozyme binds to T7 
polymerase and inhibits initiation of transcription of the target gene from the T7 promoter. 
When an inducer such as the synthetic lactose analogue isopropyl-1-thio-β-D-
galactopyranoside (IPTG) is added to the culture, the repression of T7 polymerase is 
removed and the T7 promoter can initiate expression of the target recombinant protein 
(Dubendorff and Studier, 1991). Generally, basal expression is restricted when over-
expression of recombinant protein is toxic to the host cells, leading to cell death. Although 
the neurotoxin chains are non-toxic when individually expressed, stringent control is 
beneficial to prevent any difficulties with proliferation and differentiation of the host cell which 
may be caused by the introduction of a heterologous protein. Like all B strains of E. coli, this 
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strain is deficient in the lon protease and the ompT outer membrane protease which may 
degrade proteins during purification (Grodberg and Dunn, 1988). 
 
3.4.2.3 Bacterial expression strain – E. coli OrigamiTM 2(DE3)pLysS 
The E. coli OrigamiTM2 strain is a K-12 derivative and contains mutations in the thioredoxin 
reductase (trxB) and glutathione reductase (gor) genes to create an oxidising environment 
within the E. coli cytoplasm, a condition which aids in the formation of disulfide bonds. The 
presence of an intrachain disulfide bond in the THC may indicate the requirement of such 
conditions to ensure correctly folded THC during recombinant expression in E. coli. This 
strain also contains the DE3 bacteriophage lambda lysogen and pLysS plasmid, which 
contain the T7 RNA polymerase gene and T7 phage lysozyme, respectively. Although the 
full-length tetanus toxin heavy chain has previously been expressed in a soluble form in  
E. coli (Li, Y. et al., 1999), it is possible that reducing environment of the E. coli cytoplasm 
may cause THC to misfold during cytoplasmic expression (Gill, R. T. et al., 1998).  
 
3.4.2.4 Expression vector – pRSET-A 
Sequences were cloned into the pRSET-A expression vector (Invitrogen, U.S.A.) by 
restriction enzyme digestion and the resulting recombinant protein is expressed with an  
N-terminal His6-tag under the control of a T7 promoter. Translation is initiated via an ATG 
start codon present upstream of the His6-tag and stopped by the inclusion of a TAA stop 
codon at the 3’ end of the inserted sequence. An enterokinase recognition site is present 
between the His6-tag and the coding sequence of the target gene to facilitate removal of the 
His6-tag from purified recombinant protein. The pRSET-A vector is maintained in the 
expression host through ampicillin resistance and His6-taggefd proteins were purified by a 
simple chromatographic method, immobilised metal affinity chromatography (IMAC).  
 
3.4.3 Pilot expression study 
The pilot expression study was performed in E. coli BL21(DE3)pLysS for pTLC, pTHC and 
pB/ALC, and also in E. coli OrigamiTM 2(DE3)pLysS for pTHC. Results indicate that all three 
recombinant proteins express well at both 30°C and 37°C, however TLC (Figure 3.15 – 3.16) 
and THC (Figure 3.17 – 3.20), which expressed equally well at both temperatures, expressed 
fewer non-specific proteins at 30°C. B/ALC expressed a higher yield of protein at 30°C 
(Figure 3.21 – 3.22). Expression at 30°C has been used previously for the expression of 
Clostridial genes in E. coli in order to decrease degradation of the recombinant protein within 
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the E. coli cytoplasm and to decrease the production of inclusion bodies (Baldwin et al., 
2004; Zhou et al., 1995).  
 
All of the recombinant constructs expressed successfully from the pRSET-A vector in E. coli 
and were reactive with anti-His and toxin-specific antisera. However, reactivity with proteins 
which migrated at both a higher and lower molecular weight than the target protein was 
evident. The origin of these proteins is still unclear, but may be elucidated in later sections of 
this study. Expression and IMAC purification methods will be explored in the subsequent 
chapters, along with in vitro assays to assess the activity of the individual recombinant toxin 
domains.  
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Chapter 4  
Protein expression, purification 
and functional assays of 
tetanus and botulinum type A 
toxin light chains 
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4.1 Introduction  
The preceding section outlined the development of the tetanus toxin and botulinum type A 
light chains and cloning into the pRSET-A expression vector. After evaluation of the optimal 
conditions required for expression of the recombinant proteins, this section describes the 
optimisation of small-scale expression and purification of the recombinant proteins.  
 
CNTs are the most potent toxins known to mankind, and there is a risk of toxicity associated 
with handling full-length toxins (Francis et al., 2000). For this reason, the toxin domains will 
be expressed individually and later conjugated to create the holotoxin. This will also facilitate 
the subsequent creation of various holotoxin “serotypes”. The light chains of CNTs make up 
the C-terminal catalytic domain which cleaves one of the SNARE proteins involved in 
synaptic vesicle fusion at pre-synaptic junctions. These domains, which retain their catalytic 
function independent of the heavy chain domains of CNTs, will be used to create the 
recombinant holotoxin TLC + THC, and the novel chimeric holotoxin B/ALC + THC. The 
proposed recombinant holotoxins are being created via the conjugation of individual light and 
heavy chains.   
 
The first section of this part of the study is to express the recombinant light chains in E. coli. 
Two types of growth media and various temperatures will be evaluated to determine the 
optimal conditions required to obtain a high yield of soluble protein. The second part of the 
study is to purify the proteins from the bacterial host using immobilised metal affinity 
chromatography (IMAC). IMAC utilises the N-terminal His6-tag expressed as part of the 
recombinant protein to isolate the proteins from E. coli. Multiple purification configurations will 
be evaluated to find the optimal conditions for recombinant protein purification. Following 
purification of the light chains, their activity will be assessed in functional assays which 
monitor the toxin domains for cleavage of their target substrate.  
 
Tetanus toxin light chain naturally cleaves synaptobrevin-2 (VAMP-2) at the pre-synaptic 
membrane, and a recombinant substrate will be used to assess the cleavage ability of 
purified TLC. Botulinum type A toxin light chain naturally cleaves SNAP-25, and a fluorogenic 
substrate will be used for the assessment of SNAP-25 cleavage by purified B/ALC.  
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4.2 Materials and methods 
4.2.1 Expression in LB broth 
Expression vectors pTLC and pB/ALC were electrotransformed into E. coli BL21(DE3)pLysS 
for each expression (Section 2.4.4.2). After overnight growth of transformants on LB agar 
containing the appropriate antibiotics, a single colony was sub-cultured into 2 mL LB broth 
containing antibiotics and grown at 37°C until the absorbance at 600 nm reached 0.6 – 1.0. 
The next stage of the protocol, growth to mid-log phase (absorbance at 600 nm of 0.3 – 0.6), 
was also performed in LB broth at 37°C (Section 2.6.3.3). Induction of protein expression 
with IPTG was performed in LB broth for 3 h at the required temperature. After  
3 h induction, cell lysates were prepared for IMAC purification (Section 2.6.3.5).  
 
TLC was expressed for 3 h after addition of IPTG at 25°C, 30°C, 37°C and 42°C in LB broth, 
and B/ALC was expressed for 3 h after addition of IPTG at 30°C and 37°C in LB broth.  
 
4.2.2 Expression in EnPressoTM 
Expression vectors pTLC and pB/ALC were electrotransformed into E. coli BL21(DE3)pLysS 
for each expression (Section 2.4.4.2). After overnight growth of transformants on LB agar 
containing the appropriate antibiotics, a single colony was sub-cultured into 2 mL LB broth 
containing antibiotics and grown at 37°C until the absorbance at 600 nm reached 0.6 – 1.0. 
The next stage of the protocol, growth to mid-log phase (absorbance at 600 nm of 0.3 – 0.6), 
was performed in EnPressoTM tablet medium (Section 2.3.2) at 30°C. Induction of protein 
expression with IPTG was performed in EnPressoTM tablet medium for 8 h at 30°C (Section 
2.6.3.4). After 8 h induction, cell lysates were prepared for IMAC purification (Section 
2.6.3.5). TLC and B/ALC expression in EnPressoTM was performed with and without the 
addition of 1 mM PMSF protease inhibitor (Section 2.3.1) during preparation of the cell lysate 
(Section 2.6.3.5). 
 
4.2.3 IMAC purification 
Following preparation of the cell lysate (Section 2.6.3.5), samples were purified by IMAC 
(Section 2.7.1.2). IMAC purification was performed using Chelating SepharoseTM fast flow 
(Section 2.3.1), charged with 0.2 M nickel sulphate (Ni2+) (Section 2.7.1.1), or HisPur Cobalt 
1 mL spin columns (ThermoFisher Scientific, U.S.A.), (Section 2.7.1.4). His6-tagged proteins 
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in the cell lysate were allowed to bind to the pre-charged resin, which was pre-equilibrated 
with protein binding buffer (Section 2.3.1). The column was then washed in 5 column 
volumes (CV) of protein wash buffer (Section 2.3.1) containing 20 mM and 50 mM imidazole 
and then eluted in protein elution buffer (Section 2.3.1). 
 
4.2.3.1 TLC purification 
Purification of TLC expressed in LB broth was performed by IMAC pre-charged with  
0.2 M nickel sulphate, or 0.2 M cobalt chloride (Co2+) (Section 2.7.1.2). TLC was eluted in 
protein elution buffer (Section 2.3.1) containing 100 mM imidazole. 
 
A double purification procedure using nickel IMAC was also performed for TLC expressed in 
LB broth at 30°C. Following preparation of the cell lysate, TLC was purified by IMAC (Section 
2.7.1.2), and the eluted protein was concentrated and buffer exchanged (Section 2.7.2.1), 
into protein binding buffer containing 10 mM imidazole (Section 2.3.1) to facilitate binding to 
the IMAC column during the second purification step. The concentrated protein sample was 
then purified a second time in a newly prepared nickel IMAC column using the same protocol 
(Section 2.7.2.1). TLC was eluted in protein elution buffer (Section 2.3.1) containing 100 mM 
imidazole, and the concentration and buffer exchange protocol (Section 2.7.2.1) was 
repeated. Double-purified TLC was buffer exchanged to protein storage buffer (Section 
2.3.1).  
 
Purification of TLC expressed in EnPressoTM tablet media was performed by IMAC pre-
charged with 0.2 M nickel sulphate (Section 2.7.1.2), or HisPur Cobalt 1 mL spin columns 
(ThermoFisher Scientific, U.S.A.), (Section 2.7.1.4). TLC was eluted in protein elution buffer 
(Section 2.3.1) containing 100 mM imidazole.  
 
Ten to twenty micrograms of protein was separated by SDS-PAGE (Section 2.6.2.1) and 
visualised by staining with Coomassie instant stain (Section 2.6.2.2) and by Western blot 
(Section 2.6.2.3 – 2.6.2.4), probing with antibodies directed at the His6-tag (mouse anti-His 
IgG), and to the toxin domain (rabbit anti-tetanus toxin IgG) (Section 2.3.4). 
 
4.2.3.2 B/ALC purification 
Purification of B/ALC expressed in LB broth was performed by IMAC pre-charged with  
0.2 M nickel sulphate (Section 2.7.1.2). Purification of B/ALC expressed in EnPressoTM tablet 
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media was performed by IMAC pre-charged with 0.2 M nickel sulphate (Section 2.7.1.2), or 
HisPur Cobalt 1 mL spin columns (ThermoFisher Scientific, U.S.A.), (Section 2.7.1.4).  
 
B/ALC was eluted in protein elution buffer (Section 2.3.1) containing 100 mM imidazole. Five 
to ten micrograms of protein was separated by SDS-PAGE (Section 2.6.2.1) and visualised 
by staining with Coomassie instant stain (Section 2.6.2.2) and by Western blot (Section 
2.6.2.3 – 2.6.2.4), probing with antibodies directed at the His6-tag (mouse anti-His IgG), and 
to the toxin domain (rabbit anti-C. botulinum A toxoid IgG) (Section 2.3.4). 
 
4.2.4 Concentration and buffer exchange 
Following elution of both TLC and B/ALC from the IMAC column, the proteins present in the 
protein elution buffer were applied to a pre-rinsed 30 kDa molecular weight cut-off (MWCO) 
Vivaspin 20 centrifugal device (Section 2.2), and samples were concentrated to a small 
volume (typically <1 mL) before performing buffer exchange (Section 2.7.2.1) to protein 
storage buffer (Section 2.3.1). Proteins were stored in aliquots at -20°C for up to 2 months, or 
until required. 
 
4.2.5 Enterokinase treatment 
Cleavage of the affinity tag from the recombinant proteins was performed using treatment 
with EKMaxTM enterokinase (Invitrogen, U.S.A.), (Section 2.3.3). A pilot assay (Section 
2.7.2.3) was performed to assess the optimal amount of enzyme, temperature and time of 
incubation required to remove the His6-tag from recombinant TLC and B/ALC.  
 
4.2.5.1 His6-tag removal 
Once the optimal amount of enzyme and time of incubation was determined, enterokinase 
was removed from the reaction using the Enterokinase removal kit (Invitrogen Corporation, 
U.S.A.) (Section 2.3.5), and the cleaved His6-tag was removed using a modified method of 
batch purification (protein miniprep) (Section 2.7.1.6). Samples were analysed by SDS-
PAGE (Section 2.6.2.1) and visualised by staining with Coomassie instant stain (Section 
2.6.2.2) and by Western blot (Section 2.6.2.3 – 2.6.2.4), probing with an antibody directed at 
the His6-tag (Section 2.3.4) to detect the presence of the tag. 
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4.2.6 Functional assays 
Cleavage assays were used to assess the activity of the recombinant light chains. The native 
substrate cleaved by TLC is VAMP-2 (also known as synaptobrevin-2), while B/ALC cleaves 
SANP-25. A recombinant GST-VAMP-2 substrate and a SNAP-25 FRET substrate (Section 
2.3.7), was used to assess the cleavage ability of TLC and B/ALC, respectively.  
 
4.2.6.1 VAMP-2 cleavage assay 
A GST-Synaptobrevin-2 (GST-VAMP-2) recombinant protein substrate (38 kDa) (List 
Biological Laboratories, U.S.A.), (Section 2.3.7), was used to assess the cleavage ability of 
recombinant TLC. Reactions were performed in 1.5 mL microfuge tubes and consisted of  
5 µM GST-VAMP-2 and 200 nM or 500 nM toxin in VAMP-2 cleavage buffer (Section 2.3.1) 
in a 20 µL reaction volume. Reactions were incubated for 1 h at 37°C, then visualised using 
SDS-PAGE (Section 2.6.2.1). Reactions were performed with recombinant TLC and His-free 
TLC (His6-tag removed) as test samples, a recombinant tetanus toxin light chain (List 
Biological Laboratories, U.S.A.), (Section 2.3.6) as the positive control, and recombinant 
B/ALC and His-free B/ALC (His6-tag removed) (developed in this study), as negative 
controls. Cleavage of GST-VAMP-2 by TLC reduces the size of the recombinant substrate 
from 38 kDa to 36 kDa. 
 
4.2.6.2 SNAP-25 FRET assay 
A SNAP-25 FRET substrate, SNAPtide® (FITC/DABCYL) (List Biological Laboratories, 
U.S.A.), (Section 2.3.7), was used to assess the cleavage ability of recombinant B/ALC. 
Reactions were performed in a 96-Well black polystyrene microplate (Section 2.2), and 
consisted of 5 µM SNAPtide® (FITC/DABCYL), and 5 nM toxin in SNAPtide® hydrolysis 
buffer (Section 2.3.1). Reactions were performed in a 250 µL volume and assays were 
performed in triplicate using a FLUOstar Optima microplate reader (BMG Labetech, 
Germany) (Section 2.2). The fluorogenic substrate and SNAPtide® hydrolysis buffer were 
pre-warmed at 37°C for 15 min prior to addition of toxins to ensure equilibrium. Reactions 
were initiated after the addition of the toxins and the assay was performed for 100 min at 
37°C, and relative fluorescence units were measured as an indication of SNAPtide® 
(FITC/DABCYL) cleavage over time. Increases in fluorescence upon cleavage of the 
SNAPtide® substrate were measured by excitation and emission wavelengths 490 nm and 
523 nm, respectively, with a cutoff of 495 nm. Reactions were performed with recombinant 
B/ALC and His-free B/ALC (His6-tag removed) as test samples, a recombinant botulinum 
type A toxin light chain (List Biological Laboratories, U.S.A.), (Section 2.3.6) as the positive 
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control, and recombinant TLC (developed in this study), as the negative control. Results 
were analysed using Microsoft Excel 2007. 
 
4.3 Results 
4.3.1 Protein expression 
4.3.1.1 TLC expression and purification from LB broth 
TLC was expressed with a final concentration of 1 mM IPTG for 3 h in LB broth at 25°C, 
30°C, 37°C and 42°C to investigate the effect of temperature on TLC expression. TLC 
expressed at 25°C (Figure 4.1), 30°C (Figure 4.2), 37°C (Figure 4.3), and 42°C (Figure 4.4) 
in LB broth was purified by nickel IMAC and the recombinant protein was eluted in protein 
elution buffer containing 100 mM imidazole. Following purification with IMAC, concentration 
and buffer exchange, 10 – 20 µg of protein was separated using SDS-PAGE and visualised 
by staining with Coomassie instant stain (Figures 4.1A – 4.4A). Following immunotransfer, 
membranes were probed by immunoblotting, with antisera to the His6-tag (mouse anti-His 
IgG) (Figures 4.1B – 4.4B), and tetanus toxin (rabbit anti-tetanus toxin IgG) (Figures 4.1C – 
4.4C), for the detection of the His6-tag and tetanus toxin domain, respectively. Cross-
reactivity is evident with both antisera which detect proteins at both a larger and smaller 
molecular weights to TLC.  
 
A significant amount of purified protein (10 – 20 µg) was separated by SDS-PAGE, and this 
should be taken into account when estimating the purity of TLC. TLC reacted with both His6-
tag and anti-toxin antisera, and cross-reactivity is evident with both antisera which detected 
proteins at both a larger and smaller molecular weights to TLC. TLC migrated to the 
predicted molecular weight of 56.7 kDa. Induction of protein expression at 30°C was 
determined to be optimal for TLC expression (Figure 4.2), with expression yields typically 
ranging from 0.7 – 0.9 mg/mL. 
  
Double-purification of TLC after expression at 30°C in LB broth (Figure 4.5A, Lane 2) was 
performed to remove reactive species present at both lower and higher molecular weights to 
TLC, which remained after concentrating the eluted sample in a 30 kDa MWCO Vivaspin 20 
centrifugal device. Figure 4.5A Lane 2 shows TLC after the first purification and buffer 
exchange step and Figure 4.5A, Lane 4 shows TLC after the second purification and buffer 
exchange step. Figures 4.5B and 4.5C show Western blot results after probing with anti-His6  
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Figure 4.1: TLC expressed at 25°C in LB broth and purified by Ni2+ IMAC.  
Lane 1, Marker; Lane 2, 10 µg purified TLC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of TLC probed with mouse anti-His IgG. (C) Immunoblot 
detection of TLC probed with rabbit anti-tetanus toxin IgG. 
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Figure 4.2: TLC expressed at 30°C in LB broth and purified by Ni2+ IMAC.  
Lane 1, Marker; Lane 2, 20 µg purified TLC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of TLC probed with mouse anti-His IgG. (C) Immunoblot 
detection of TLC probed with rabbit anti-tetanus toxin IgG. 
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Figure 4.3: TLC expressed at 37°C in LB broth and purified by Ni2+ IMAC.  
Lane 1, Marker; Lane 2, 10 µg purified TLC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of TLC probed with mouse anti-His IgG. (C) Immunoblot 
detection of TLC probed with rabbit anti-tetanus toxin IgG. 
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Figure 4.4: TLC expressed at 42°C in LB broth and purified by Ni2+ IMAC.  
Lane 1, 10 µg purified TLC; Lane 2, Marker. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of TLC probed with mouse anti-His IgG. (C) Immunoblot 
detection of TLC probed with rabbit anti-tetanus toxin IgG. 
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Figure 4.5: TLC expressed at 30°C in LB broth and purified twice by Ni2+ IMAC.  
(A) SDS-PAGE stained with Coomassie instant stain. Lane 1 and 3, Marker; Lane 2, 20 µg 
purified TLC (first purification); Lane 4, 20 µg purified TLC (second purification). (B) and (C) 
Lane 1, Marker; Lane 2, 20 µg purified TLC (first purification); Lane 3, 20 µg purified TLC 
(second purification). (B) Immunoblot detection of TLC probed with mouse anti-His IgG. (C) 
Immunoblot detection of TLC probed with rabbit anti-tetanus toxin IgG. 
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IgG and anti-tetanus toxin IgG antisera, respectively. 
 
Cross-reactivity is evident with both antisera which detected proteins at both higher and 
lower molecular weights to TLC. Results indicate that the double-purification procedure did 
not remove these proteins. 
 
4.3.1.2 TLC expression and purification from EnPressoTM tablet media 
TLC purification after expression in EnPressoTM tablet media was performed using both 
nickel and cobalt IMAC. Induction of protein expression was performed for 8 h at 30°C in 
EnPressoTM, however all subsequent steps leading to purification were identical to those in 
previous section for LB broth (Section 4.3.1.1).  
 
TLC expressed in EnPressoTM tablet media was purified using nickel IMAC and 5 – 10 µg of 
purified, concentrated and buffer exchanged protein was separated by SDS-PAGE and 
visualised by staining with Coomassie instant stain (Figure 4.6A). Following immunotransfer 
membranes were probed by immunoblotting, with antisera to the His6-tag (mouse anti-His 
IgG) (Figure 4.6B), and tetanus toxin (rabbit anti-tetanus toxin IgG), (Figure 4.6C) for the 
detection of the His6-tag and tetanus toxin domain, respectively.  
 
Protein yields of ~1.5 mg/mL of purified TLC were obtained from expression in EnPressoTM. 
When considering that a significant amount of purified protein (5 – 10 µg) has been analysed 
by SDS-PAGE, TLC appears to be 80 – 90% pure. TLC expression in EnPressoTM media 
(Figure 4.6 – 4.7) produced a higher yield of recombinant TLC with fewer lower molecular 
weight proteins, compared to expression at various temperatures in LB broth (Figures 4.1 – 
4.4). However, it must be noted that TLC often migrated to just below the 50 kDa band in the 
protein standard marker when expressed in EnPressoTM. 
 
To compare the influence of the metal ion used in IMAC purification, TLC expressed in 
EnPressoTM was also purified using cobalt IMAC. Five micrograms of purified, concentrated 
and buffer exchanged protein was separated by SDS-PAGE and visualised by staining with 
Coomassie instant stain (Figure 4.7A) and Western blot, with membranes probed by 
immunoblotting with antisera to the His6-tag (mouse anti-His IgG) (Figures 4.7B), and tetanus 
toxin (rabbit anti-tetanus toxin IgG) (Figure 4.7C). The use of cobalt IMAC did not show a 
reduction in the number of reactive species present at either higher or lower molecular 
weights to TLC (Figure 4.6 – 4.7). 
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Figure 4.6: TLC expressed at 30°C in EnPressoTM and purified by Ni2+ IMAC.  
Lane 1, Marker; Lane 2, 10 µg purified TLC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of TLC probed with mouse anti-His IgG. (C) Immunoblot 
detection of TLC probed with rabbit anti-tetanus toxin IgG. 
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Figure 4.7: TLC expressed at 30°C in EnPressoTM, and purified by Co2+ IMAC.  
Lane 1, Marker. Lane 2, 5 µg purified TLC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of TLC probed with mouse anti-His IgG. (C) Immunoblot 
detection of TLC probed with rabbit anti-tetanus toxin IgG. 
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TLC expressed in EnPressoTM was also purified after treatment with protease inhibitor PMSF 
during preparation of the cell lysate. Figures 4.8A, B and C show 10 µg of purified, 
concentrated and buffer exchanged protein separated by SDS-PAGE and visualised by 
staining with Coomassie instant stain and Western blot, probing with antisera to the His6-tag 
(mouse anti-His IgG), and tetanus toxin (rabbit anti-tetanus toxin IgG), respectively. The use 
of PMSF did not demonstrate a reduction in the number of reactive species present at either 
higher or lower molecular weights to TLC detected after immunoblotting (Figure 4.8). 
 
4.3.1.3 B/ALC expression and purification from LB broth 
B/ALC expression was performed with a final concentration of 1 mM IPTG for 3 h in LB broth 
at 30°C and 37°C to investigate the effect of temperature on B/ALC expression. B/ALC 
expressed at 30°C (Figure 4.9) and 37°C (Figure 4.10) in LB broth was purified by nickel 
IMAC and the recombinant protein was eluted in protein elution buffer containing 100 mM 
imidazole. Following purification by IMAC, concentration and buffer exchange, 5 – 10 µg of 
protein was separated using SDS-PAGE and visualised by staining with Coomassie instant 
stain (Figures 4.9A – 4.10A). Following immunotransfer, membranes were probed by 
immunoblotting, with antisera to the His6-tag (mouse anti-His IgG) (Figures 4.9B – 4.10B), 
and C. botulinum type A toxin (rabbit anti-C. botulinum A toxoid IgG) (Figure 4.9C – 4.10C), 
for the detection of the His6-tag and C. botulinum toxin domain, respectively. His6-tagged 
B/ALC migrated to the predicted molecular weight of 56 kDa and the yield of B/ALC 
expressed at 30°C in LB broth (Figure 4.9) was higher and showed fewer proteins at a lower 
molecular weight to B/ALC when compared to expression at 37°C (Figure 4.10). 
 
4.3.1.4 B/ALC expression and purification from EnPressoTM tablet media 
The purification of B/ALC after expression in EnPressoTM tablet media was performed using 
both nickel and cobalt IMAC. Induction of protein expression was performed for 8 h at 30°C in 
EnPressoTM, however all subsequent steps leading to purification were identical to those in 
previous section for LB broth (Section 4.3.1.3).  
 
B/ALC expressed in EnPressoTM tablet media was purified using nickel IMAC and 10 µg of 
purified, concentrated and buffer exchanged protein was separated by SDS-PAGE and 
visualised by staining with Coomassie instant stain (Figure 4.11A). Following 
immunotransfer, membranes were probed by immunoblotting with antisera to the His6-tag 
(mouse anti-His IgG) (Figure 4.11B), and C. botulinum type A toxin (rabbit anti-C. botulinum  
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Figure 4.8: TLC expressed at 30°C in EnPressoTM with PMSF and purified by Ni2+ IMAC.  
Lane 1, Marker; Lane 2, 10 µg purified TLC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of TLC probed with mouse anti-His IgG. (C) Immunoblot 
detection of TLC probed with rabbit anti-tetanus toxin IgG. 
  
144 
 
 
 
 
Figure 4.9: B/ALC expressed at 30°C in LB broth and purified by Ni2+ IMAC.  
Lane 1, Marker; Lane 2, 10 µg purified B/ALC. (A) SDS-PAGE stained with Coomassie 
instant stain. (B) Immunoblot detection of B/ALC probed with mouse anti-His IgG.  
(C) Immunoblot detection of B/ALC probed with rabbit anti-C. botulinum A toxoid IgG. 
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Figure 4.10: B/ALC expressed at 37°C in LB broth and purified by Ni2+ IMAC.  
Lane 1, Marker; Lane 2, 5 µg purified B/ALC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of B/ALC probed with mouse anti-His IgG. (C) Immunoblot 
detection of B/ALC probed with rabbit anti-C. botulinum A toxoid IgG. 
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Figure 4.11: B/ALC expressed at 30°C in EnPressoTM and purified by Ni2+ IMAC.  
Lane 1, Marker; Lane 2, 10 µg purified B/ALC. (A) SDS-PAGE stained with Coomassie 
instant stain. (B) Immunoblot detection of B/ALC probed with mouse anti-His IgG. (C) 
Immunoblot detection of B/ALC probed with rabbit anti-C. botulinum A toxoid IgG. 
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A toxoid IgG) (Figure 4.11C), for the detection of the His6-tag and C. botulinum toxin domain, 
respectively. B/ALC expression in EnPressoTM media (Figure 4.11) produced a higher yield of 
recombinant B/ALC with fewer proteins present at a lower molecular weight to B/ALC when 
compared to expression at 30°C (Figure 4.9) and 37°C (Figure 4.10) in LB broth. 
 
B/ALC expressed in EnPressoTM was also purified after treatment with protease inhibitor 
PMSF during preparation of the cell lysate (Section 2.6.1.4). Figures 4.12A, B and C show  
10 µg of purified, concentrated and buffer exchanged protein separated by SDS-PAGE and 
stained with Coomassie instant stain. Following immunotransfer, membranes were probed 
with antisera to the His6-tag (mouse anti-His IgG), and C. botulinum type A toxin (rabbit anti-
C. botulinum A toxoid IgG), respectively. The use of PMSF showed some improvements in 
the reduction of reactive species present at a lower molecular weight to B/ALC, detected 
after immunoblotting (Figure 4.12). 
 
To compare the influence on the metal ion used for IMAC purification of B/ALC, B/ALC 
expressed in EnPressoTM was also purified using cobalt IMAC. Ten micrograms of purified, 
concentrated and buffer exchanged protein was separated by SDS-PAGE and visualised by 
staining with Coomassie instant stain (Figure 4.13A) and Western blot, probing with antisera 
to the His6-tag (mouse anti-His IgG) (Figures 4.13B), and C. botulinum type A toxin (rabbit 
anti-C. botulinum A toxoid IgG) (Figure 4.13C). The use of cobalt IMAC did not remove 
reactive species present at both higher and lower molecular weights to B/ALC.  
 
4.3.2 His6-tag cleavage and removal 
4.3.2.1 Enterokinase treatment 
Cleavage of the affinity tag from the recombinant proteins was performed by treatment with 
enterokinase. A pilot assay was performed to assess the optimal amount of enzyme, 
temperature and time of incubation required to remove the His6-tag from TLC and B/ALC. 
Figures 4.14A – D and figures 4.15A – D show the enterokinase pilot assay for TLC and 
B/ALC, respectively.  
 
For TLC, His6-tag removal was achieved after incubation with 1 U enterokinase for 2 h at 
room temperature, indicated by the absence of a band on the anti-His Western blot for this 
sample (Figure 4.14B). The inability of the anti-His antibody to produce a colorimetric 
reaction for this sample indicates the absence of a detectable limit of His6-tag within the 
sample.  
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Figure 4.12: B/ALC expressed at 30°C in EnPressoTM with PMSF and purified by Ni2+ 
IMAC.  
Lane 1, Marker; Lane 2, 10 µg purified B/ALC. (A) SDS-PAGE stained with Coomassie 
instant stain. (B) Immunoblot detection of B/ALC probed with mouse anti-His IgG. (C) 
Immunoblot detection of B/ALC probed with rabbit anti-C. botulinum A toxoid IgG. 
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Figure 4.13: B/ALC expressed at 30°C in EnPressoTM and purified by Co2+ IMAC.  
Lane 1, Marker; Lane 2, 10 µg purified B/ALC. (A) SDS-PAGE stained with Coomassie 
instant stain. (B) Immunoblot detection of B/ALC probed with mouse anti-His IgG. (C) 
Immunoblot detection of B/ALC probed with rabbit anti-C. botulinum A toxoid IgG. 
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Figure 4.14: TLC enterokinase pilot assay.  
(A) – (C) SDS-PAGE stained with Coomassie instant stain. Lane 1, Marker; Lane 2 – 7,  
20 µg TLC treated with 0, 0.001, 0.01, 0.1, 1 and 4 U enterokinase, respectively. (A) TLC 
enterokinase pilot assay incubated for 1 h at room temperature. (B) TLC enterokinase pilot 
assay incubated for 2 h at room temperature. (C) TLC enterokinase pilot assay incubated for 
16 h at room temperature; Lane 8, Marker. (D) Immunoblot detection of TLC enterokinase 
pilot assay probed with mouse anti-His IgG. Lane 1 – 3, 20 µg TLC treated with 0, 0.1, 1 U 
enterokinase for 2 h at room temperature; Lane 4, Marker. 
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Figure 4.15: B/ALC enterokinase pilot assay.  
(A) and (C) SDS-PAGE stained with Coomassie instant stain. Lane 1, Marker; Lane 2 – 7,  
20 µg B/ALC treated with 0, 0.001, 0.01, 0.1, 1 and 4 U enterokinase, respectively. (A) 
B/ALC enterokinase pilot assay incubated for 1 h at room temperature. (B) B/ALC 
enterokinase pilot assay incubated for 2 h at room temperature. Lane 1 and 6, Marker; Lane 
2, 3, 4, 5, 7 and 8, 20 µg B/ALC treated with 0, 0.001, 0.01, 0.1, 1 and 4 U enterokinase, 
respectively. (C) B/ALC enterokinase pilot assay incubated for 16 h at room temperature. (D) 
Immunoblot detection of B/ALC enterokinase pilot assay probed with mouse anti-His IgG. 
Lane 1, Marker; Lane 2 – 4, 20 µg B/ALC treated with 0, 0.1, 1 U enterokinase for 1 h at 
room temperature; Lane 5 – 7, 20 µg B/ALC treated with 0, 0.1, 1 U enterokinase for 2 h at 
room temperature. 
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For B/ALC, His6-tag removal was achieved after incubation with 1 U enterokinase for 2 h at 
room temperature, indicated by the absence of a band on the anti-His Western blot for this 
sample (Figure 4.15B).  
 
4.3.2.2 His6-tag removal 
Prior to the removal of the free His6-tag cleaved from the recombinant proteins during 
enterokinase treatment, the enzyme was first removed from the reaction using the 
Enterokinase removal kit (Invitrogen Corporation, U.S.A.). Following enterokinase removal, 
cleaved His6-tag was removed using a modified method of batch purification (protein 
miniprep). Samples were analysed by SDS-PAGE and a Western blot, probing with an 
antibody directed at the His6-tag to detect the presence of the affinity tag. Protein migrated to 
the predicted molecular weight for both His-free TLC (data not shown) and B/ALC (Figure 
4.16). No bands were present on anti-His Western blots (data not shown), indicating that 
His6-tag was completely removed from the enterokinase-treated protein. 
 
4.3.3 Functional assays 
Functional assays were performed for the detection of cleavage activity of recombinant TLC 
and B/ALC. A cleavage assay for the detection of TLC activity was analysed by observing a 
shift in molecular weight of the GST-VAMP-2 substrate by SDS-PAGE, and cleavage of a 
fluorogenic SNAP-25 substrate by B/ALC was analysed by measuring fluorescence emitted 
by FRET.  
 
4.3.3.1 VAMP-2 cleavage assay 
Samples containing recombinant positive control TLC, and the recombinant TLC (Figure 
4.17A), and His-free TLC (Figure 4.17B) developed in this study show a shift in the size of 
GST-VAMP-2 from 38 kDa to 36 kDA, indicating cleavage of GST-VAMP-2 at the target 
peptide bond of native TLC. Incubation of GST-VAMP-2 with recombinant B/ALC (Figure 
4.17A), His-free B/ALC (Figure 4.17C), and without the addition of toxin (Figure 4.17A, B, C), 
does not display the 36 kDa cleavage product of GST-VAMP-2.  
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Figure 4.16: His6-tag removal from B/ALC.  
SDS-PAGE stained with Coomassie instant stain. B/ALC treated with enterokinase and 
removal of cleaved His6-tag by batch purification. Lane 1, Marker; Lane 2, 200 mM imidazole 
wash (contains cleaved His6-tag, ~6 kDa); Lane 3, His-free B/ALC collected after His6-tag 
was removed from the sample.  
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Figure 4.17: VAMP-2 cleavage assay. 
(A) to (C) SDS-PAGE stained with Coomassie instant stain. (A) Lane 1, Marker; Lane 2, 200 
nM recombinant TLC (positive control); Lane 3, 500 nM recombinant TLC (positive control); 
Lane 4, 200 nM TLC (this study); Lane 5, 500 nM TLC; Lane 6, 200 nM B/ALC (this study, 
negative control); Lane 7, 500 nM B/ALC; Lane 8, GST-VAMP-2 only. (B) Lane 1, Marker; 
Lane 2, GST-VAMP-2 only; Lane 3, 200 nM His-free TLC; Lane 4, 500 nM His-free TLC. (C) 
Lane 1, Marker; Lane 2, GST-VAMP-2 only; Lane 3, 200 nM His-free B/ALC (negative 
control); Lane 4, 500 nM His-free B/ALC. NB. GST-VAMP-2 substrate used in (B) and (C) 
was provided as a 50% pure preparation from List Biological Laboratories, U.S.A., which 
explains the presence of two major bands at ~26 – 30 kDa in figures (B) and (C).  
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4.3.3.2 SNAP-25 FRET assay 
A fluorogenic SNAP-25 substrate, SNAPtide® was used to assess the cleavage ability of 
B/ALC FRET analysis. The positive control BoNT/A LC showed the highest increase in 
fluorescence over time, following by B/ALC, His-free B/ALC, and the negative control TLC 
showed the lowest fluorescence over the course of the assay (Figure 4.18). 
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Figure 4.18: SNAP-25 FRET assay. 
LC/A (dark blue), recombinant B/ALC positive control (List Biological Laboratories, U.S.A); 
B/ALC (purple), B/ALC developed in this study; His-free B/ALC (aqua), His-free B/ALC 
developed in this study; TLC (red), TLC developed in this study (negative control).  
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4.4 Discussion 
This section of the study reports the recombinant expression of soluble, catalytically active 
tetanus toxin light chain and botulinum type A toxin light chain. The individual catalytic light 
chain domains of CNTs have previously been expressed in E. coli for use in the 
characterisation of residues involved in catalytic activity and mode of action (Agarwal et al., 
2005; Baldwin et al., 2004; Chen, S. and Barbieri, 2006; 2011; Chen, S. et al., 2008b; Chen, 
S. et al., 2007; Fernandez-Salas et al., 2004; Gul et al., 2010; Kurazono et al., 1992; Sikorra 
et al., 2008). The LCs have been used in structural characterisation studies (Arndt et al., 
2006a; Breidenbach and Brunger, 2004; 2005a; Gul et al., 2010; Li, L. and Singh, 2000; Rao 
et al., 2005; Silvaggi et al., 2008), and to investigate light chain inhibitors for the prevention of 
CNT toxicity (Li, B. et al., 2011; Silvaggi et al., 2008; Yiadom et al., 2005). Light chains have 
also been produced by recombinant expression with the aim of creating a CNT holotoxin 
either expressed as a single-chain holotoxin or via conjugation with a CNT heavy chain 
domain (Li, Y. et al., 1994; Wang et al., 2008), or other cell-targeting moiety (Duggan et al., 
2002; Hopp and Woods, 1981; Stancombe et al., 2012).  
 
The use of E. coli for heterologous expression of LCs has proved to be a convenient host for 
the expression of recombinant CNT light chains in a soluble form (Agarwal et al., 2004; 
Baldwin et al., 2004; Chen, S. and Barbieri, 2006; 2011; Chen, S. et al., 2008b; Chen, S. et 
al., 2007; Fernandez-Salas et al., 2004; Gilsdorf et al., 2006; Jensen et al., 2003; Li, L. and 
Singh, 2000; Rawat et al., 2008; Sikorra et al., 2008; Yiadom et al., 2005). Yields of TLC and 
B/ALC recombinant proteins from EnPressoTM were typically ~1.5 mg/mL, and the TLC and 
B/ALC light chain domains developed in this study were expressed in a soluble form and 
shown to be catalytically active both in the presence and absence of the N-terminal affinity 
tag.  
 
4.4.1 TLC expression and purification 
TLC expression in LB broth at both 30°C and 37°C produced a high yield of soluble protein in 
a relatively pure form. TLC expressed at the predicted molecular weight of ~56.7 kDa. The 
presence of proteins at both higher and lower molecular weights to TLC were initially thought 
to be non-specific proteins which had co-purified with the His6-tagged TLC. These proteins 
were present when TLC was expressed between 25°C to 37°C, but not when expressed at 
42°C. Taking into consideration the significant decrease in yield of TLC expression at this 
temperature, this temperature was not deemed ideal for recombinant TLC production. A 
significant amount of purified protein (10 – 20 µg) was separated by SDS-PAGE for TLC 
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expressed at 25°C, 30°C and 37°C (Figures 4.1 – 4.3), and when considering this, the purity 
of TLC can be estimated at between 80 – 90%. However, further attempts to remove these 
“non-specific” proteins by means of double-purification by IMAC, by expression in 
EnPressoTM tablet media, with the use of ions with different affinities for binding the His6-tag 
during IMAC, and the use of PMSF during the preparation of the cell lysate were performed.  
 
The second step of the double-purification protocol was performed to remove non-specific 
proteins, and the second purification step was performed to purify TLC from a sample with 
fewer non-specific proteins, which may have allowed for more specific binding of TLC to the 
IMAC column. Results indicate that the “non-specific” proteins remained after the second 
purification step, even after the sample concentration following the first purification. The use 
of a 30 kDa MWCO centrifugal device should have removed the smaller molecular weight 
proteins, however proteins as small as 10 kDa which reacted with the His6-tag and anti-toxin 
antisera, remained following concentration with the device. 
 
Of the ions commonly used in IMAC, nickel has the least affinity to the His6-tag and it may 
therefore allow the binding of endogenous proteins which have a minimum of at least two 
consecutive histidine residues (Stewart et al., 1998). In an attempt to increase the affinity for 
His6-tagged proteins during IMAC purification, divalent cobalt was tested. Cobalt is able to 
bind His6-tags with a higher affinity than nickel; however the “non-specific” proteins continued 
to co-purify with TLC and reacted with the His6-tag and anti-toxin antisera (Stewart et al., 
1998).  
 
The use of the protease inhibitor PMSF during preparation of the cell lysate to inhibit 
cleavage of TLC by proteases produced by E. coli, did not have an effect on the amount of 
“non-specific” proteins present after TLC purification. 
 
These results taken together indicate that these “non-specific” proteins may in fact be C-
terminal degradation products of TLC. These truncated products would retain the N-terminal 
His6-tag and therefore bind to the column with high affinity during purification and co-elute 
with full-length TLC. It has yet to be determined whether these truncated products are as 
result of premature termination of translation or due to proteolytic degradation of a small 
percentage of TLC species which may have misfolded after expression. The presence of 
these truncated TLC proteins in the purified sample constituted only about 10 – 20% of the 
total protein content, and was not deemed to be of concern due to the presence of a high 
yield of soluble TLC.  
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A protein which migrates between 100 – 150 kDa was present after purification and also 
detected during immunblotting within some TLC samples (Figures 4.2 – 4.8, with the 
exception of Figure 4.4). It is unknown what this reactive species migrating at ~100 kDa is, 
but given its reaction with antisera, it may be a doublet of TLC which is present due to 
incomplete reduction of the sample.  
 
TLC expressed in EnPressoTM produced a higher yield of protein than expression in LB broth, 
which was expected due to the nature of this growth medium. EnPressoTM is designed as a 
fed-batch expression system and includes an enzymatically controlled slow release glucose 
delivery which allows slow bacterial growth at 30°C (Baneyx and Mujacic, 2004). Slow 
growth results in slower recombinant protein production, which allows more time for the 
proteins to fold correctly in the E. coli host. Recombinant expression using EnPressoTM was 
performed for 8 h (6 – 24 h is recommended) and slow-release glucose delivery during 
induction of protein expression and addition of proprietary enzymes (EnZI’m, BioSilta), 
resulted in a high yield of recombinant TLC protein expression.  
 
TLC was successfully expressed and purified from E. coli BL21 in a high yield at a relatively 
high purity and was assessed for activity in the VAMP-2 cleavage assay in the presence and 
absence of the His6-tag.  
 
4.4.1.1 His6-tag removal  
His6-tag removal was performed to assess whether the affinity tag and/or the method used 
for its removal would impact on the activity of TLC in the functional assay. The final 
conjugated holotoxin would not contain the affinity tags, thus it was important to assess if 
catalytic activity was maintained after its removal. Optimal conditions of His6-tag cleavage 
were treatment with 1 U enterokinase for 2 h at room temperature (Figure 4.14). The 
absence of reactive species in the enterokinase-treated sample after Western blot with anti-
His antisera, provided further evidence to suggest that the majority of proteins present in the 
sample were C-terminal degradation products of TLC (present due to either premature 
termination of translation or degradation of misfolded protein after expression) and retained 
the N-terminal His6-tag. 
 
Following enterokinase removal with a commercial kit, batch purification (small-scale IMAC) 
was performed to remove the free and uncleaved His6-tag from TLC. Removal of the His6-tag 
was confirmed by SDS-PAGE and immunoblotting with antisera targeting the His6-tag. The 
absence of a visible colorimetric detection on the Western blot confirmed the absence of the 
His6-tag (data not shown).  
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4.4.1.2 VAMP-2 functional assay 
The GST-VAMP-2 substrate (List Biological Laboratories, U.S.A.), is a 38 kDa recombinant 
protein consisting of the 97 residue GST-tag, and 116 residues of native VAMP-2 (lacking 
the final 19 residues of the native VAMP-2), and is usually provided as a 90% pure protein 
from the manufacturer (List Biological Laboratories, U.S.A.). Upon cleavage of GST-VAMP-2 
at the Gln76 – Phe77 peptide bond of VAMP-2, the size of the recombinant substrate 
displays a shift in molecular weight from 38 kDa to 36 kDa.  
 
TLC expressed in EnPressoTM for 8 h at 30°C was used for the assessment of catalytic 
activity in the VAMP-2 cleavage assay. Test samples showed that the TLC developed in this 
study displayed catalytic activity comparable to that of the recombinant TLC positive control 
(51.2 kDa) (List Biological Laboratories, U.S.A.). TLC both with and without the His6-tag 
cleaves GST-VAMP-2 in a concentration-dependent manner, as seen by an increase in the 
amount of cleavage product, and concomitant decrease in the amount of uncleaved GST-
VAMP-2 between the 200 nM and 500 nM toxin reactions (Figure 4.17). B/ALC and His-free 
B/ALC developed in this study, served as a negative control for the VAMP-2 assay, and did 
not demonstrate cleavage ability for VAMP-2 (Figure 4.16). As this is not a natural substrate 
for B/ALC, this was expected. 
 
4.4.2 B/ALC expression and purification 
B/ALC expression in LB broth produced a high yield of protein at the predicted molecular 
weight of B/ALC (~56 kDa). B/ALC expression at 30°C produced a higher yield of protein 
than expression at 37°C; however expression in EnPressoTM for 8 h at 30°C gave the highest 
yield of B/ALC expression. There were fewer non-specific proteins present at a smaller 
molecular weight to B/ALC in the preparation compared to that of TLC; however despite the 
use of a 30 kDa MWCO centrifugal device, these bands remained in the sample after 
concentration. The origin of these smaller molecular weight proteins were assumed to be C-
terminal degradation products, as seen during purification of TLC (Section 4.4.1), since they 
reacted with both anti-His and anti-C. botulinum A toxoid antisera. The use of PMSF was 
therefore investigated to inhibit proteolytic degradation of B/ALC; however it did not reduce 
the number of truncated proteins which remained after purification. The use of cobalt IMAC 
purification did not alter the purification profile of B/ALC, which was anticipated once the 
proteins were determined to be C-terminal degradation products which retained the N-
terminal His6-tag.   
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A protein which migrates between 100 – 150 kDa was present after purification and was 
reactive with anti-His and anti-toxin antisera within B/ALC samples (Figures 4.9A, 4.11, 4.12, 
4.13). Much like the case with TLC (Section 4.4.1), it is likely that this reactive species 
migrating at ~100 kDa is a doublet of the B/ALC which may be present due to incomplete 
reduction of the sample. The presence of truncated forms of B/ALC in the sample (albeit very 
few products when compared to those observed in the TLC preparation), was not deemed to 
be of concern due to the presence of a high yield of soluble B/ALC.  
 
B/ALC was successfully expressed and purified from E. coli BL21 in a high yield at a 
relatively high purity and was assessed for activity in the SNAP-25 FRET assay in the 
presence and absence of the His6-tag.  
 
4.4.2.1 His6-tag removal  
Optimal conditions of His6-tag cleavage were treatment with 1 U enterokinase for 2 h at room 
temperature (Figure 4.15). Although a faint band is present within the Western blot probed 
with antisera to the His6-tag in this sample (Figure 4.15D, Lane 7), any uncleaved His6-tag 
still associated with B/ALC would have been removed during batch purification, and would 
therefore not be present in the final His6-free sample.  
 
Successful removal of the His6-tag was confirmed by SDS-PAGE and immunoblotting with 
antisera targeting the His6-tag. The absence of a visible colorimetric detection on the 
Western blot confirmed the absence of the His6-tag (data not shown).  
 
4.4.2.2 SNAP-25 functional assay 
The SNAP-25 FRET substrate, SNAPtide® (FITC/DABCYL) (List Biological Laboratories, 
U.S.A.) was used to measure catalytic activity of toxins with the amount of substrate cleaved 
proportional to the increase in fluorescence over time. B/ALC expressed in EnPressoTM for  
8 h at 30°C was used for the assessment of catalytic activity in the SNAP-25 FRET assay. 
Test samples showed that the B/ALC developed in this study displayed catalytic activity. The 
TLC developed in this study served as a negative control for the SNAP-25 assay, and did not 
demonstrate cleavage ability for SNAP-25 (Figure 4.18). As this is not a natural substrate for 
TLC, this was expected. 
 
B/ALC both with and without the His6-tag demonstrated a higher fluorescence than the 
negative control TLC (this study); however neither B/ALC preparation displayed fluorescence 
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as high as that of the recombinant full-length B/ALC positive control (50 kDa) (List Biological 
Laboratories, U.S.A.). The fluorescence of B/ALC over time was higher than that of His-free 
B/ALC, indicating that the method of His6-tag removal may have reduced the catalytic activity 
of the protein, however the causes of the reduced activity need to be further investigated.  
4.5 Conclusion 
This section of the study has described the recombinant expression of the tetanus toxin and 
botulinum toxin type A light chains in E. coli. Recombinant proteins were purified at a high 
yield in soluble form and displayed catalytic activity comparable to that displayed by the 
positive control proteins. TLC was demonstrated to be equally as active as the positive 
control protein when assayed for VAMP-2 substrate cleavage, however B/ALC, although 
clearly active compared to the negative control TLC, was not as active as the positive control 
B/ALC.  
 
One study has demonstrated the importance of the C-terminus of LCs in solubility, stability 
and catalytic activity of the LC domain due to the presence of hydrogen bonds which stabilise 
the structure of the domain and maintain the catalytic active site (Baldwin et al., 2004). It is 
possible that the difference in catalytic activity seen between B/ALC and its positive control 
may be due to the misfolding of the B/ALC protein or alterations to the C-terminal residues. 
Western blot analysis of both TLC and B/ALC demonstrated C-terminal degradation products 
(many more in TLC than B/ALC), which were not significantly inhibited with the use of the 
protease inhibitor, PMSF. It is unclear as to whether degradation is caused by endogenous 
proteases, or perhaps by zinc-metalloprotease activity of the LCs themselves, which has 
been reported by Baldwin (Baldwin et al., 2004).  
 
Further investigation to optimise the expression and purification of both TLC and B/ALC is 
required and may also include different methods of purification, the use of a protease 
inhibitor cocktail to inhibit proteolytic attack by other proteases to which TLC and B/ALC are 
predicted to be susceptible (Table 3.2). Although B/LC activity is currently not optimal, it may 
still be useful for the conjugation to THC to create the chimeric Clostridial holotoxin.  
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Chapter 5 
Protein expression and 
purification of tetanus toxin 
heavy chain 
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5.1 Introduction 
Following the expression of the tetanus toxin (TLC) and botulinum type A (B/ALC) toxin light 
chains in the previous section; this final section of the study outlines the small-scale 
expression and purification of the recombinant tetanus toxin heavy chain (THC) domain. In 
order for the novel chimeric holotoxin to perform its catalytic function within inhibitory 
interneurons in the CNS, the resulting molecule must be able to bind to the native receptors 
on the neuronal target cells and following internalisation, have the ability to translocate the 
catalytic light chain into the cytosol of the cell where it can then cleave its target SNARE 
protein. 
 
Expression of the heavy chain domain of tetanus toxin normally includes the C-terminal 
binding domain, HC (or fragment-C), which is sufficient for cell-binding and retrograde 
trafficking, but does not retain the translocation function of the HN domain. However, 
expression of full-length tetanus toxin heavy chain in E. coli has also been reported (Li, Y. et 
al., 1999).  
 
The recombinant heavy chain protein expressed in this section of the study contains an N-
terminal His6-tag and the native ~50 kDa N-terminal (HN) domain (residues S458 – V879), 
which is mostly alpha-helical and displays pore-forming ability to translocate the LC domain 
from the endosome and into the cytosol of the cell after internalisation, a step which is critical 
for the catalytic activity of the LC (Boquet and Duflot, 1982). It also contains the ~50 kDa  
C-terminal (HC) receptor binding domain (residues I880 – D1315) of native tetanus toxin. The 
C-terminal portion of the heavy chain (HC), can further be divided into the N-terminal (HCN) 
domain (residues 865 – 1110), displaying a lectin-like jelly roll domain, and C-terminal (HCC) 
(residues 1110 – 1315), with a β-trefoil domain (Emsley et al., 2000). The HCC domain 
contains residues critical for receptor binding, however, it is still unclear as to the function of 
the HCN domain (Swaminathan, 2011). THC binds to gangliosides GT1b and a secondary 
protein receptor present on the surface on neuronal cells through binding sites present in the 
C-terminal domain of the HC (HCC) (Montecucco, 1986).  
 
The first section of this part of the study is to express the recombinant heavy chain in E. coli. 
Two types of growth media and two strains of E. coli will be evaluated, as well as a cell-free 
culture method to determine the optimal conditions required to obtain a high yield of soluble 
protein. The second section of the study aims to purify the heavy chain using IMAC. IMAC 
utilises the N-terminal His6-tag expressed as part of THC for isolation from E. coli. Multiple 
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purification configurations will be evaluated to find the optimal conditions for purification of 
the recombinant proteins.  
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5.2 Materials and methods 
5.2.1 Expression in LB broth 
Expression vector pTHC was electrotransformed into E. coli BL21(DE3)pLysS or E. coli 
OrigamiTM2(DE3)pLysS for each expression (Section 2.4.4.2). After overnight growth of 
transformants on LB agar containing the appropriate antibiotics, a single colony was sub-
cultured into 2 mL LB broth containing antibiotics and grown at 37°C until the absorbance at 
600 nm reached 0.6 – 1.0. The next stage of the protocol, growth to mid-log phase 
(absorbance at 600 nm of 0.3 – 0.6), was also performed in LB broth at 37°C (Section 
2.6.3.3). Induction of protein expression with IPTG was performed in LB broth for 3 h at the 
required temperature. After 3 h induction, cell lysates were prepared for IMAC purification 
(Section 2.6.3.5). Induction of protein expression with IPTG was performed in LB broth for  
3 h at 25°C, 30°C, 37°C and 42°C in E. coli BL21(DE3)pLysS, and for 3 h at 37°C in E. coli 
OrigamiTM2(DE3)pLysS. 
 
5.2.2 Expression in EnPressoTM 
Expression vector pTHC was electrotransformed into E. coli BL21(DE3)pLysS or E. coli 
OrigamiTM2(DE3)pLysS for each expression (Section 2.4.4.2). After overnight growth of 
transformants on LB agar containing the appropriate antibiotics, a single colony was sub-
cultured into 2 mL LB broth containing antibiotics and grown at 37°C until the absorbance at 
600 nm reached 0.6 – 1.0. The next stage of the protocol, growth to mid-log phase 
(absorbance at 600 nm of 0.3 – 0.6), was performed in EnPressoTM tablet medium (Section 
2.3.2) at 30°C. Induction of protein expression with IPTG was performed in EnPressoTM tablet 
medium for 8 h at 30°C (Section 2.6.3.4). After 8 h induction, cell lysates were prepared for 
IMAC purification (Section 2.6.3.5). THC expressed in EnPressoTM was performed with and 
without the addition of 1 mM PMSF protease inhibitor (Section 2.3.1) during preparation of 
the cell lysate. 
 
5.2.3 Detection of inclusion bodies 
THC expressed in E. coli BL21(DE3)pLysS in LB broth at 37°C and in EnPressoTM at 30°C 
was assessed for inclusion body formation (Section 2.6.4.1). THC expressed in E. coli 
OrigamiTM2(DE3)pLysS in LB broth at 37°C was also assessed for inclusion body formation 
(Section 2.6.2.1). Following expression of THC and preparation of cell lysate, samples were 
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assessed for the presence of inclusion bodies by analysing the cell debris which remained 
after preparation of the cell lysate. After addition of 5x SDS sample loading buffer and 
heating at 100°C for 3 min, the presence of THC in the “pellet” sample was indicative of 
inclusion bodies. 
 
5.2.3.1 Pilot solubilisation of inclusion bodies 
Following the determination of inclusion body formation, a pilot study was performed to 
assess conditions required to solubilise inclusion bodies present in the cell lysate (Section 
2.6.4.2). Inclusion bodies were solubilised in 0.1 M Tris-HCl of varying pH (pH 8 – 12.5), with 
and without 2 M urea. Supernatant released from solubilised inclusions bodies and the 
remaining cell debris were analysed by SDS-PAGE (Section 2.6.2.1).  
 
5.2.4 Cell-free expression 
Expression vector pTHC was purified using the PureYieldTM plasmid miniprep system 
(Promega, U.S.A.), (Section 2.3.5) following the manufacturer’s instructions for expression in 
the S30 T7 High-yield protein expression system (Promega, U.S.A.), (Section 2.3.1). Due to 
the small volume of cell-free expression, THC was purified by batch purification (Section 
2.7.1.6) using nickel IMAC. The IMAC resin was washed in 5 column volumes (CV) of protein 
wash buffer (Section 2.3.1) containing 50 mM imidazole and THC was eluted in protein 
elution buffer (Section 2.3.1) containing 100 mM imidazole and samples were analysed by 
SDS-PAGE (Section 2.6.2.1).   
 
5.2.5 IMAC purification 
Following preparation of the cell lysate (Section 2.6.3.5), samples were purified using IMAC 
(Section 2.7.1.2). IMAC purification was performed using Chelating SepharoseTM fast flow 
(Section 2.3.1), charged with 0.2 M nickel sulphate (Ni2+) or 0.2 M cobalt chloride (Co2+)  
(Section 2.7.1.1). After the His6-tagged proteins in the cell lysate were allowed to bind to the 
pre-charged resin, which was pre-equilibrated with protein binding buffer (Section 2.3.1). The 
column was then washed in 5 CV of protein wash buffers (Section 2.3.1) containing 20 mM 
and 50 mM imidazole. THC was eluted in protein elution buffer (Section 2.3.1) containing  
100 mM imidazole (Section 2.3.1).  
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5.2.5.1 THC purification 
A double purification procedure using Ni2+ IMAC was performed for THC expressed in LB 
broth at 30°C. Following preparation of the cell lysate, THC was purified using IMAC (Section 
2.7.1.2), and the eluted protein was concentrated and buffer exchanged (Section 2.7.2.1), 
into protein binding buffer containing 10 mM imidazole (Section 2.3.1) to facilitate binding to 
the IMAC column during the second purification step. The concentrated protein sample was 
then purified a second time in a newly prepared nickel IMAC column, using the same 
protocol (Section 2.7.2.1). The THC protein was eluted in protein elution buffer (Section 
2.3.1) containing 100 mM imidazole, and the concentration and buffer exchange protocol 
(Section 2.7.2.1) was repeated. The double-purified THC was buffer exchanged to protein 
storage buffer (Section 2.3.1).  
 
Purification of THC expressed in EnPressoTM tablet media was performed using IMAC pre-
charged with 0.2 M nickel sulphate or 0.2 M cobalt chloride (Section 2.7.1.2), and THC was 
eluted in protein elution buffer (Section 2.3.1) containing 100 mM imidazole.  
 
THC expressed in cell-free culture and THC expressed in EnPressoTM following the 
solubilisation of inclusion bodies were purified using nickel batch purification (protein 
miniprep) (Section 2.7.1.6). Samples were analysed by SDS-PAGE (Section 2.6.2.1) and 
visualised by staining with Coomassie instant stain (Section 2.6.2.2) and by Western blot 
(Section 2.6.2.3 – 2.6.2.4), probing with antisera directed at the His6-tag (mouse anti-His 
IgG), and to the toxin domain (rabbit anti-tetanus toxin IgG) (Section 2.3.4). 
 
5.2.6 Concentration and buffer exchange 
Following the elution of THC from the IMAC column, protein present in protein elution buffer 
was applied to a pre-rinsed 50 kDa molecular weight cut-off (MWCO) Vivaspin 20 centrifugal 
device (Section 2.2), and samples were concentrated to a small volume (typically <1 mL) 
before performing buffer exchange (Section 2.7.2.1) to protein storage buffer (Section 2.3.1). 
Protein was stored in aliquots at -20°C for up to 2 months, or until required. 
 
5.2.7 Enterokinase treatment 
Cleavage of the affinity tag from the recombinant proteins was performed using treatment 
with EKMaxTM enterokinase (Invitrogen, U.S.A.), (Section 2.3.3). A pilot assay (Section 
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2.7.2.3) was performed to assess the optimal amount of enzyme, temperature and time of 
incubation required to remove the His6-tag from recombinant THC.  
 
5.2.7.1 His6-tag removal 
Once the optimal amount of enzyme and time of incubation was determined, enterokinase 
was removed from the reaction using the Enterokinase removal kit (Invitrogen Corporation, 
U.S.A.) (Section 2.3.5), and the cleaved His6-tag was removed using a modified method of 
batch purification (protein miniprep) (Section 2.7.1.6). Samples were analysed by SDS-
PAGE (Section 2.6.2.1) and visualised by staining with Coomassie instant stain (Section 
2.6.2.2) and by Western blot (Section 2.6.2.3 – 2.6.2.4), probing with an antibody directed at 
the His6-tag (Section 2.3.4) to detect the presence of the tag. 
 
5.3 Results  
5.3.1 Protein expression 
5.3.1.1 THC expression and purification from LB broth in E. coli BL21 
THC was expressed in E. coli BL21(DE3)pLysS with a final concentration of 1 mM IPTG for  
3 h in LB broth at 25°C, 30°C, 37°C and 42°C to investigate the effect of temperature on 
THC expression. THC expressed at 25°C (Figure 5.1), 30°C (Figure 5.2), 37°C (Figure 5.3), 
and 42°C (Figure 5.4) in LB broth was purified by nickel IMAC and the recombinant protein 
was eluted in protein elution buffer containing 100 mM imidazole. Following purification with 
IMAC, concentration and buffer exchange, 5 – 15 µg of protein was separated using SDS-
PAGE and visualised by staining with Coomassie instant stain (Figures 5.1A – 5.4A). 
Following immunotransfer, membranes were probed by immunoblotting, with antisera to the 
His6-tag (mouse anti-His IgG) (Figures 5.1B – 5.4B), and tetanus toxin (rabbit anti-tetanus 
toxin IgG) (Figures 5.1C – 5.4C), for the detection of the His6-tag and tetanus toxin domain, 
respectively. Cross-reactivity is evident with both antisera which detect proteins at both a 
larger and smaller molecular weights to THC. His6-tagged THC migrated to the predicted 
molecular weight of 102.7 kDa and induction of protein expression was optimal between 
25°C (Figure 5.1) and 30°C (Figure 5.2). However, due to the extended length of time 
required for growth at 25°C, THC expression at 30°C was determined to be optimal for high 
yield production of THC. 
  
170 
 
 
 
 
Figure 5.1: THC expressed in E. coli BL21 at 25°C in LB broth and purified by Ni2+ 
IMAC.  
Lane 1, Marker; Lane 2, 15 µg purified THC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of THC probed with mouse anti-His IgG. (C) Immunoblot 
detection of THC probed with rabbit anti-tetanus toxin IgG. 
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Figure 5.2: THC expressed in E. coli BL21 at 30°C in LB broth and purified by Ni2+ 
IMAC.  
Lane 1, Marker; Lane 2, 10 µg purified THC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of THC probed with mouse anti-His IgG. (C) Immunoblot 
detection of THC probed with rabbit anti-tetanus toxin IgG. 
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Figure 5.3: THC expressed in E. coli BL21 at 37°C in LB broth and purified by Ni2+ 
IMAC.  
Lane 1, Marker; Lane 2, 10 µg purified THC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of THC probed with mouse anti-His IgG. (C) Immunoblot 
detection of THC probed with rabbit anti-tetanus toxin IgG. 
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Figure 5.4: THC expressed in E. coli BL21 at 42°C in LB broth and purified by Ni2+ 
IMAC.  
Lane 1, Marker; Lane 2, 5 µg purified THC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of THC probed with mouse anti-His IgG. (C) Immunoblot 
detection of THC probed with rabbit anti-tetanus toxin IgG. 
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Double-purification of THC expressed in E. coli BL21(DE3)pLysS at 30°C (Figure 5.5A) was 
performed to remove “non-specific” proteins which remained after concentrating the eluted 
sample in a 50 kDa MWCO Vivaspin 20 centrifugal device. Figure 5.5A, Lane 2 shows THC 
after the first purification and buffer exchange step, and Figure 5.5A, Lane 4 shows THC 
after the second purification and buffer exchange step. Figures 5.5B and 5.5C show Western 
blot results after probing with anti-His IgG and anti-tetanus toxin IgG antisera, respectively.  
 
Cross-reactivity is evident with both antisera which detected proteins at lower molecular 
weights to THC. Results indicate that the double-purification procedure did not remove the 
non-specific proteins present at both higher and lower molecular weight to the THC.  
 
5.3.1.2 THC expression and purification from EnPressoTM tablet media in  
E. coli BL21 
THC expressed in E. coli BL21(DE3)pLysS in EnPressoTM tablet media was purified using 
both nickel and cobalt IMAC. Induction of protein expression was performed for 8 h at 30°C 
in EnPressoTM, however all subsequent steps leading to purification were identical to those in 
previous section (Section 5.3.1.1).  
 
THC expressed in EnPressoTM tablet media was purified using nickel IMAC and 10 µg of 
purified, concentrated and buffer exchanged protein was separated by SDS-PAGE and 
stained with Coomassie instant stain (Figure 5.6A). Following immunotransfer, membranes 
were probed by immunoblotting with antisera to the His6-tag (mouse anti-His IgG) (Figure 
5.6B), and tetanus toxin (rabbit anti-tetanus toxin IgG) (Figure 5.6C), for the detection of the 
His6-tag and tetanus toxin domain, respectively.  
 
THC expressed in EnPressoTM (Figure 5.6) did not significantly increase the yield of 
recombinant THC when compared to THC expressed at 25°C – 37°C in LB broth (Figures 
5.1 – 5.3). However, due to the more simple method of expression with EnPressoTM than with 
LB broth, THC expressed at 30°C in EnPressoTM was determined to be optimal for this study. 
It must be noted that noted that THC often migrated to just below the 100 kDa band in the 
protein standard marker when expressed in EnPressoTM. 
 
To compare the influence of the metal ion used for IMAC purification of THC, THC expressed 
in EnPressoTM was also purified using cobalt IMAC. Ten micrograms of purified, concentrated 
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Figure 5.5: THC expressed in E. coli BL21 at 30°C in LB broth and purified twice by 
Ni2+ IMAC.  
(A) SDS-PAGE stained with Coomassie instant stain. Lane 1 and 3, Marker; Lane 2, 10 µg 
purified THC (first purification); Lane 4, 10 µg purified THC (second purification). (B) and (C) 
Lane 1, Marker; Lane 2, 10 µg purified THC (first purification); Lane 3, 10 µg purified THC 
(second purification). (B) Immunoblot detection of THC probed with mouse anti-His IgG. (C) 
Immunoblot detection of THC probed with rabbit anti-tetanus toxin IgG. 
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Figure 5.6: THC expressed in E. coli BL21 at 30°C in EnPressoTM and purified by Ni2+ 
IMAC.  
Lane 1, Marker; Lane 2, 10 µg purified THC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of THC probed with mouse anti-His IgG. (C) Immunoblot 
detection of THC probed with rabbit anti-tetanus toxin IgG. 
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and buffer exchanged protein was separated by SDS-PAGE and visualised by staining with 
Coomassie instant stain (Figure 5.7A). Western blotting was performed and membranes 
were probed by immunoblotting with antisera to the His6-tag (mouse anti-His IgG) (Figures 
5.7B), and tetanus toxin (rabbit anti-tetanus toxin IgG) (Figure 5.7C). The use of cobalt IMAC 
did not result in a reduction in the number of proteins at a lower molecular weight to THC 
when the results of Figure 5.6 and Figure 5.7 are compared. 
 
THC expressed in EnPressoTM was also purified after treatment with protease inhibitor PMSF 
during preparation of the cell lysate. Figures 5.8A, B and C show 10 µg of purified, 
concentrated and buffer exchanged protein separated by SDS-PAGE and visualised by 
staining with Coomassie instant stain, and Western blot probed with antisera to the His6-tag 
(mouse anti-His IgG), and tetanus toxin (rabbit anti-tetanus toxin IgG), respectively. The use 
of PMSF showed some improvements in reducing the amount of non-specific protein 
detected after immunoblotting. 
 
5.3.1.3 THC expression and purification from LB broth in E. coli OrigamiTM2 
THC expressed in E. coli OrigamiTM2(DE3)pLysS was performed with a final concentration of 
1 mM IPTG for 3 h in LB broth at 30°C (Figure 5.9), and was purified by cobalt IMAC. THC 
was eluted in protein elution buffer containing 100 mM imidazole. Following purification by 
IMAC, concentration and buffer exchange, 5 µg of protein was separated using SDS-PAGE 
and visualised by staining with Coomassie instant stain and by Western blot, probing with 
antisera to the His6-tag (mouse anti-His IgG) (Figure 5.9B), and tetanus toxin (rabbit anti-
tetanus toxin IgG) (Figure 5.9C), for the detection of the His6-tag and tetanus toxin domain, 
respectively. THC was expressed at a lower yield from E. coli OrigamiTM2(DE3)pLysS in LB 
broth compared to expression at the same temperature in E. coli BL21(DE3)pLysS (Figure 
5.2), however there were fewer reactive species of a lower molecular weight to THC present 
after expression in E. coli OrigamiTM2(DE3)pLysS.  
 
5.3.1.4 THC expression and purification from EnPressoTM tablet media in  
E. coli OrigamiTM2 
THC expressed in E. coli OrigamiTM2(DE3)pLysS for 8 h at 30°C in EnPressoTM tablet media 
was purified using cobalt IMAC (Figure 5.10). Three micrograms of purified, concentrated  
  
178 
 
 
 
Figure 5.7: THC expressed in E. coli BL21 at 30°C in EnPressoTM and purified by Co2+ 
IMAC.  
Lane 1, Marker; Lane 2, 10 µg purified THC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of THC probed with mouse anti-His IgG. (C) Immunoblot 
detection of THC probed with rabbit anti-tetanus toxin IgG. 
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Figure 5.8: THC expressed in E. coli BL21 at 30°C in EnPressoTM with PMSF and 
purified by Co2+ IMAC.  
Lane 1, Marker; Lane 2, 10 µg purified THC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of THC probed with mouse anti-His IgG. (C) Immunoblot 
detection of THC probed with rabbit anti-tetanus toxin IgG. 
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Figure 5.9: THC expressed in E. coli OrigamiTM2 at 30°C in LB broth and purified by 
Co2+ IMAC.  
Lane 1, Marker; Lane 2, 5 µg purified THC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of THC probed with mouse anti-His IgG. (C) Immunoblot 
detection of THC probed with rabbit anti-tetanus toxin IgG. 
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Figure 5.10: THC expressed in E. coli OrigamiTM2 at 30°C in EnPressoTM and purified by 
Co2+ IMAC.  
Lane 1, Marker; Lane 2, 3 µg purified THC. (A) SDS-PAGE stained with Coomassie instant 
stain. (B) Immunoblot detection of THC probed with mouse anti-His IgG. (C) Immunoblot 
detection of THC probed with rabbit anti-tetanus toxin IgG. 
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and buffer exchanged protein was separated by SDS-PAGE and visualised by staining with 
Coomassie instant stain (Figure 5.10A). Following immunotransfer, membranes were probed 
by immunoblotting with antisera to the His6-tag (mouse anti-His IgG) (Figure 5.10B), and 
tetanus toxin (rabbit anti-tetanus toxin IgG) (Figure 5.10C), for the detection of the His6-tag 
and tetanus toxin domain, respectively. THC was expressed from E. coli 
OrigamiTM2(DE3)pLysS in EnPressoTM at a yield comparable to that after expression in  
E. coli BL21(DE3)pLysS in EnPressoTM with PMSF (Figure 5.8). There was a reduction in the 
number of reactive species present at a lower molecular weight compared to THC expressed 
in E. coli BL21(DE3)pLysS at 30°C in EnPressoTM (Figure 5.7). 
 
5.3.2 Detection of inclusion bodies 
5.3.2.1 Detection of inclusion bodies from E. coli BL21 
THC expressed in E. coli BL21(DE3)pLysS at 37°C in LB broth (Figure 5.11) and at 30°C in 
EnPressoTM (Figure 5.12) was analysed for the presence of inclusion bodies. Ten microlitres 
of cell lysate and cell debris or “pellet” sample were analysed by SDS-PAGE and visualised 
by staining with Coomassie instant stain (Figure 5.11A and 5.12A), and by Western blot, 
probing with antisera to the His6-tag (mouse anti-His IgG) (Figure 5.11B and 5.12B), and 
tetanus toxin (rabbit anti-tetanus toxin IgG) (Figure 5.11C and 5.12C), for the detection of the 
His6-tag and tetanus toxin domain, respectively. THC was detected in the pellet sample 
indicating the presence of inclusion bodies after expression in at 37°C in LB broth (Figure 
5.11) and at 30°C in EnPressoTM (Figure 5.12).  
 
5.3.2.2 Detection of inclusion bodies from E. coli OrigamiTM2 
THC expressed in E. coli OrigamiTM2(DE3)pLysS at 37°C in LB broth and at 30°C in 
EnPressoTM was analysed for the presence of inclusion bodies. Ten microlitres of cell lysate 
and cell debris or “pellet” sample were analysed by SDS-PAGE and stained with Coomassie 
instant stain (Figure 5.13A and 5.14A), and probing with antisera to the His6-tag (mouse anti-
His IgG) (Figure 5.13B and 5.14B), and tetanus toxin (rabbit anti-tetanus toxin IgG) (Figure 
5.13C and 5.14C) for the detection of the His6-tag and tetanus toxin domain, respectively, 
following immunotransfer. THC was detected in the pellet sample indicating the presence of 
inclusion bodies after expression at 37°C in LB broth (Figure 5.13) and at 30°C in 
EnPressoTM (Figure 5.14). 
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Figure 5.11: Detection of inclusion bodies for THC expressed in E. coli BL21 at 37°C in 
LB broth.  
Lane 1, Marker; Lane 2, 10 µL soluble fraction; Lane 3, 10 µL insoluble fraction. (A) SDS-
PAGE stained with Coomassie instant stain. (B) Immunoblot detection of THC probed with 
mouse anti-His IgG. (C) Immunoblot detection of THC probed with rabbit anti-tetanus toxin 
IgG. 
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Figure 5.12: Detection of inclusion bodies for THC expressed in E. coli BL21 at 30°C in 
EnPressoTM.  
Lane 1, Marker; Lane 2, 10 µL insoluble fraction; Lane 3, 10 µL soluble fraction. (A) SDS-
PAGE stained with Coomassie instant stain. (B) Immunoblot detection of THC probed with 
mouse anti-His IgG. (C) Immunoblot detection of THC probed with rabbit anti-tetanus toxin 
IgG. 
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Figure 5.13: Detection of inclusion bodies for THC expressed in E. coli OrigamiTM2 at 
37°C in LB broth.  
Lane 1, Marker; Lane 2, 10 µL soluble fraction; Lane 3, 10 µL insoluble fraction. (A) SDS-
PAGE stained with Coomassie instant stain. (B) Immunoblot detection of THC probed with 
mouse anti-His IgG. (C) Immunoblot detection of THC probed with rabbit anti-tetanus toxin 
IgG. 
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Figure 5.14: Detection of inclusion bodies for THC expressed in E. coli OrigamiTM2 at 
30°C in EnPressoTM.  
Lane 1, Marker; Lane 2, 10 µL soluble fraction; Lane 3, 10 µL insoluble fraction. (A) SDS-
PAGE stained with Coomassie instant stain. (B) Immunoblot detection of THC probed with 
mouse anti-His IgG. (C) Immunoblot detection of THC probed with rabbit anti-tetanus toxin 
IgG. 
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5.3.3 Solubilisation of inclusion bodies  
Following the detection of inclusion body formation after THC was expressed in E. coli 
BL21(DE3)pLysS) at 37°C in LB broth (Figure 5.11) and at 30°C in EnPressoTM (Figure 
5.12), a pilot study was performed to determine the optimal conditions required to solubilise 
the inclusion bodies. Inclusion bodies were isolated following THC expression at 37°C in LB 
broth (Figure 5.15) and at 30°C in EnPressoTM (Figure 5.16), and were treated with buffer 
containing 0.1 M Tris-HCl at varying pH with and without 2 M urea. The pellet samples and 
the supernatant collected following cell lysis were analysed by SDS-PAGE and stained with 
Coomassie instant stain (Figure 5.15A – C and 5.16A – C) and by Western blot, probing with 
antisera to the His6-tag (mouse anti-His IgG) (Figure 5.15D and 5.16D), and tetanus toxin 
(rabbit anti-tetanus toxin IgG) (Figure 5.15E and 5.16E), for the detection of the His6-tag and 
tetanus toxin domain, respectively. The presence of THC at ~102.7 kDa in supernatant 
samples was indicative of solubilised THC, whilst the presence of THC in pellet samples 
indicated THC had not been completely solubilised in the buffer.  
 
THC expressed in inclusion bodies at 37°C in LB broth was completely solubilised by 
treatment with buffer containing 0.1 M Tris-HCl pH 12.5 and with buffer containing 0.1 M Tris-
HCl pH 12 and 2M urea as indicated by the absence of protein in the pellet sample after 
treatment with these buffers (Figure 5.15B, Lane 4; Figure 5.15C, Lane 6; Figure 5.15D, 
Lane 5 and 9; and Figure 5.15E, Lane 4 and 8).  
 
THC expressed in inclusion bodies at 30°C in EnPressoTM was not completely solubilised 
after treatment with the buffers assessed, however buffer containing 0.1 M Tris-HCl pH 12.5 
and 2 M urea solubilised the majority of THC as indicated by a reduction in the amount of 
THC present in the pellet sample and a larger amount of THC present in the corresponding 
supernatant sample (Figure 5.16C, Lane 6 and 7; and Figure 5.16D – 5.16E, Lane 4 and 5).  
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Figure 5.15: Solubilisation of inclusion bodies for THC expressed in E. coli BL21 at 
37°C in LB broth.  
(A) SDS-PAGE stained with Coomassie instant stain. Lane 1 and 4, Marker; Lane 2 and 3, 
0.1 M Tris-HCl pH 12.5, 10 µL insoluble and soluble fraction; Lane 5 and 6, 0.1 M Tris-HCl 
pH 12 and 2 M urea, 10 µL insoluble and soluble fraction. (C) and (D) Lane 1 and 6, Marker; 
Lane 2 and 3, 0.1 M Tris-HCl pH 12.5, 10 µL insoluble and soluble fraction; Lane 4 and 5,  
0.1 M Tris-HCl pH 12.5 and 2 M urea, 10 µL insoluble and soluble fraction. (C) Immunoblot 
detection of THC probed with mouse anti-His IgG. (D) Immunoblot detection of THC probed 
with rabbit anti-tetanus toxin IgG.  
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Figure 5.16: Solubilisation of inclusion bodies for THC expressed in E. coli BL21 at 
30°C in EnPressoTM.  
(A) SDS-PAGE stained with Coomassie instant stain. Lane 1 and 4, Marker; Lane 2 and 3, 
0.1 M Tris-HCl pH 12.5, 10 µL insoluble and soluble fraction; Lane 5 and 6, 0.1 M Tris-HCl 
pH 12.5 and 2 M urea, 10 µL insoluble and soluble fraction. (C) and (D) Lane 1 and 6, 
Marker; Lane 2 and 3, 0.1 M Tris-HCl pH 12.5, 10 µL insoluble and soluble fraction; Lane 4 
and 5, 0.1 M Tris-HCl pH 12.5 and 2 M urea, 10 µL insoluble and soluble fraction. (C) 
Immunoblot detection of THC probed with mouse anti-His IgG. (D) Immunoblot detection of 
THC probed with rabbit anti-tetanus toxin IgG.  
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5.3.3.1 Purification of solubilised inclusion bodies  
THC was purified from inclusion bodies following expression in E. coli BL21(DE3)pLysS at 
30°C in EnPressoTM and solubilisation in 0.1 M Tris-HCl pH 12.5 and 2 M urea (determined in 
Section 5.3.3), using batch purification (Figure 5.17). There is a high degree of cross-
reactivity evident with antisera directed at the His6-tag (Figure 5.17B) which detected proteins 
at both a smaller and larger molecular weights to THC, however the immunoblot probed with 
antisera to tetanus toxin (Figure 5.17C) shows a dominant protein at the approximate 
molecular weight of THC. THC is present in the flow-through collected after the cell lysate 
was bound to the column, indicating that not all of the THC bound to the nickel resin.  
 
5.3.4 Cell-free expression 
THC was expressed in the S30 T7 High-Yield protein expression system using E. coli-
extracted factors for transcription and translation in a cell-free system. Following batch 
purification using nickel IMAC, 8 µL of the cell-free reaction (representing approximately 20% 
of the 50 µL reaction) was separated using SDS-PAGE and visualised by staining with 
Coomassie instant stain (Figure 5.18A) and by Western blot, probing with antisera to the 
His6-tag (mouse anti-His IgG) (Figures 5.18B). During batch purification, the resin was 
washed with protein wash buffer containing 50 mM imidazole (Figure 5.18A and B, Lane 2), 
and eluted in protein elution buffer containing 100 mM imidazole (Figure 5.18A and B, Lane 
3). THC was detected at ~102.7 kDa in both wash and elution samples of the Western blot 
(Figure 5.18B), and there was no cross-reactivity demonstrated with the anti-His antisera.  
 
5.3.5 His6-tag cleavage and removal 
5.3.5.1 Enterokinase treatment 
Cleavage of the affinity tag from recombinant THC was performed using treatment with 
enterokinase. A pilot assay was performed to assess the optimal amount of enzyme, 
temperature and time of incubation required to remove the His6-tag from THC. Figures 5.19A 
– D show the enterokinase pilot assay for THC.  
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Figure 5.17: Solubilised inclusion bodies for THC expressed in E. coli BL21 at 30°C in 
EnPressoTM purified by Ni2+ IMAC.  
Lane 1, Marker; Lane 2, 20 µL of column flow through; Lane 3, 20 µL of 100 mM imidazole 
elution. (A) SDS-PAGE stained with Coomassie instant stain. (B) Immunoblot detection of 
THC probed with mouse anti-His IgG. (C) Immunoblot detection of THC probed with rabbit 
anti-tetanus toxin IgG. 
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Figure 5.18: THC expressed by cell-free expression and purified by Ni2+ IMAC.  
Lane1, Marker; Lane 2, 20 µL of 50 mM imidazole wash; Lane 3, 20 µL of 100 mM imidazole 
elution. (A) SDS-PAGE stained with Coomassie instant stain. (B) Immunoblot detection of 
THC probed with mouse anti-His IgG. 
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Figure 5.19: THC enterokinase pilot assay.  
(A) – (C) SDS-PAGE stained with Coomassie instant stain. Lane 1, Marker; Lane 2 – 7,  
20 µg THC treated with 0, 0.001, 0.01, 0.1, 1 and 4 U enterokinase, respectively. (A) THC 
enterokinase pilot assay incubated for 1 h at room temperature. (B) THC enterokinase pilot 
assay incubated for 2 h at room temperature. Lane 8, Marker. (C) THC enterokinase pilot 
assay incubated for 16 h at room temperature. (D) Immunoblot detection of THC 
enterokinase pilot assay probed with mouse anti-His IgG. Lane 1, Marker; Lane 2 – 4, 20 µg 
THC treated with 0, 0.1, 1 U enterokinase for 2 h at room temperature.  
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Complete His6-tag removal was achieved after incubation with 1 U enterokinase for 2 h at 
room temperature, indicated by the absence of a band on the anti-His Western blot for this 
sample (Figure 5.19D). The inability of the anti-His antibody to produce a colorimetric 
reaction for this sample indicates the absence of a detectable limit of His6-tag within the 
sample.  
 
5.3.5.2 His6-tag removal 
Prior to the removal of the free His6-tag cleaved from recombinant THC during enterokinase 
treatment, the enterokinase enzyme was first removed from the reaction using the 
Enterokinase removal kit (Invitrogen Corporation, U.S.A.). Following enterokinase removal, 
cleaved His6-tag was removed using a modified method of batch purification (protein 
miniprep). Samples were analysed by SDS-PAGE and a Western blot probing with an 
antibody directed at the His6-tag to detect the presence of the affinity tag. Protein migrated to 
the predicted molecular weight for His-free THC (Figure 5.20) and no bands were present on 
anti-His Western blots (data not shown), indicating that His6-tag was completely removed 
from the enterokinase-treated protein. 
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Figure 5.20: His6-tag removal from THC.  
SDS-PAGE stained with Coomassie instant stain. THC treated with enterokinase and 
removal of cleaved His6-tag by batch purification. Lane 1, Marker; Lane 2, 200 mM imidazole 
wash (contains cleaved His6-tag, ~6 kDa); Lane 3, His-free THC collected after His6-tag was 
removed from the sample.  
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5.4 Discussion 
This section of the study reports the recombinant expression of tetanus toxin heavy chain. 
Fragment-C of tetanus toxin, which contains the C-terminal domains involved in cell-binding 
and retrograde trafficking of TeNT is generally used in the development of CNT-based 
therapeutic molecules (Charles et al., 1991; Francis et al., 2004a). However, in order to 
create a chimeric holotoxin which is able to deliver the light chain domain to inhibitory 
interneurons in the CNS and translocate the LC into the cytosol, the cell-binding and 
trafficking function of fragment-C and the translocation function of the HN domain needed to 
be retained. Therefore, full-length recombinant THC was expressed in this study. A previous 
report has demonstrated the successful production of recombinant full-length tetanus toxin 
heavy chain from E. coli for the purpose of creating a recombinant tetanus holotoxin by 
reconstitution of the heavy chain with recombinant tetanus toxin light chain (Li, Y. et al., 
1999). Based on the success of this report, this study attempted to produce recombinant 
THC from E. coli BL21 and E. coli OrigamiTM2.  
 
5.4.1 THC expression and purification from E. coli BL21 
There was some difficulty in obtaining THC in a highly pure form after purification by IMAC. 
C-terminal degradation of THC was indicated by the presence of proteins of a smaller 
molecular weight which reacted with both anti-His and anti-tetanus toxin antisera. The use of 
PMSF showed a slight reduction in the amount of non-specific protein, providing further 
evidence that these proteins may be degradation products of recombinant THC. Degradation 
has possibly occurred at both N- and C-terminal ends of THC, however only C-terminal 
degradation products have co-purified with full-length THC since they retain the N-terminal 
His6-tag required for purification by IMAC.  
 
Due to the reducing environment in the E. coli cytoplasm disulfide bond formation will be 
prevented, which may cause misfolding of the protein (Baneyx and Mujacic, 2004; Stewart et 
al., 1998). The detection of THC in both soluble and insoluble fractions indicated the possible 
misfolding of THC in the cytoplasm of E. coli BL21 and subsequent partial deposition into 
insoluble aggregates in the form of inclusion bodies. Protein misfolding may cause exposure 
of protease-sensitive regions which undergo proteolytic attack by endogenous protoeases 
present in the E. coli cytoplasm. Inclusion bodies are resistant to proteolysis and should be 
comprised solely of full-length misfolded recombinant THC, however, solubilisation of 
inclusion bodies still failed to achieve THC in a pure form.  
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5.4.2 THC expression and purification from E. coli OrigamiTM2 
In an attempt to produce an optimal environment for the formation of the intrachain disulfide 
bond and thus correctly folded recombinant THC, THC was expressed in the  
E. coli OrigamiTM2 strain. This strain has been designed to enhance disulfide bond formation 
in the E. coli cytoplasm by the introduction of mutations in the thioredoxin reductase (trxB) 
and glutathione reductase (gor) genes. Analysis of THC expressed in E. coli OrigamiTM2 
indicated that there were fewer reactive proteins present at a lower molecular weight to THC 
after IMAC purification; however these proteins were similar to those which reacted from 
THC expressed in E. coli BL21. THC was detected in the insoluble fraction after expression 
in E. coli OrigamiTM2, indicating that THC was not correctly folded and continued to form 
insoluble aggregates.  
 
5.4.3 Cell-free expression 
The S30 T7 High-Yield protein expression system (Promega, U.S.A.) allows for transcription 
and translation of DNA sequences with a T7 promoter by using T7 RNA polymerase for 
transcription and factors required for translation extracted from E. coli for cell-free protein 
synthesis. The use of a cell-free expression system for recombinant THC production did not 
achieve completely pure THC, but demonstrated a single reactive protein at ~102.7 kDa in 
the anti-His Western blot. The presence of only a single reactive protein indicated that THC 
was not degraded during cell-free expression, the intrachain disulfide bond was potentially 
formed and the protein was most likely present in its correctly folded form. Difficulties in 
obtaining pure THC from cell-free expression indicated that this method of recombinant THC 
production is still not optimal for this study. 
 
Despite the inability to obtain pure, correctly folded recombinant THC, the function of THC 
was assessed using an ELISA. THC was assessed for its ability to bind to its native receptor, 
ganglioside GT1b; however difficulties with the assay prevented any conclusions being drawn 
about the binding activity of recombinant THC (data not shown).  
 
In summary, full-length THC was successfully expressed in E. coli, however as many others 
have found it is difficult to obtain this in a pure, homogenous form. In the next chapter, future 
studies that may be performed to overcome the limitations of this expression system will be 
discussed. 
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Chapter 6  
Conclusion and future direction 
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Obstructive sleep apnoea affects 2 – 4% of the population (Young et al., 1993) and causes 
significant comorbidities which impact on the quality of life. Current treatment options such as 
oral appliances cause significant discomfort (Malhotra and White, 2002), while 
pharmacotherapy has resulted in adverse side effects (Black et al., 2010; Darwish et al., 
2010). Surgery is a significantly invasive procedure that may not be suitable for some 
individuals or may not completely reverse symptoms in patients with severe OSA (Ejaz et al., 
2011; Olszewska et al., 2012). Although the most successful treatment for reversing OSA 
symptoms, the non-invasive CPAP device still displays a 50% non-compliance rate 1 year 
after prescription (Ballard et al., 2007). It is evident that a treatment for OSA which is 
convenient and more widely accepted by sufferers is necessary.  
 
Tetanus toxin, which causes muscle spasticity by increasing muscle tone, may be used in 
the treatment of OSA. Controlled administration of tetanus toxin to the muscles of the upper 
airway involved in obstruction during sleep may increase muscle tone by inducing localised 
tetany. The use of tetanus toxin in the treatment of airway obstruction which occurs during 
sleep and under anaesthesia in British Bulldogs, has demonstrated that controlled injection 
of the toxin into muscles of the upper airway, does in fact relieve OSA symptoms without 
adverse effects from toxin administration (Sasse et al., 2005). 
 
The tetanus toxin heavy chain domain has been used as a carrier for the transport of cargo 
proteins to the central nervous system (Bizzini et al., 1977; Francis et al., 2004a) indicating 
that although the majority of the population are vaccinated against tetanus, the toxin domains 
are still feasible for use in therapeutic molecules (Fishman et al., 2006). Nevertheless, a 
method to reduce the potential immunogenicity of the toxin molecule is to replace the tetanus 
toxin light chain domain with that of the botulinum type A light chain. This chimeric CNT 
holotoxin will employ the tetanus toxin heavy chain to deliver the botulinum type A light chain 
to the CNS where it can act on inhibitory interneurons to cause muscle spasticity in the area 
of injection. The botulinum toxin light chain domain has been used in targeted secretion 
inhibitors (Stancombe et al., 2012), and the use of the botulinum type A holotoxin in the 
treatment of muscle spasticity disorders (Truong and Jost, 2006) demonstrates that 
controlled toxicity with CNTs has therapeutic potential. It may also be possible to replace 
regions of the heavy chain not involved in neuronal targeting with botulinum sequences. 
 
Recombinant toxin molecules comprising domains from various CNTs have previously been 
reported (Poulain et al., 1991; Wang et al., 2008), and recombinant CNT domains have been 
expressed individually in E. coli and later reconstituted to create an active chimeric holotoxin 
(Li, Y. et al., 1999; Li, Y. et al., 1994). The aims of this study were to express recombinant 
CNT toxin domains of tetanus toxin light (TLC) and heavy (THC) chains and the botulinum 
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type A toxin light chain (B/ALC) in order to create a novel chimeric CNT holotoxin comprising 
B/ALC + THC for the treatment of OSA. The native tetanus toxin would be re-created using 
recombinantly expressed TLC + THC to assess the method of expression and conjugation to 
create the chimeric holotoxin by comparing its activity to the native tetanus toxin.  
 
The strategy used in this study was to express the heavy and light chains as individual 
proteins, with a view to conjugation to form active toxin. This was done for both safety 
concerns (the individual chains are non-toxic) and to facilitate easy domain swapping when 
making the different “serotypes”. This study demonstrated the expression of the tetanus toxin 
and botulinum type A light chain domains in a relatively pure and active form. Recombinant 
light chains were purified to 80 – 90% purity via IMAC after expression in E. coli, and were 
shown to be active in functional assays. The tetanus toxin light chain was at least as active 
as the commercially obtained positive control tetanus toxin light chain as demonstrated by 
the successful cleavage of its native substrate, VAMP-2. The BoNT/A light chain developed 
in this study was catalytically active as demonstrated by the cleavage of its native substrate, 
SNAP-25 in a FRET assay; although activity was slightly reduced from that of the 
commercially obtained positive control BoNT/A light chain.  
 
Proteins which migrated at both a higher and lower molecular weight to the light chains 
observed in both preparations after purification were thought to be C-terminal degradation 
products which retain the N-terminal His-tag and thus co-purified with the full-length light 
chain proteins. These proteins were reactive with both anti-His and anti-toxin-specific 
antisera, indicating that they are truncated forms of the full-length protein. Given the amount 
of protein loaded onto SDS-PAGE gels, these impurities comprise only 10 – 20% of the total 
protein obtained after purification of the light chain toxin domains, and both light chains 
display catalytic activity even in the presence of these impurities. In preparation for animal 
experiemnts, a final clean-up of the light chain proteins may be performed using methods 
such as size-exclusion chromatography or ion exchange chromatography for the removal of 
truncated forms of the proteins. The tetanus and botulinum type A toxin light chain domains 
developed in this study were catalytically active and are satisfactory for use in the 
reconstitution with the tetanus toxin heavy chain to create the final chimeric holotoxin.  
 
Difficulty in the expression of the tetanus toxin heavy chain domain meant that it could not be 
obtained in a pure, soluble form. The majority of the literature reports the soluble expression 
of the C-terminal heavy chain domain (HCC) also known as fragment-C (Bizzini et al., 1977; 
Francis et al., 2004a; Lalli and Schiavo, 2002; Larsen et al., 2006). This 50 kDa domain has 
been expressed successfully in E. coli and retains the cell-binding and trafficking activity of 
the tetanus toxin, but lacks the translocation activity of the HN domain. The full-length heavy 
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chain of tetanus toxin has previously been expressed in E. coli in a pure and soluble form (Li, 
Y. et al., 1999), however the use of THC expressed from pRSET-A in E. coli performed in 
this study, could not provide optimal conditions to obtain THC in a pure form. The study by Li 
et al. (1999) expressed THC with an MBP-fusion tag and the protein was purified by amylose 
affinity chromatography. The presence of the MBP-tag may have facilitated the soluble 
expression of THC (Kapust and Waugh, 1999). 
 
The tetanus toxin heavy chain contains four sulfhydryl groups, one involved in forming the 
interchain disulfide bridge with the LC, two free sulfhydryl groups, and two which form an 
intramolecular disulfide bond (Krieglstein et al., 1990). The presence of this intramolecular 
disulfide bond may have an impact on the correct folding of the protein in the E. coli 
cytoplasm during expression. The reducing environment of the E. coli cytoplasm is typically 
not favourable for the formation of disulfide bonds (de Marco, 1999), however since THC has 
previously been expressed in a soluble form from E. coli, it was expected that the same 
would be possible in this study. Despite the unfavourable conditions of the E. coli cytoplasm, 
it was expected that even if recombinant THC was expressed in a misfolded form, the 
conditions required to reconstitute the LC and HC to create the final chimeric holotoxin which 
involves reducing and then oxidising the proteins, would allow formation of the intrachain and 
interchain disulfide bonds (Li et al., 1999).  
 
The detection of THC in inclusion bodies after expression in E. coli BL21 indicated that THC 
was possibly misfolding during expression and forming protein aggregates within the E. coli 
cytosol. THC expressed using the EnPressoTM tablet media at 30°C was expected to both 
increase the yield of recombinant protein, and prevent the formation of protein aggregates 
due to the nature of the expression system. The EnPressoTM tablet media uses a slow 
release glucose delivery providing a fed-batch system for the slow growth of E. coli. The rate 
at which recombinant protein is produced is reduced increasing the time for synthesis and 
folding to occur (Krause et al., 2010). It has been demonstrated that over-expression or 
expression at a fast rate of recombinant proteins may result in the aggregation of folding 
intermediates within the cell cytoplasm (Vasina and Baneyx, 1997). Initially, the reducing 
environment of the E. coli cytoplasm was not deemed an obstacle, since proteins would be 
exposed to a reduced environment followed by an oxidised environment during the 
reconstitution process (Li et al., 1999). However, since inclusion bodies were formed both 
after expression in E. coli BL21 in LB broth at 37°C and in EnPressoTM at 30°C, it was 
evident that the reducing conditions within the E. coli cytoplasm may have been hampering 
the correct folding of recombinant THC.  
 
202 
 
Expression of THC in E. coli OrigamiTM gave promising results. This strain contains a double 
mutation (trxB and gor) to create an oxidising environment within the E. coli cytoplasm to 
enhance expression of recombinant proteins containing disulfide bonds (de Marco, 1999). 
Although THC was still present in inclusion bodies after expression in this strain, the protein 
was purified in a highly pure form from the soluble fraction of the cell lysate, as indicated by 
fewer non-specific or truncated THC proteins present after purification. These results indicate 
that THC expression in E. coli OrigamiTM may provide optimal conditions for the formation of 
the intrachain disulfide bond within THC and therefore create correctly folded recombinant 
protein. This strain has previously been used for the expression of proteins (Seras-Franzoso 
et al., 2012) and antibodies (Subedi et al., 2012) which have proved to be difficult to express 
in a soluble form due to the presence of one or more disulfide bonds, and it has also been 
used for the expression of the light chain and translocation domain of BoNT/A (LHN/A) which 
retains the interchain disulfide bond (Stancombe et al., 2012). The misoflding of THC and 
accumulation of the protein in inclusion bodies may be used to an advantage. Catalytically 
active BoNT/A, B/ and /E LC has successfully been purified in an active form from inclusion 
bodies (Ahmed and Smith, 2000; Zdanovsky and Zdanovskaia, 2000), indicating that it may 
be possible to optimise conditions for the purification of THC from inclusion bodies. However, 
purification of full-length THC from inclusion bodies has not been reported in the literature.  
 
Further optimisation of THC expression is required to elucidate the mechanism behind 
protein misfolding. It is possible that proteases present within the E. coli cytoplasm are 
contributing to the degradation of the C-terminal region of THC. Protease inhibitor PMSF 
showed some improvements in the reduction of C-terminal degradation products when used 
during purification to protect the recombinant protein from proteolytic attack during cell lysis. 
However, a protease inhibitor cocktail containing multiple protease inhibitors may show 
further improvements be inhibiting the activity of a wider range of proteases. Another strategy 
to limit proteolytic attack during protein expression is to use an expression vector that targets 
the recombinant THC to the periplasm of E. coli. Secretion of recombinant proteins to the 
oxidising environment of the periplasm following expression has been shown to enhance 
folding of proteins containing disulfide bonds (de Marco, 1999). The pMAL expression 
vectors (NEB, U.S.A.) are able to express recombinant protein fused to a maltose-binding 
protein (MBP), which has been shown to increase solubility of recombinant proteins (Kapust 
and Waugh, 1999).  
 
For safety reasons, the toxin domains created in this study were expressed individually with 
the aim to the reconstitute the light and heavy chains to create the active di-chain molecule. 
However, expression of full-length single-chain toxins has been performed and is a feasible 
option for the future development of chimeric CNT holotoxins (Li et al., 2001; Wang et al., 
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2008). The ultimate aims of the project will include the production of sequence variants of 
chimeric holotoxins in an attempt to create tetanus subtypes that maintain the native function 
of THC, but are less immunogenic than the native toxin. Expression of single chain sequence 
variants will not facilitate easy domain swapping for the creation of different “serotypes”, but 
will allow for rapid production of active molecules to assess activity of the novel toxins.  
 
The work undertaken in this study demonstrates that it is possible to create catalytically 
active recombinant CNT toxin molecules by expression in E. coli. Functional assays for the 
detection of catalytic activity of CNT light chains has also been established and this study 
provides a firm basis for the expression of CNT toxins as therapeutic molecules. However, 
further work to optimise the soluble expression of THC is required before the novel chimeric 
CNT holotoxin can be created for the treatment of OSA. 
204 
 
References 
Agarwal, R., Binz, T. & Swaminathan, S. (2005). Analysis of active site residues of botulinum 
neurotoxin E by mutational, functional, and structural studies: Glu335Gln is an 
apoenzyme. Biochemistry 44:8291-8302. 
 
Agarwal, R., Eswaramoorthy, S., Kumaran, D., Dunn, J.J. & Swaminathan, S. (2004). 
Cloning, high level expression, purification, and crystallization of the full length 
Clostridium botulinum neurotoxin type E light chain. Protein Expr Purif 34:95-102. 
 
Akerstedt, T., Fredlund, P., Gillberg, M. & Jansson, B. (2002). A prospective study of fatal 
occupational accidents -- relationship to sleeping difficulties and occupational factors. 
J Sleep Res 11:69-71. 
 
Al Lawati, N.M., Patel, S.R. & Ayas, N.T. (2009). Epidemiology, risk factors, and 
consequences of obstructive sleep apnea and short sleep duration. Prog Cardiovasc 
Dis 51:285-293. 
 
Allam, J.S., Olson, E.J., Gay, P.C. & Morgenthaler, T.I. (2007). Efficacy of adaptive 
servoventilation in treatment of complex and central sleep apnea syndromes. Chest 
132:1839-1846. 
 
Aloia, M.S., Ilniczky, N., Di Dio, P., Perlis, M.L. et al. (2003). Neuropsychological changes 
and treatment compliance in older adults with sleep apnea. J Psychosom Res 54:71-
76. 
 
Amersdorfer, P., Wong, C., Smith, T., Chen, S. et al. (2002). Genetic and immunological 
comparison of anti-botulinum type A antibodies from immune and non-immune 
human phage libraries. Vaccine 20:1640-1648. 
 
Anderson, R., Gao, X.M., Papakonstantinopoulou, A., Roberts, M. & Dougan, G. (1996). 
Immune response in mice following immunization with DNA encoding fragment C of 
tetanus toxin. Infect Immun 64:3168-3173. 
 
Andersson, S.G. & Kurland, C.G. (1990). Codon preferences in free-living microorganisms. 
Microbiol Rev 54:198-210. 
 
Ankichetty, S., Wong, J. & Chung, F. (2011). A systematic review of the effects of sedatives 
and anesthetics in patients with obstructive sleep apnea. J Anaesthesiol Clin 
Pharmacol 27:447-458. 
 
Arndt, J.W., Chai, Q., Christian, T. & Stevens, R.C. (2006a). Structure of botulinum 
neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 
substrate specificity. Biochemistry 45:3255-3262. 
 
Arndt, J.W., Jacobson, M.J., Abola, E.E., Forsyth, C.M. et al. (2006b). A structural 
perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J 
Mol Biol 362:733-742. 
 
Arnon, S.S., Schechter, R., Inglesby, T.V., Henderson, D.A. et al. (2001). Botulinum toxin as 
a biological weapon: medical and public health management. JAMA 285:1059-1070. 
 
205 
 
Aurora, R.N., Chowdhuri, S., Ramar, K., Bista, S.R. et al. (2012). The treatment of central 
sleep apnea syndromes in adults: practice parameters with an evidence-based 
literature review and meta-analyses. Sleep 35:17-40. 
 
Bade, S., Rummel, A., Reisinger, C., Karnath, T. et al. (2004). Botulinum neurotoxin type D 
enables cytosolic delivery of enzymatically active cargo proteins to neurones via 
unfolded translocation intermediates. J Neurochem 91:1461-1472. 
 
Bakker, J.P., Neill, A.M. & Campbell, A.J. (2012). Nasal versus oronasal continuous positive 
airway pressure masks for obstructive sleep apnea: a pilot investigation of pressure 
requirement, residual disease, and leak. Sleep Breath 16:709-716. 
 
Baldwin, M.R. & Barbieri, J.T. (2007). Association of botulinum neurotoxin serotypes a and B 
with synaptic vesicle protein complexes. Biochemistry 46:3200-3210. 
 
Baldwin, M.R., Bradshaw, M., Johnson, E.A. & Barbieri, J.T. (2004). The C-terminus of 
botulinum neurotoxin type A light chain contributes to solubility, catalysis, and 
stability. Protein Expr Purif 37:187-195. 
 
Baldwin, M.R., Tepp, W.H., Przedpelski, A., Pier, C.L. et al. (2008). Subunit vaccine against 
the seven serotypes of botulism. Infect Immun 76:1314-1318. 
 
Ballard, R.D., Gay, P.C. & Strollo, P.J. (2007). Interventions to improve compliance in sleep 
apnea patients previously non-compliant with continuous positive airway pressure. J 
Clin Sleep Med 3:706-712. 
 
Band, P.A., Blais, S., Neubert, T.A., Cardozo, T.J. & Ichtchenko, K. (2010). Recombinant 
derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal 
delivery. Protein Expr Purif 71:62-73. 
 
Baneyx, F. & Mujacic, M. (2004). Recombinant protein folding and misfolding in Escherichia 
coli. Nat Biotechnol 22:1399-1408. 
 
Barati, S., Chegini, F., Hurtado, P. & Rush, R.A. (2002). Hybrid tetanus toxin C fragment-
diphtheria toxin translocation domain allows specific gene transfer into PC12 cells. 
Exp Neurol 177:75-87. 
 
Bawden, F.C., Oliveira, C.A. & Caramelli, P. (2011). Impact of obstructive sleep apnea on 
cognitive performance. Arq Neuropsiquiatr 69:585-589. 
 
Behrensdorf-Nicol, H.A., Kegel, B., Bonifas, U., Silberbach, K. et al. (2008). Residual 
enzymatic activity of the tetanus toxin light chain present in tetanus toxoid batches 
used for vaccine production. Vaccine 26:3835-3841. 
 
Benn, S.C., Ay, I., Bastia, E., Chian, R.J. et al. (2005). Tetanus toxin fragment C fusion 
facilitates protein delivery to CNS neurons from cerebrospinal fluid in mice. J 
Neurochem 95:1118-1131. 
 
Bergey, G.K., Habig, W.H., Bennett, J.I. & Lin, C.S. (1989). Proteolytic cleavage of tetanus 
toxin increases activity. J Neurochem 53:155-161. 
 
Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G. et al. (2000). The Protein Data Bank. 
Nucleic Acids Res 28:235-242. 
 
Binz, T., Kurazono, H., Wille, M., Frevert, J. et al. (1990). The complete sequence of 
botulinum neurotoxin type A and comparison with other clostridial neurotoxins. J Biol 
Chem 265:9153-9158. 
206 
 
 
Bizzini, B., Stoeckel, K. & Schwab, M. (1977). An antigenic polypeptide fragment isolated 
from tetanus toxin: chemical characterization, binding to gangliosides and retrograde 
axonal transport in various neuron systems. J Neurochem 28:529-542. 
 
Black, J.E., Hull, S.G., Tiller, J., Yang, R. & Harsh, J.R. (2010). The long-term tolerability and 
efficacy of armodafinil in patients with excessive sleepiness associated with treated 
obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension 
study. J Clin Sleep Med 6:458-466. 
 
Blaustein, R.O., Germann, W.J., Finkelstein, A. & DasGupta, B.R. (1987). The N-terminal 
half of the heavy chain of botulinum type A neurotoxin forms channels in planar 
phospholipid bilayers. FEBS Lett 226:115-120. 
 
Blumen, M.B., Buchet, I., Meulien, P., Hausser Hauw, C. et al. (2009). 
Complications/adverse effects of maxillomandibular advancement for the treatment of 
OSA in regard to outcome. Otolaryngol Head Neck Surg 141:591-597. 
 
Boquet, P. & Duflot, E. (1982). Tetanus toxin fragment forms channels in lipid vesicles at low 
pH. Proc Natl Acad Sci U S A 79:7614-7618. 
 
Boucher, P., Sato, H., Sato, Y. & Locht, C. (1994). Neutralizing antibodies and 
immunoprotection against pertussis and tetanus obtained by use of a recombinant 
pertussis toxin-tetanus toxin fusion protein. Infect Immun 62:449-456. 
 
Boyd, S.B., Walters, A.S., Song, Y. & Wang, L. (2012). Comparative Effectiveness of 
Maxillomandibular Advancement and Uvulopalatopharyngoplasty for the Treatment of 
Moderate to Severe Obstructive Sleep Apnea. J Oral Maxillofac Surg  
 
Breidenbach, M.A. & Brunger, A.T. (2004). Substrate recognition strategy for botulinum 
neurotoxin serotype A. Nature 432:925-929. 
 
Breidenbach, M.A. & Brunger, A.T. (2005a). 2.3 A crystal structure of tetanus neurotoxin light 
chain. Biochemistry 44:7450-7457. 
 
Breidenbach, M.A. & Brunger, A.T. (2005b). New insights into clostridial neurotoxin-SNARE 
interactions. Trends Mol Med 11:377-381. 
 
Brisinda, G., Bentivoglio, A.R., Maria, G. & Albanese, A. (2004). Treatment with botulinum 
neurotoxin of gastrointestinal smooth muscles and sphincters spasms. Mov Disord 19 
Suppl 8:S146-156. 
 
Bruggemann, H. & Gottschalk, G. (2004). Insights in metabolism and toxin production from 
the complete genome sequence of Clostridium tetani. Anaerobe 10:53-68. 
 
Brunger, A.T., Breidenbach, M.A., Jin, R., Fischer, A. et al. (2007). Botulinum neurotoxin 
heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog 
3:1191-1194. 
 
Burgen, A.S., Dickens, F. & Zatman, L.J. (1949). The action of botulinum toxin on the neuro-
muscular junction. J Physiol 109:10-24. 
 
Caleo, M. & Schiavo, G. (2009). Central effects of tetanus and botulinum neurotoxins. 
Toxicon 54:593-599. 
 
Cavallone, L.F. & Vannucci, A. (2013). Review article: extubation of the difficult airway and 
extubation failure. Anesth Analg 116:368-383. 
207 
 
 
CDC. (2010). Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed 
botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal 
Wkly Rep 59:299. 
 
CDC. (2011). Notice of CDC's Discontinuation of Investigational Pentavalent (ABCDE) 
Botulinum Toxoid Vaccine for Workers at Risk for Occupational Exposure to 
Botulinum Toxins. MMWR Morb Mortal Wkly Rep 60:1454-1455. 
 
Chaddock, J.A. & Marks, P.M. (2006). Clostridial neurotoxins: structure-function led design of 
new therapeutics. Cell Mol Life Sci 63:540-551. 
 
Chaddock, J.A., Purkiss, J.R., Friis, L.M., Broadbridge, J.D. et al. (2000). Inhibition of 
vesicular secretion in both neuronal and nonneuronal cells by a retargeted 
endopeptidase derivative of Clostridium botulinum neurotoxin type A. Infect Immun 
68:2587-2593. 
 
Chalk, C., Benstead, T.J. & Keezer, M. (2011). Medical treatment for botulism. Cochrane 
Database Syst Rev 3:CD008123. 
 
Charles, I.G., Rodgers, B.C., Makoff, A.J., Chatfield, S.N. et al. (1991). Synthesis of tetanus 
toxin fragment C in insect cells by use of a baculovirus expression system. Infect 
Immun 59:1627-1632. 
 
Chen, C., Baldwin, M.R. & Barbieri, J.T. (2008a). Molecular basis for tetanus toxin coreceptor 
interactions. Biochemistry 47:7179-7186. 
 
Chen, C., Fu, Z., Kim, J.J., Barbieri, J.T. & Baldwin, M.R. (2009). Gangliosides as high 
affinity receptors for tetanus neurotoxin. J Biol Chem 284:26569-26577. 
 
Chen, S. & Barbieri, J.T. (2006). Unique substrate recognition by botulinum neurotoxins 
serotypes A and E. J Biol Chem 281:10906-10911. 
 
Chen, S. & Barbieri, J.T. (2011). Association of Botulinum Neurotoxin Serotype A Light Chain 
with Plasma Membrane-bound SNAP-25. J Biol Chem 286:15067-15072. 
 
Chen, S., Hall, C. & Barbieri, J.T. (2008b). Substrate recognition of VAMP-2 by botulinum 
neurotoxin B and tetanus neurotoxin. J Biol Chem 283:21153-21159. 
 
Chen, S., Kim, J.J. & Barbieri, J.T. (2007). Mechanism of substrate recognition by botulinum 
neurotoxin serotype A. J Biol Chem 282:9621-9627. 
 
Cheng, J.H., Hua, C.C., Chen, N.H., Liu, Y.C. & Yu, C.C. (2011). Autonomic activity 
difference during continuous positive airway pressure titration in patients with 
obstructive sleep apnea/hypopnea syndrome with or without hypertension. Chang 
Gung Med J 34:410-417. 
 
Clayton, M.A., Clayton, J.M., Brown, D.R. & Middlebrook, J.L. (1995). Protective vaccination 
with a recombinant fragment of Clostridium botulinum neurotoxin serotype A 
expressed from a synthetic gene in Escherichia coli. Infect Immun 63:2738-2742. 
 
Coleman, J.E. (1992). Zinc proteins: enzymes, storage proteins, transcription factors, and 
replication proteins. Annu Rev Biochem 61:897-946. 
 
ColoradoStateUniversity. Protein Hydropathicity Plots. 
http://www.vivo.colostate.edu/molkit/hydropathy/index.html (Accessed 2008). 
 
208 
 
 
Couesnon, A., Raffestin, S. & Popoff, M.R. (2006). Expression of botulinum neurotoxins A 
and E, and associated non-toxin genes, during the transition phase and stability at 
high temperature: analysis by quantitative reverse transcription-PCR. Microbiology 
152:759-770. 
 
Crone, N.E. & Reder, A.T. (1992). Severe tetanus in immunized patients with high anti-
tetanus titers. Neurology 42:761-764. 
 
Dahlenborg, M., Borch, E. & Radstrom, P. (2001). Development of a combined selection and 
enrichment PCR procedure for Clostridium botulinum Types B, E, and F and its use 
to determine prevalence in fecal samples from slaughtered pigs. Appl Environ 
Microbiol 67:4781-4788. 
 
Darwish, M., Kirby, M., D'Andrea, D.M., Yang, R. et al. (2010). Pharmacokinetics of 
armodafinil and modafinil after single and multiple doses in patients with excessive 
sleepiness associated with treated obstructive sleep apnea: a randomized, open-
label, crossover study. Clin Ther 32:2074-2087. 
 
DasGupta, B.R. & Dekleva, M.L. (1990). Botulinum neurotoxin type A: sequence of amino 
acids at the N-terminus and around the nicking site. Biochimie 72:661-664. 
 
Davletov, B., Bajohrs, M. & Binz, T. (2005). Beyond BOTOX: advantages and limitations of 
individual botulinum neurotoxins. Trends Neurosci 28:446-452. 
 
Deinhardt, K., Berninghausen, O., Willison, H.J., Hopkins, C.R. & Schiavo, G. (2006). 
Tetanus toxin is internalized by a sequential clathrin-dependent mechanism initiated 
within lipid microdomains and independent of epsin1. J Cell Biol 174:459-471. 
 
Dekleva, M.L. & DasGupta, B.R. (1989). Nicking of single chain Clostridium botulinum type A 
neurotoxin by an endogenous protease. Biochemical and Biophysical Research 
Communications 162:767-772. 
 
DiMari, S.J., Hash, J.H. & Robinson, J.P. (1982). Characterization of tetanus toxins and toxin 
components by amino terminal analyses. Arch Biochem Biophys 214:354-365. 
 
Dolly, J.O. & O'Connell, M.A. (2012). Neurotherapeutics to inhibit exocytosis from sensory 
neurons for the control of chronic pain. Curr Opin Pharmacol 12:100-108. 
 
Dong, M., Yeh, F., Tepp, W.H., Dean, C. et al. (2006). SV2 is the protein receptor for 
botulinum neurotoxin A. Science 312:592-596. 
 
Drager, L.F., Bortolotto, L.A., Figueiredo, A.C., Krieger, E.M. & Lorenzi, G.F. (2007). Effects 
of continuous positive airway pressure on early signs of atherosclerosis in obstructive 
sleep apnea. Am J Respir Crit Care Med 176:706-712. 
 
Driemeier, D., Schild, A.L., Fernandes, J.C., Colodel, E.M. et al. (2007). Outbreaks of tetanus 
in beef cattle and sheep in Brazil associated with disophenol injection. J Vet Med A 
Physiol Pathol Clin Med 54:333-335. 
 
Dubendorff, J.W. & Studier, F.W. (1991). Controlling basal expression in an inducible T7 
expression system by blocking the target T7 promoter with lac repressor. J Mol Biol 
219:45-59. 
 
Duggan, M.J., Quinn, C.P., Chaddock, J.A., Purkiss, J.R. et al. (2002). Inhibition of release of 
neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium 
209 
 
botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol 
Chem 277:34846-34852. 
 
Eckert, D.J., Jordan, A.S., Merchia, P. & Malhotra, A. (2007). Central sleep apnea: 
Pathophysiology and treatment. Chest 131:595-607. 
 
Eisel, U., Jarausch, W., Goretzki, K., Henschen, A. et al. (1986). Tetanus toxin: primary 
structure, expression in E. coli, and homology with botulinum toxins. EMBO J 5:2495-
2502. 
 
Ejaz, S.M., Khawaja, I.S., Bhatia, S. & Hurwitz, T.D. (2011). Obstructive sleep apnea and 
depression: a review. Innov Clin Neurosci 8:17-25. 
 
Eleopra, R., Tugnoli, V., Rossetto, O., De Grandis, D. & Montecucco, C. (1998). Different 
time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E 
in humans. Neurosci Lett 256:135-138. 
 
Emsley, P., Fotinou, C., Black, I., Fairweather, N.F. et al. (2000). The structures of the H(C) 
fragment of tetanus toxin with carbohydrate subunit complexes provide insight into 
ganglioside binding. J Biol Chem 275:8889-8894. 
 
Ermolaeva, M.D. (2001). Synonymous codon usage in bacteria. Curr Issues Mol Biol 3:91-
97. 
 
Fairweather, N.F., Lyness, V.A., Pickard, D.J., Allen, G. & Thomson, R.O. (1986). Cloning, 
nucleotide sequencing, and expression of tetanus toxin fragment C in Escherichia 
coli. J Bacteriol 165:21-27. 
 
Fairweather, N.F., Sanders, D., Slater, D., Hudel, M. et al. (1993). Production of biologically 
active light chain of tetanus toxin in Escherichia coli. Evidence for the importance of 
the C-terminal 16 amino acids for full biological activity. FEBS Lett 323:218-222. 
 
Fernandez-Salas, E., Steward, L.E., Ho, H., Garay, P.E. et al. (2004). Plasma membrane 
localization signals in the light chain of botulinum neurotoxin. Proc Natl Acad Sci U S 
A 101:3208-3213. 
 
Fezza, J.P., Howard, J., Wiley, R., Wesley, R.E. et al. (2000). The effects of tetanus toxin on 
the orbicularis oculi muscle. Ophthal Plast Reconstr Surg 16:101-113. 
 
Finn, C.W., Jr., Silver, R.P., Habig, W.H., Hardegree, M.C. et al. (1984). The structural gene 
for tetanus neurotoxin is on a plasmid. Science 224:881-884. 
 
Fischer, A. & Montal, M. (2007). Crucial role of the disulfide bridge between botulinum 
neurotoxin light and heavy chains in protease translocation across membranes. J Biol 
Chem 282:29604-29611. 
 
Fischer, A., Sambashivan, S., Brunger, A.T. & Montal, M. (2012). Beltless translocation 
domain of botulinum neurotoxin A embodies a minimum ion-conductive channel. J 
Biol Chem 287:1657-1661. 
 
Fisher, A. & Montal, M. (2006). Characterization of Clostridial botulinum neurotoxin channels 
in neuroblastoma cells. Neurotox Res 9:93-100. 
 
Fishman, P.S., Matthews, C.C., Parks, D.A., Box, M. & Fairweather, N.F. (2006). 
Immunization does not interfere with uptake and transport by motor neurons of the 
binding fragment of tetanus toxin. J Neurosci Res 83:1540-1543. 
 
210 
 
Foran, P.G., Mohammed, N., Lisk, G.O., Nagwaney, S. et al. (2003). Evaluation of the 
therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the 
long lasting type A. Basis for distinct durations of inhibition of exocytosis in central 
neurons. J Biol Chem 278:1363-1371. 
 
Foster, K.A., Adams, E.J., Durose, L., Cruttwell, C.J. et al. (2006). Re-engineering the target 
specificity of Clostridial neurotoxins - a route to novel therapeutics. Neurotox Res 
9:101-107. 
 
Fotinou, C., Emsley, P., Black, I., Ando, H. et al. (2001). The crystal structure of tetanus toxin 
Hc fragment complexed with a synthetic GT1b analogue suggests cross-linking 
between ganglioside receptors and the toxin. J Biol Chem 276:32274-32281. 
 
Francis, J.W., Bastia, E., Matthews, C.C., Parks, D.A. et al. (2004a). Tetanus toxin fragment 
C as a vector to enhance delivery of proteins to the CNS. Brain Res 1011:7-13. 
 
Francis, J.W., Brown, R.H., Jr., Figueiredo, D., Remington, M.P. et al. (2000). Enhancement 
of diphtheria toxin potency by replacement of the receptor binding domain with 
tetanus toxin C-fragment: a potential vector for delivering heterologous proteins to 
neurons. J Neurochem 74:2528-2536. 
 
Francis, J.W., Figueiredo, D., vanderSpek, J.C., Ayala, L.M. et al. (2004b). A survival motor 
neuron:tetanus toxin fragment C fusion protein for the targeted delivery of SMN 
protein to neurons. Brain Res 995:84-96. 
 
Francis, J.W., Hosler, B.A., Brown, R.H., Jr. & Fishman, P.S. (1995). CuZn superoxide 
dismutase (SOD-1):tetanus toxin fragment C hybrid protein for targeted delivery of 
SOD-1 to neuronal cells. J Biol Chem 270:15434-15442. 
 
Fredheim, J.M., Rollheim, J., Omland, T., Hofso, D. et al. (2011). Type 2 diabetes and pre-
diabetes are associated with obstructive sleep apnea in extremely obese subjects: a 
cross-sectional study. Cardiovasc Diabetol 10:84. 
 
Friedman, B.C. & Goldman, R.D. (2011). Anti-inflammatory therapy for obstructive sleep 
apnea in children. Can Fam Physician 57:891-893. 
 
Gagnadoux, F., Le Vaillant, M., Goupil, F., Pigeanne, T. et al. (2011). Influence of marital 
status and employment status on long-term adherence with continuous positive 
airway pressure in sleep apnea patients. PLoS One 6:e22503. 
 
Gali, B., Whalen, F.X., Schroeder, D.R., Gay, P.C. & Plevak, D.J. (2009). Identification of 
patients at risk for postoperative respiratory complications using a preoperative 
obstructive sleep apnea screening tool and postanesthesia care assessment. 
Anesthesiology 110:869-877. 
 
Gasteiger E., H.C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D., Bairoch A. (2005). 
Protein Identification and Analysis Tools on the ExPASy Server. John M. Walker (ed): 
The Proteomics Protocols Handbook, Humana Press. 571-607. 
 
GenScript. Bioinformatics Tools: Molecular Biology. http://www.genscript.com/cgi-
bin/tools/rare_codon_analysis; http://www.genscript.com/codon_opt.html. (Accessed 2008). 
 
Ghanem, F.M., Ridpath, A.C., Moore, W.E. & Moore, L.V. (1991). Identification of Clostridium 
botulinum, Clostridium argentinense, and related organisms by cellular fatty acid 
analysis. J Clin Microbiol 29:1114-1124. 
 
211 
 
Gill, D.M. (1982). Bacterial toxins: a table of lethal amounts. Microbiol Rev 46:86-94. 
 
Gill, R.T., Cha, H.J., Jain, A., Rao, G. & Bentley, W.E. (1998). Generating controlled reducing 
environments in aerobic recombinant Escherichia coli fermentations: effects on cell 
growth, oxygen uptake, heat shock protein expression, and in vivo CAT activity. 
Biotechnol Bioeng 59:248-259. 
 
Gilmartin, G.S., Daly, R.W. & Thomas, R.J. (2005). Recognition and management of 
complex sleep-disordered breathing. Curr Opin Pulm Med 11:485-493. 
 
Gilsdorf, J., Gul, N. & Smith, L.A. (2006). Expression, purification, and characterization of 
Clostridium botulinum type B light chain. Protein Expr Purif 46:256-267. 
 
Goldman, A. & Wollina, U. (2010). Facial rejuvenation for middle-aged women: a combined 
approach with minimally invasive procedures. Clin Interv Aging 5:293-299. 
 
Goodnough, M.C., Oyler, G., Fishman, P.S., Johnson, E.A. et al. (2002). Development of a 
delivery vehicle for intracellular transport of botulinum neurotoxin antagonists. FEBS 
Lett 513:163-168. 
 
Gordon, V.M. & Leppla, S.H. (1994). Proteolytic activation of bacterial toxins: role of bacterial 
and host cell proteases. Infect Immun 62:333-340. 
 
Grantham, R., Gautier, C., Gouy, M., Jacobzone, M. & Mercier, R. (1981). Codon catalog 
usage is a genome strategy modulated for gene expressivity. Nucleic Acids Res 
9:r43-74. 
 
Grantham, R., Gautier, C., Gouy, M., Mercier, R. & Pave, A. (1980). Codon catalog usage 
and the genome hypothesis. Nucleic Acids Res 8:r49-r62. 
 
Grodberg, J. & Dunn, J.J. (1988). ompT encodes the Escherichia coli outer membrane 
protease that cleaves T7 RNA polymerase during purification. J Bacteriol 170:1245-
1253. 
 
Grosjean, H. & Fiers, W. (1982). Preferential codon usage in prokaryotic genes: the optimal 
codon-anticodon interaction energy and the selective codon usage in efficiently 
expressed genes. Gene 18:199-209. 
 
Guex, N. & Peitsch, M.C. (1997). SWISS-MODEL and the Swiss-PdbViewer: an environment 
for comparative protein modeling. Electrophoresis 18:2714-2723. 
 
Gul, N., Smith, L.A. & Ahmed, S.A. (2010). Light chain separated from the rest of the type a 
botulinum neurotoxin molecule is the most catalytically active form. PLoS One 
5:e12872. 
 
Habermann, E. & Dreyer, F. (1986). Clostridial neurotoxins: handling and action at the 
cellular and molecular level. Curr Top Microbiol Immunol 129:93-179. 
 
Halpern, J.L., Habig, W.H., Neale, E.A. & Stibitz, S. (1990). Cloning and expression of 
functional fragment C of tetanus toxin. Infect Immun 58:1004-1009. 
 
Halpern, J.L. & Loftus, A. (1993). Characterization of the receptor-binding domain of tetanus 
toxin. J Biol Chem 268:11188-11192. 
 
Han, J.H., Choi, Y.S., Kim, W.J., Jeon, Y.H. et al. (2010). Codon optimization enhances 
protein expression of human peptide deformylase in E. coli. Protein Expr Purif 
70:224-230. 
212 
 
 
Hanahan, D. (1983). Studies on transformation of Escherichia coli with plasmids. J Mol Biol 
166:557-580. 
 
Hatheway, C.L. (1990). Toxigenic clostridia. Clin Microbiol Rev 3:66-98. 
 
Helting, T.B., Parschat, S. & Engelhardt, H. (1979). Structure of tetanus toxin. Demonstration 
and separation of a specific enzyme converting intracellular tetanus toxin to the 
extracellular form. J Biol Chem 254:10728-10733. 
 
Henkel, J.S., Tepp, W.H., Przedpelski, A., Fritz, R.B. et al. (2011). Subunit vaccine efficacy 
against Botulinum neurotoxin subtypes. Vaccine 29:7688-7695. 
 
Herreros, J., Lalli, G., Montecucco, C. & Schiavo, G. (2000). Tetanus toxin fragment C binds 
to a protein present in neuronal cell lines and motoneurons. J Neurochem 74:1941-
1950. 
 
Herreros, J., Ng, T. & Schiavo, G. (2001). Lipid rafts act as specialized domains for tetanus 
toxin binding and internalization into neurons. Molecular Biology of the Cell 12:2947-
2960. 
 
Hoch, D.H., Romero-Mira, M., Ehrlich, B.E., Finkelstein, A. et al. (1985). Channels formed by 
botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to 
translocation of proteins across membranes. Proc Natl Acad Sci U S A 82:1692-1696. 
 
Hopp, T.P. & Woods, K.R. (1981). Prediction of protein antigenic determinants from amino 
acid sequences. Proc Natl Acad Sci U S A 78:3824-3828. 
 
Hsieh, Y.J. & Liao, Y.F. (2012). Effects of maxillomandibular advancement on the upper 
airway and surrounding structures in patients with obstructive sleep apnoea: a 
systematic review. Br J Oral Maxillofac Surg.  
Hudgel, D.W. & Fung, C. (2000). A long-term randomized, cross-over comparison of auto-
titrating and standard nasal continuous airway pressure. Sleep 23:645-648. 
 
Humeau, Y., Doussau, F., Grant, N.J. & Poulain, B. (2000). How botulinum and tetanus 
neurotoxins block neurotransmitter release. Biochimie 82:427-446. 
 
Irwin, M.R., Carrillo, C. & Olmstead, R. (2010). Sleep loss activates cellular markers of 
inflammation: sex differences. Brain Behav Immun 24:54-57. 
 
Jabbari, B. (2008). Botulinum neurotoxins in the treatment of refractory pain. Nat Clin Pract 
Neurol 4:676-685. 
 
Javaheri, S. (2006). Acetazolamide improves central sleep apnea in heart failure: a double-
blind, prospective study. Am J Respir Crit Care Med 173:234-237. 
 
Jayaraman, S., Eswaramoorthy, S., Kumaran, D. & Swaminathan, S. (2005). Common 
binding site for disialyllactose and tri-peptide in C-fragment of tetanus neurotoxin. 
Proteins 61:288-295. 
 
Jensen, M.J., Smith, T.J., Ahmed, S.A. & Smith, L.A. (2003). Expression, purification, and 
efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation 
domain variants. Toxicon 41:691-701. 
 
Kapust, R.B. & Waugh, D.S. (1999). Escherichia coli maltose-binding protein is uncommonly 
effective at promoting the solubility of polypeptides to which it is fused. Protein Sci 
8:1668-1674. 
213 
 
 
Kaw, R., Michota, F., Jaffer, A., Ghamande, S. et al. (2006). Unrecognized sleep apnea in 
the surgical patient: implications for the perioperative setting. Chest 129:198-205. 
 
Kegel, B., Behrensdorf-Nicol, H.A., Bonifas, U., Silberbach, K. et al. (2007). An in vitro assay 
for detection of tetanus neurotoxin activity: using antibodies for recognizing the 
proteolytically generated cleavage product. Toxicol In Vitro 21:1641-1649. 
 
Keith, F. & John, C. (2010). Targeted secretion inhibitors-innovative protein therapeutics. 
Toxins (Basel) 2:2795-2815. 
 
Keller, J.E. (2008). Characterization of new formalin-detoxified botulinum neurotoxin toxoids. 
Clin Vaccine Immunol 15:1374-1379. 
 
Keller, J.E., Cai, F. & Neale, E.A. (2004). Uptake of botulinum neurotoxin into cultured 
neurons. Biochemistry 43:526-532. 
 
Kitasato, S. (1891). Experimentelle Untersuchungen über das Tetanusgift. Zeitschrift für 
Hygiene 10:267-305. 
 
Kondo, Y., Kuwahira, I., Shimizu, M., Nagai, A. et al. (2011). Significant relationship between 
platelet activation and apnea-hypopnea index in patients with obstructive sleep apnea 
syndrome. Tokai J Exp Clin Med 36:79-83. 
 
Koriazova, L.K. & Montal, M. (2003). Translocation of botulinum neurotoxin light chain 
protease through the heavy chain channel. Nat Struct Biol 10:13-18. 
 
Krieglstein, K., Henschen, A., Weller, U. & Habermann, E. (1990). Arrangement of disulfide 
bridges and positions of sulfhydryl groups in tetanus toxin. Eur J Biochem 188:39-45. 
 
Kukreja, R.V. & Singh, B.R. (2007). Comparative role of neurotoxin-associated proteins in 
the structural stability and endopeptidase activity of botulinum neurotoxin complex 
types A and E. Biochemistry 46:14316-14324. 
 
Kurazono, H., Mochida, S., Binz, T., Eisel, U. et al. (1992). Minimal essential domains 
specifying toxicity of the light chains of tetanus toxin and botulinum neurotoxin type A. 
J Biol Chem 267:14721-14729. 
 
Kushida, C.A., Littner, M.R., Morgenthaler, T., Alessi, C.A. et al. (2005). Practice parameters 
for the indications for polysomnography and related procedures: an update for 2005. 
Sleep 28:499-521. 
 
Kuzniar, T.J. & Morgenthaler, T.I. (2008). Treatment of complex sleep apnea syndrome. Curr 
Treat Options Neurol 10:336-341. 
 
Kyte, J. & Doolittle, R.F. (1982). A simple method for displaying the hydropathic character of 
a protein. J Mol Biol 157:105-132. 
 
La Piana, G.E., Scartabellati, A., Chiesa, L., Ronchi, L. et al. (2011). Long-term adherence to 
CPAP treatment in patients with obstructive sleep apnea: importance of educational 
program. Patient Prefer Adherence 5:555-562. 
 
Lacy, D.B. & Stevens, R.C. (1999). Sequence homology and structural analysis of the 
clostridial neurotoxins. J Mol Biol 291:1091-1104. 
 
Lacy, D.B., Tepp, W., Cohen, A.C., DasGupta, B.R. & Stevens, R.C. (1998). Crystal structure 
of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5:898-902. 
214 
 
 
Lalli, G., Herreros, J., Osborne, S.L., Montecucco, C. et al. (1999). Functional 
characterisation of tetanus and botulinum neurotoxins binding domains. J Cell Sci 
112 ( Pt 16):2715-2724. 
 
Lalli, G. & Schiavo, G. (2002). Analysis of retrograde transport in motor neurons reveals 
common endocytic carriers for tetanus toxin and neurotrophin receptor p75NTR. J 
Cell Biol 156:233-239. 
 
Langner, K.F., Schenk, H.C., Leithaeuser, C., Tholen, H. & Simon, D. (2011). Localised 
tetanus in a cat. Vet Rec 169:126. 
 
Larsen, K.E., Benn, S.C., Ay, I., Chian, R.J. et al. (2006). A glial cell line-derived neurotrophic 
factor (GDNF):tetanus toxin fragment C protein conjugate improves delivery of GDNF 
to spinal cord motor neurons in mice. Brain Res 1120:1-12. 
 
Launois, S.H., Pepin, J.L. & Levy, P. (2007). Sleep apnea in the elderly: a specific entity? 
Sleep Med Rev 11:87-97. 
 
Lazarovici, P. & Yavin, E. (1986). Affinity-purified tetanus neurotoxin interaction with synaptic 
membranes: properties of a protease-sensitive receptor component. Biochemistry 
25:7047-7054. 
 
Lebeda, F.J. & Olson, M.A. (1994). Secondary structural predictions for the clostridial 
neurotoxins. Proteins 20:293-300. 
 
Levy, R., Forsyth, C.M., LaPorte, S.L., Geren, I.N. et al. (2007). Fine and domain-level 
epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast 
surface display. J Mol Biol 365:196-210. 
 
Li, B., Cardinale, S.C., Butler, M.M., Pai, R. et al. (2011). Time-dependent botulinum 
neurotoxin serotype A metalloprotease inhibitors. Bioorg Med Chem 19:7338-7348. 
 
Li, L. & Singh, B.R. (2000). Spectroscopic analysis of pH-induced changes in the molecular 
features of type A botulinum neurotoxin light chain. Biochemistry 39:6466-6474. 
 
Li, Y., Aoki, R. & Dolly, J.O. (1999). Expression and characterisation of the heavy chain of 
tetanus toxin: reconstitution of the fully-recombinant dichain protein in active form. J 
Biochem 125:1200-1208. 
 
Li, Y., Foran, P., Fairweather, N.F., de Paiva, A. et al. (1994). A single mutation in the 
recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes 
the toxicity seen after reconstitution with native heavy chain. Biochemistry 33:7014-
7020. 
 
Li, Y., Foran, P., Lawrence, G., Mohammed, N. et al. (2001). Recombinant forms of tetanus 
toxin engineered for examining and exploiting neuronal trafficking pathways. J Biol 
Chem 276:31394-31401. 
 
Liao, Y.D., Jeng, J.C., Wang, C.F., Wang, S.C. & Chang, S.T. (2004). Removal of N-terminal 
methionine from recombinant proteins by engineered E. coli methionine 
aminopeptidase. Protein Sci 13:1802-1810. 
 
Lindstrom, M., Keto, R., Markkula, A., Nevas, M. et al. (2001). Multiplex PCR assay for 
detection and identification of Clostridium botulinum types A, B, E, and F in food and 
fecal material. Appl Environ Microbiol 67:5694-5699. 
 
215 
 
Lindstrom, M. & Korkeala, H. (2006). Laboratory diagnostics of botulism. Clin Microbiol Rev 
19:298-314. 
 
Liu, S.R., Yi, H.L., Yin, S.K., Guan, J. et al. (2012). Primary maxillomandibular advancement 
with concomitant revised uvulopalatopharyngoplasty with uvula preservation for 
severe obstructive sleep apnea-hypopnea syndrome. J Craniofac Surg 23:1649-
1653. 
 
Livorsi, D.J., Eaton, M. & Glass, J. (2010). Generalized tetanus despite prior vaccination and 
a protective level of anti-tetanus antibodies. Am J Med Sci 339:200-201. 
 
Mackay, S.G., Carney, A.S., Woods, C., Antic, N. et al. (2013). Modified 
uvulopalatopharyngoplasty and coblation channeling of the tongue for obstructive 
sleep apnea: a multi-centre Australian trial. J Clin Sleep Med 9:117-124. 
 
Mahant, N., Clouston, P.D. & Lorentz, I.T. (2000). The current use of botulinum toxin. J Clin 
Neurosci 7:389-394. 
 
Mahrhold, S., Rummel, A., Bigalke, H., Davletov, B. & Binz, T. (2006). The synaptic vesicle 
protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS 
Lett 580:2011-2014. 
 
Makoff, A.J., Oxer, M.D., Romanos, M.A., Fairweather, N.F. & Ballantine, S. (1989). 
Expression of tetanus toxin fragment C in E. coli: high level expression by removing 
rare codons. Nucleic Acids Res 17:10191-10202. 
 
Maksymowych, A.B., Reinhard, M., Malizio, C.J., Goodnough, M.C. et al. (1999). Pure 
botulinum neurotoxin is absorbed from the stomach and small intestine and produces 
peripheral neuromuscular blockade. Infect Immun 67:4708-4712. 
 
Maksymowych, A.B. & Simpson, L.L. (1998). Binding and transcytosis of botulinum 
neurotoxin by polarized human colon carcinoma cells. J Biol Chem 273:21950-21957. 
 
Malhotra, A., Ayas, N.T. & Epstein, L.J. (2000). The art and science of continuous positive 
airway pressure therapy in obstructive sleep apnea. Curr Opin Pulm Med 6:490-495. 
 
Malhotra, A. & White, D.P. (2002). Obstructive sleep apnoea. Lancet 360:237-245. 
 
Marshall, N.S., MacKay, S., Gallagher, R. & Robinson, S. (2010). Uvulopalatopharyngoplasty 
funded by the Australian government's Medicare scheme (1995-2007). Otolaryngol 
Head Neck Surg 142:S10-14. 
 
Marshall, N.S., Wilsmore, B.R., McEvoy, R.D., Wheatley, J.R. et al. (2007). 
Polysomnography in Australia--trends in provision. J Clin Sleep Med 3:281-284. 
 
Maruyama, K., Morishita, E., Sekiya, A., Omote, M. et al. (2012). Plasma levels of platelet-
derived microparticles in patients with obstructive sleep apnea syndrome. J 
Atheroscler Thromb 19:98-104. 
 
Matteoli, M., Verderio, C., Rossetto, O., Iezzi, N. et al. (1996). Synaptic vesicle endocytosis 
mediates the entry of tetanus neurotoxin into hippocampal neurons. Proc Natl Acad 
Sci U S A 93:13310-13315. 
 
Mayers, C.N., Holley, J.L. & Brooks, T. (2001). Antitoxin therapy for botulinum intoxication. 
Rev Med Microbiol 12:29-37. 
 
216 
 
McMahon, H.T., Ushkaryov, Y.A., Edelmann, L., Link, E. et al. (1993). Cellubrevin is a 
ubiquitous tetanus-toxin substrate homologous to a putative synaptic vesicle fusion 
protein. Nature 364:346-349. 
 
Meunier, F.A., Lisk, G., Sesardic, D. & Dolly, J.O. (2003). Dynamics of motor nerve terminal 
remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration 
are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci 22:454-466. 
 
Middlebrook, J.L. (2005). Production of vaccines against leading biowarfare toxins can utilize 
DNA scientific technology. Adv Drug Deliv Rev 57:1415-1423. 
 
Miyagi, K. & Shah, A.K. (2011). Tetanus prophylaxis in the management of patients with 
acute wounds. J Plast Reconstr Aesthet Surg 64:e267-269. 
 
Mocchetti, I. (2005). Exogenous gangliosides, neuronal plasticity and repair, and the 
neurotrophins. Cell Mol Life Sci 62:2283-2294. 
 
Montecucco, C. (1986). How do tetanus and botulinum toxins bind to neuronal membranes? 
Trends in Biochemical Sciences 11:314-317. 
 
Morgenthaler, T.I., Gay, P.C., Gordon, N. & Brown, L.K. (2007). Adaptive servoventilation 
versus noninvasive positive pressure ventilation for central, mixed, and complex 
sleep apnea syndromes. Sleep 30:468-475. 
 
Morrell, M.J., McRobbie, D.W., Quest, R.A., Cummin, A.R. et al. (2003). Changes in brain 
morphology associated with obstructive sleep apnea. Sleep Med 4:451-454. 
 
Olsen, S., Smith, S. & Oei, T.P. (2008). Adherence to continuous positive airway pressure 
therapy in obstructive sleep apnoea sufferers: a theoretical approach to treatment 
adherence and intervention. Clin Psychol Rev 28:1355-1371. 
 
Olszewska, E., Rutkowska, J., Czajkowska, A. & Rogowski, M. (2012). Selected surgical 
managements in snoring and obstructive sleep apnea patients. Med Sci Monit 
18:CR13-18. 
 
Pardridge, W.M. (2002). Drug and gene delivery to the brain: the vascular route. Neuron 
36:555-558. 
 
Park, J.B. & Simpson, L.L. (2003). Inhalational poisoning by botulinum toxin and inhalation 
vaccination with its heavy-chain component. Infect Immun 71:1147-1154. 
 
Patocka, J., Splino, M. & Merka, V. (2005). Botulism and bioterrorism: how serious is this 
problem? Acta Medica (Hradec Kralove) 48:23-28. 
 
Pellett, S., Tepp, W.H., Stanker, L.H., Band, P.A. et al. (2011). Neuronal targeting, 
internalization, and biological activity of a recombinant atoxic derivative of botulinum 
neurotoxin A. Biochem Biophys Res Commun 405:673-677. 
 
Penner, R., Neher, E. & Dreyer, F. (1986). Intracellularly injected tetanus toxin inhibits 
exocytosis in bovine adrenal chromaffin cells. Nature 324:76-78. 
 
Poulain, B., Mochida, S., Weller, U., Hogy, B. et al. (1991). Heterologous combinations of 
heavy and light chains from botulinum neurotoxin A and tetanus toxin inhibit 
neurotransmitter release in Aplysia. J Biol Chem 266:9580-9585. 
 
217 
 
Puhar, A., Johnson, E.A., Rossetto, O. & Montecucco, C. (2004). Comparison of the pH-
induced conformational change of different clostridial neurotoxins. Biochemical and 
Biophysical Research Communications 319:66-71. 
 
Punjabi, N.M. (2008). The epidemiology of adult obstructive sleep apnea. Proc Am Thorac 
Soc 5:136-143. 
 
Qazi, O., Bolgiano, B., Crane, D., Svergun, D.I. et al. (2007). The HC fragment of tetanus 
toxin forms stable, concentration-dependent dimers via an intermolecular disulphide 
bond. J Mol Biol 365:123-134. 
 
Qazi, O., Sesardic, D., Tierney, R., Soderback, Z. et al. (2006). Reduction of the ganglioside 
binding activity of the tetanus toxin HC fragment destroys immunogenicity: 
implications for development of novel tetanus vaccines. Infect Immun 74:4884-4891. 
 
Ramar, K., Desrues, B., Ramar, P. & Morgenthaler, T.I. (2012). Analysis of cardiopulmonary 
coupling to assess adaptive servo-ventilation success in complex sleep apnea 
management. Sleep Breath  
Rao, K.N., Kumaran, D., Binz, T. & Swaminathan, S. (2005). Structural analysis of the 
catalytic domain of tetanus neurotoxin. Toxicon 45:929-939. 
 
Rawat, R., Ashraf Ahmed, S. & Swaminathan, S. (2008). High level expression of the light 
chain of botulinum neurotoxin serotype C1 and an efficient HPLC assay to monitor its 
proteolytic activity. Protein Expr Purif 60:165-169. 
 
Reeves-Hoche, M.K., Hudgel, D.W., Meck, R., Witteman, R. et al. (1995). Continuous versus 
bilevel positive airway pressure for obstructive sleep apnea. Am J Respir Crit Care 
Med 151:443-449. 
 
Rossetto, O., Seveso, M., Caccin, P., Schiavo, G. & Montecucco, C. (2001). Tetanus and 
botulinum neurotoxins: turning bad guys into good by research. Toxicon 39:27-41. 
 
Roux, S., Saint Cloment, C., Curie, T., Girard, E. et al. (2006). Brain-derived neurotrophic 
factor facilitates in vivo internalization of tetanus neurotoxin C-terminal fragment 
fusion proteins in mature mouse motor nerve terminals. Eur J Neurosci 24:1546-
1554. 
 
Rummel, A., Bade, S., Alves, J., Bigalke, H. & Binz, T. (2003). Two carbohydrate binding 
sites in the H(CC)-domain of tetanus neurotoxin are required for toxicity. J Mol Biol 
326:835-847. 
 
Rummel, A., Mahrhold, S., Bigalke, H. & Binz, T. (2004). The HCC-domain of botulinum 
neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype 
specific carbohydrate interaction. Mol Microbiol 51:631-643. 
 
Sali, A. & Blundell, T.L. (1993). Comparative protein modelling by satisfaction of spatial 
restraints. J Mol Biol 234:779-815. 
 
Sambrook, J., Russell, D.W. Molecular Cloning, A Laboratory Manual, (Cold Spring Harbor 
Laboratory Press, Cold Spring Harbor, New York, 2001). 
 
Sandvig, K. & Olsnes, S. (1980). Diphtheria toxin entry into cells is facilitated by low pH. J 
Cell Biol 87:828-832. 
 
Sari, E. & Menillo, S. (2011). Comparison of titratable oral appliance and mandibular 
advancement splint in the treatment of patients with obstructive sleep apnea. ISRN 
Dent 2011:581692. 
218 
 
 
Sasse, A., Conduit, R., Ryan, D., Woods, W. & Tucker, A.P. (2005). A pharmacotherapy for 
obstructive sleep apnea. Sleep 28:1015-1016. 
 
Schiavo, G., Matteoli, M. & Montecucco, C. (2000). Neurotoxins affecting neuroexocytosis. 
Physiol Rev 80:717-766. 
 
Schiavo, G., Papini, E., Genna, G. & Montecucco, C. (1990). An intact interchain disulfide 
bond is required for the neurotoxicity of tetanus toxin. Infect Immun 58:4136-4141. 
 
Schiavo, G., Poulain, B., Rossetto, O., Benfenati, F. et al. (1992a). Tetanus toxin is a zinc 
protein and its inhibition of neurotransmitter release and protease activity depend on 
zinc. EMBO J 11:3577-3583. 
 
Schiavo, G., Rossetto, O., Santucci, A., DasGupta, B.R. & Montecucco, C. (1992b). 
Botulinum neurotoxins are zinc proteins. J Biol Chem 267:23479-23483. 
 
Schwab, R.J. (2005). Genetic determinants of upper airway structures that predispose to 
obstructive sleep apnea. Respir Physiol Neurobiol 147:289-298. 
 
Scott, A.B. (1981). Botulinum toxin injection of eye muscles to correct strabismus. Trans Am 
Ophthalmol Soc 79:734-770. 
 
Selim, B.J., Junna, M.R. & Morgenthaler, T.I. (2012). Therapy for sleep hypoventilation and 
central apnea syndromes. Curr Treat Options Neurol 14:427-437. 
 
Series, F. (2002). Upper airway muscles awake and asleep. Sleep Med Rev 6:229-242. 
 
Shapiro, R.E., Specht, C.D., Collins, B.E., Woods, A.S. et al. (1997). Identification of a 
ganglioside recognition domain of tetanus toxin using a novel ganglioside 
photoaffinity ligand. J Biol Chem 272:30380-30386. 
 
Sharp, P.M. & Li, W.H. (1987). The codon Adaptation Index--a measure of directional 
synonymous codon usage bias, and its potential applications. Nucleic Acids Res 
15:1281-1295. 
 
Sheridan, R.E. (1998). Gating and permeability of ion channels produced by botulinum toxin 
types A and E in PC12 cell membranes. Toxicon 36:703-717. 
 
Shi, Z., Zeng, M., Yang, G., Siegel, F. et al. (2001). Protection against tetanus by needle-free 
inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol 
75:11474-11482. 
 
Shiomi, F.K., Pisa, I.T. & Campos, C.J. (2011). Computerized analysis of snoring in sleep 
apnea syndrome. Braz J Otorhinolaryngol 77:488-498. 
 
Sikorra, S., Henke, T., Galli, T. & Binz, T. (2008). Substrate recognition mechanism of 
VAMP/synaptobrevin-cleaving clostridial neurotoxins. J Biol Chem 283:21145-21152. 
 
Silvaggi, N.R., Wilson, D., Tzipori, S. & Allen, K.N. (2008). Catalytic features of the botulinum 
neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide 
complex. Biochemistry 47:5736-5745. 
 
Simpson, L.L. (2004). Identification of the major steps in botulinum toxin action. Annu Rev 
Pharmacol Toxicol 44:167-193. 
 
219 
 
Simpson, L.L., Coffield, J.A. & Bakry, N. (1993). Chelation of zinc antagonizes the 
neuromuscular blocking properties of the seven serotypes of botulinum neurotoxin as 
well as tetanus toxin. J Pharmacol Exp Ther 267:720-727. 
 
Singh, B.R., Thirunavukkarasu, N., Ghosal, K., Ravichandran, E. et al. (2010). Clostridial 
neurotoxins as a drug delivery vehicle targeting nervous system. Biochimie 92:1252-
1259. 
 
Sinha, K., Box, M., Lalli, G., Schiavo, G. et al. (2000). Analysis of mutants of tetanus toxin Hc 
fragment: ganglioside binding, cell binding and retrograde axonal transport properties. 
Mol Microbiol 37:1041-1051. 
 
Smith, S., Lang, C., Sullivan, K. & Warren, J. (2004). Two new tools for assessing patients' 
knowledge and beliefs about obstructive sleep apnea and continuous positive airway 
pressure therapy. Sleep Med 5:359-367. 
 
Smith, T.J., Lou, J., Geren, I.N., Forsyth, C.M. et al. (2005). Sequence variation within 
botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect 
Immun 73:5450-5457. 
 
Stancombe, P.R., Masuyer, G., Birch-Machin, I., Beard, M. et al. (2012). Engineering 
botulinum neurotoxin domains for activation by toxin light chain. FEBS J 279:515-523. 
 
Stanker, L.H., Merrill, P., Scotcher, M.C. & Cheng, L.W. (2008). Development and partial 
characterization of high-affinity monoclonal antibodies for botulinum toxin type A and 
their use in analysis of milk by sandwich ELISA. J Immunol Methods 336:1-8. 
 
Stewart, E.J., Aslund, F. & Beckwith, J. (1998). Disulfide bond formation in the Escherichia 
coli cytoplasm: an in vivo role reversal for the thioredoxins. EMBO J 17:5543-5550. 
 
Stratford, R., Douce, G., Zhang-Barber, L., Fairweather, N. et al. (2000). Influence of codon 
usage on the immunogenicity of a DNA vaccine against tetanus. Vaccine 19:810-815. 
 
Sutton, R.B., Fasshauer, D., Jahn, R. & Brunger, A.T. (1998). Crystal structure of a SNARE 
complex involved in synaptic exocytosis at 2.4 A resolution. Nature 395:347-353. 
 
Svennerholm, L. (1964). THE GANGLIOSIDES. J Lipid Res 5:145-155. 
 
Swaminathan, S. (2011). Molecular Structures and Functional Relationships in Clostridial 
Neurotoxins. FEBS J  
 
Terry, T.D., Downes, J.E., Dowideit, S.J., Mabbett, A.N. & Jennings, M.P. (2005). 
Investigation of ansB and sspA derived promoters for multi- and single-copy antigen 
expression in attenuated Salmonella enterica var. typhimurium. Vaccine 23:4521-
4531. 
 
Thomas, R.J., Rosen, B.R., Stern, C.E., Weiss, J.W. & Kwong, K.K. (2005). Functional 
imaging of working memory in obstructive sleep-disordered breathing. J Appl Physiol 
98:2226-2234. 
 
Torrez, C.V. & Hunt, G.B. (2006). Results of surgical correction of abnormalities associated 
with brachycephalic airway obstruction syndrome in dogs in Australia. J Small Anim 
Pract 47:150-154. 
 
Tregoning, J.S., Nixon, P., Kuroda, H., Svab, Z. et al. (2003). Expression of tetanus toxin 
Fragment C in tobacco chloroplasts. Nucleic Acids Res 31:1174-1179. 
 
220 
 
Trujillo, M.H., Castillo, A., Espana, J., Manzo, A. & Zerpa, R. (1987). Impact of intensive care 
management on the prognosis of tetanus. Analysis of 641 cases. Chest 92:63-65. 
 
Truong, D.D. & Jost, W.H. (2006). Botulinum toxin: clinical use. Parkinsonism Relat Disord 
12:331-355. 
 
Turton, K., Chaddock, J.A. & Acharya, K.R. (2002). Botulinum and tetanus neurotoxins: 
structure, function and therapeutic utility. Trends in Biochemical Sciences 27:552-
558. 
 
Umland, T.C., Wingert, L.M., Swaminathan, S., Furey, W.F. et al. (1997). Structure of the 
receptor binding fragment HC of tetanus neurotoxin. Nat Struct Biol 4:788-792. 
 
Victor, L.D. (1999). Obstructive sleep apnea. Am Fam Physician 60:2279-2286. 
 
Villaflores, O.B., Hsei, C.M., Teng, C.Y., Chen, Y.J. et al. (2013). Easy expression of the C-
terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine 
candidate using a bi-cistronic baculovirus system. J Virol Methods 189:58-64. 
 
Walsh, J.K., Griffin, K.S., Forst, E.H., Ahmed, H.H. et al. (2011). A convenient expiratory 
positive airway pressure nasal device for the treatment of sleep apnea in patients 
non-adherent with continuous positive airway pressure. Sleep Med 12:147-152. 
 
Wang, J., Meng, J., Lawrence, G.W., Zurawski, T.H. et al. (2008). Novel chimeras of 
botulinum neurotoxins A and E unveil contributions from the binding, translocation, 
and protease domains to their functional characteristics. J Biol Chem 283:16993-
17002. 
 
Wang, J., Zurawski, T.H., Meng, J., Lawrence, G. et al. (2011). A dileucine in the protease of 
botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a 
novel potential therapeutic. J Biol Chem 286:6375-6385. 
 
Weaver, T.E., Chasens, E.R. & Arora, S. (2009). Modafinil improves functional outcomes in 
patients with residual excessive sleepiness associated with CPAP treatment. J Clin 
Sleep Med 5:499-505. 
 
Wey, J.J., Tang, S.S. & Wu, T.Y. (2006). Disulfide bond reduction corresponds to 
dimerization and hydrophobi-city changes of Clostridium botulinum type A neurotoxin. 
Acta Pharmacol Sin 27:1238-1246. 
 
WHO. (2006). Tetanus vaccine. Wkly Epidemiol Rec 81:198-208. 
 
Willson, G.N., Wilcox, I., Piper, A.J., Flynn, W.E. et al. (2001). Noninvasive pressure preset 
ventilation for the treatment of Cheyne-Stokes respiration during sleep. Eur Respir J 
17:1250-1257. 
 
Winter, A., Ulrich, W.P., Wetterich, F., Weller, U. & Galla, H.J. (1996). Gangliosides in 
phospholipid bilayer membranes: interaction with tetanus toxin. Chem Phys Lipids 
81:21-34. 
 
Wolk, R., Kara, T. & Somers, V.K. (2003). Sleep-disordered breathing and cardiovascular 
disease. Circulation 108:9-12. 
 
Wortzman, M.S. & Pickett, A. (2009). The science and manufacturing behind botulinum 
neurotoxin type A-ABO in clinical use. Aesthet Surg J 29:S34-42. 
 
221 
 
Yavin, E. & Nathan, A. (1986). Tetanus toxin receptors on nerve cells contain a trypsin-
sensitive component. Eur J Biochem 154:403-407. 
 
Yiadom, K.P., Muhie, S. & Yang, D.C. (2005). Peptide inhibitors of botulinum neurotoxin by 
mRNA display. Biochem Biophys Res Commun 335:1247-1253. 
 
Young, T., Palta, M., Dempsey, J., Skatrud, J. et al. (1993). The occurrence of sleep-
disordered breathing among middle-aged adults. N Engl J Med 328:1230-1235. 
 
Young, T., Peppard, P.E. & Gottlieb, D.J. (2002). Epidemiology of obstructive sleep apnea: a 
population health perspective. Am J Respir Crit Care Med 165:1217-1239. 
 
Yumino, D. & Bradley, T.D. (2008). Central sleep apnea and Cheyne-Stokes respiration. 
Proc Am Thorac Soc 5:226-236. 
 
Yumino, D., Wang, H., Floras, J.S., Newton, G.E. et al. (2009). Prevalence and physiological 
predictors of sleep apnea in patients with heart failure and systolic dysfunction. J 
Card Fail 15:279-285. 
 
Zdanovsky, A.G., Karassina, N.V., Simpson, D. & Zdanovskaia, M.V. (2001). Peptide phage 
display library as source for inhibitors of clostridial neurotoxins. J Protein Chem 
20:73-80. 
 
Zdanovsky, A.G. & Zdanovskaia, M.V. (2000). Simple and efficient method for heterologous 
expression of clostridial proteins. Appl Environ Microbiol 66:3166-3173. 
 
Zhang, L., Lin, W.J., Li, S. & Aoki, K.R. (2003). Complete DNA sequences of the botulinum 
neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain. Gene 
315:21-32. 
 
Zhou, L., de Paiva, A., Liu, D., Aoki, R. & Dolly, J.O. (1995). Expression and purification of 
the light chain of botulinum neurotoxin A: a single mutation abolishes its cleavage of 
SNAP-25 and neurotoxicity after reconstitution with the heavy chain. Biochemistry 
34:15175-15181. 
 
Zichel, R., Mimran, A., Keren, A., Barnea, A. et al. (2010). Efficacy of a potential trivalent 
vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-
free expression system. Clin Vaccine Immunol 17:784-792. 
 
Zozula, R. & Rosen, R. (2001). Compliance with continuous positive airway pressure 
therapy: assessing and improving treatment outcomes. Curr Opin Pulm Med 7:391-
398. 
 
 
 
 
 
 
 
 
 
222 
 
 
Appendices 
  
223 
 
Appendix 1 – DNA standard 
 
 
 
 
 
 
 
Figure A1. λ-DNA ladder 
(A) Lambda DNA digested with PstI. PstI digested λ-DNA separated by agarose gel 
electrophoresis with size and quantity of individual DNA fragments specified. Reproduced 
from Lambda DNA/PstI marker certificate of analysis (Fermentas). 
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Appendix 2 – Protein standards 
 
 
 
 
 
 
Figure A2. Protein standards 
(A) Precision Plus ProteinTM standard (unstained). Reproduced from Precision Plus ProteinTM 
standard product specifications sheet (BioRad). (B) Precision Plus ProteinTM Dual Colour 
Standard. Reproduced from Precision Plus ProteinTM Dual Color standard product 
specifications sheet (BioRad). (C) Precision Plus ProteinTM KaleidoscopeTM prestained 
standard. Reproduced from Precision Plus ProteinTM KaleidoscopeTM standard product 
specifications sheet (BioRad). 
 
